AKB-6548-CI-0015 (Study Registry ID: [REMOVED]; EudraCT Number: 2015-004774-14)
1.Original Protocol
2.Final Protocol
3.Rationale for Change for Protocol Amendments````AKB-6548-CI-0015 
This Supplement Contains: 
Date: 26 Feb 2019 
Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 1 of 80 CLINICAL PROTOCOL 
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY 
E
VALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE 
M
AINTENANCE TREATMEN T OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-
DEP
ENDENT CHRONIC KIDNEY DISEASE ( NDD -CKD) 
(PRO 2TECT - CONVERSION) 
Compound:  Vadadustat (AKB -6548)  
Protocol Number:  AKB -6548 -CI-0015  
US IND Number:  102,[ADDRESS_495564] Number  2015 -004774 -14 
Phase:  Phase 3  
Status/ Date:  Version 1.0/  
Sponsor:  Akebia Therapeutics, Inc.  
[ADDRESS_495565]  
Cambridge, MA  [ZIP_CODE]  
[LOCATION_002] of America  
This document contains information that is confidential and proprietary to the Sponsor, Akebia Therapeutics, Inc .  
This information is being provided to you solely for the purpose of evaluating and/or conducting a clinical study  
for the Sponsor .  You may disclose the contents of this document only to study personnel under your supervision, 
the Institutional Review Boar d, the [LOCATION_002] Food and Drug Administration, or duly authorized 
representatives of regulatory agencies for this purpose under the condition that they maintain confidentiality .  The 
contents of this document may not be used in any other clinical study , disclosed to any other person or entity, 
and/or published without the prior written permission of the Sponsor .  The foregoing shall not apply to disclosure 
required by [CONTACT_17140]; however, you will give prompt notice to the Sponsor of any such discl osure.  

Protocol No. AKB-6548-CI-0015 
CLINICAL PROTOCOL APPROVAL FORM 
Protocol Title: 
Compound: 
Protocol N um her: 
Status/Date: 
Sponsor Approval: Phase 3, Randomized, Open-Label, Active-Controlled Study 
Evaluating the Efficacy and Safety of Oral Vadadustat for 
the Maintenance Treatment of Anemia in Subjects with 
Non-Dialysis-Dependent Chronic Kidney Disease (NDD­
CKD) (PRO2TECT- Conversion) 
Vadadustat (AKB-6548) 
AKB-6548-CI-0015 
Version 1.0/[ADDRESS_495566] read and that I approve this protocol and that this 
document has been prepared in accordance with the principles of Good Clinical Practices, as 
outlined by [CONTACT_394646], and applicable regional regulations. 
Signature: 
[CONTACT_225949], Inc. 
Akebia -Company Confidential Date 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495567] the rights, safety, privacy, and well-being 
of study subjects in accordance with the following: 
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonization Guidance for Industry, Good Clinical Practice
E6.
All applicable laws and regulations, including, without limitation, data privacy laws and
regulations.
Regulatory requirements for reporting serious adverse events defined in this protocol.
Terms outlined in the Clinical Study Site Agreement.
Signature [CONTACT_63240] (print or type)  
Investigator’s Title  
Phone Number  
Full Address  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495568] Discontinuation ................................ ...................................  33 
[IP_ADDRESS]
 Temporary Interruption of Study Medication ............................................... 34 
[IP_ADDRESS]
 Permanent Discontinuation of Study Medication ......................................... 34 
[IP_ADDRESS]
 Complete Withdrawal from Further Study Visits/Assessments ................... 34 
[IP_ADDRESS]
 Procedures to Encourage Continued Study Participation ............................. 35 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 5 of 80 [IP_ADDRESS] Procedures to Prevent “Lost to Follow-up” .................................................. [ADDRESS_495569] Accountability and Destruction ................................................................ 37 
8.4 Tr eatment of Subjects ............................................................................................. 38 
8.4.1
 Treatment Group Assignments .......................................................................... 38 
8.4.2
 Randomization ................................................................................................... 38 
8.4.3
 Blinding ............................................................................................................. 39 
8.4.4
 Dosing and Dose Adjustment Guidelines .......................................................... 39 
[IP_ADDRESS]
 Vadadustat Dosing and Dose Adjustment Guidelines .................................. 40 
[IP_ADDRESS]
 Darbepoetin Alfa Dosing and Dose Adjustment Guidelines ........................ 41 
8.4.5
 Late or Missed Doses ........................................................................................ 41 
8.4.6
 Iron Supplementation ........................................................................................ 41 
8.4.7
 Rescue Therapy ................................................................................................. 41 
[IP_ADDRESS]
 ESA Rescue (Optional) ................................................................................. 42 
[IP_ADDRESS]
 Red Blood Cell Transfusion ......................................................................... 42 
8.4.8
 Phlebotomy ........................................................................................................ 42 
8.4.9
 Treatment Compliance ...................................................................................... 43 
8.4.10
 Continuation of Treatment ................................................................................ 43 
8.5 P rior and Concomitant Therapy ............................................................................. 43 
8.5.1
 General .............................................................................................................. 43 
8.5.2
 Investigational Medications ............................................................................... 43 
9 S TUDY PROCEDURES AND SCHEDULE OF ACTIVITIES ................................  43 
9.1 Administrative Procedures ..................................................................................... 44 
9.1.1
 Informed Consent .............................................................................................. 44 
9.1.2
 Documentation of Screen Failures ................................ ....................................  44 
9.1.3
 Contraception and Pregnancy Avoidance Measures .........................................  44 
9.1.4
 Laboratory Accreditation and Reference Ranges ..............................................  45 
9.2 Study Procedures and Evaluations ......................................................................... 45 
9.2.1
 Clinical Evaluations ........................................................................................... 45 
9.2.2
 Laboratory Evaluations .....................................................................................  46 
9.3 S chedule of Activities ............................................................................................ 49 
9.3.1
 Pre-Screening Visit ............................................................................................  49 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 6 of 80 9.3.2 Screening Visits ................................................................................................. 49 
[IP_ADDRESS]
 Screening Visit 1 (SV1) ................................................................................ 49 
[IP_ADDRESS]
 Screening Visit 2 (SV2) ................................................................................ 50 
[IP_ADDRESS]
 Subject Retesting .......................................................................................... [ADDRESS_495570] Rescreening .......................................................................................... 50 
9.3.4
 Baseline Visit (Day 1) ....................................................................................... 50 
9.3.5
 Year 1 Treatment Period Visits (Day 2 through Week 52) ............................... 51 
9.3.6
 Year 2 Treatment Period Visits (Weeks 53 through 104) ................................. 52 
9.3.7
 Year 3/4 Treatment Period Visits (Weeks 116 through 208) ............................ 53 
9.3.8
 End of Treatment Visit ...................................................................................... 53 
9.3.9
 Follow-Up Visit ................................................................................................. 54 
10 AD VERSE EVENTS ..................................................................................................  54 
10.1
 Definitions .............................................................................................................. 54 
10.1.1
 Adverse Events .................................................................................................. 54 
10.1.2
 Serious Adverse Events ..................................................................................... 57 
10.2
 Eliciting Adverse Event Information ..................................................................... 58 
10.3
 Reporting ................................................................................................................ 58 
10.3.1
 Reporting Period ................................................................................................ 58 
10.3.2
 Reporting AEs ................................................................................................... 58 
10.3.3
 Reporting SAEs ................................................................................................. 58 
10.3.4
 Reporting Study Endpoints ................................................................................ 59 
10.3.5
 Relationship to Study Medication ..................................................................... 59 
10.3.6
 Severity .............................................................................................................. 60 
10.3.7
 Follow-Up of Unresolved Events ...................................................................... 60 
10.4
 Exposure In Utero .................................................................................................. 60 
10.5
 Special Situations ................................................................................................... 61 
11 DA TA ANALYSIS .....................................................................................................  62 
11.1
 Sample Size Determination .................................................................................... 62 
11.1.1
 Sample Size for the Primary Efficacy Endpoint ................................................  62 
11.1.2
 Sample Size for the Primary Safety Endpoint ................................................... 63 
11.2
 Study Analysis Populations .................................................................................... 63 
11.3
 Analysis of Demographic and Pretreatment Variables .......................................... 63 
11.4
 Disposition of Subjects ........................................................................................... 64 
11.5
 Missing Data .......................................................................................................... 64 
11.6
 Efficacy Analyses ................................................................................................... 64 
11.6.1
 Analysis of Primary Efficacy Endpoint .............................................................  65 
[IP_ADDRESS]
 Primary Analysis of Primary Efficacy Endpoint .......................................... 65 
[IP_ADDRESS]
 Sensitivity Analyses of Primary Efficacy Endpoint ..................................... 65 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 7 of 80 11.6.2 Analysis of Key Secondary Efficacy Endpoints ............................................... 66 
[IP_ADDRESS] Ana lysis of Mean Change in HGB Value between Baseline (Mean 
Pretreatment HGB) and the Secondary Evaluation Period (Weeks 40-52) .. 66 
[IP_ADDRESS]
 Analysis of Proportion of Subjects with Mean HGB within the Target Range 
during the Primary Evaluation Period (Weeks 24-36) ................................. 66 
[IP_ADDRESS]
 Analysis of Mean Weekly Dose of IV Elemental Iron Administered from 
Baseline to Week 52 ..................................................................................... 66 
[IP_ADDRESS]
 Analysis of Proportion of Subjects Receiving RBC Transfusion(s) from 
Baseline to Week [ADDRESS_495571] KEEPI[INVESTIGATOR_1645] ......................................................  69 
12.1
 Case Report Forms/Electronic Data Capture ......................................................... [ADDRESS_495572] Retention .................................................................................................... 69 
13 QU ALITY CONTROL (QC) AND QUALITY ASSURANCE (QA) .......................  70 
13.1
 Investigative Site Monitoring Visits ...................................................................... 70 
13.2
 Protocol Deviations ................................................................................................ 70 
14 S TUDY DISCONTINUATION/INVESTIGATIVE STUDY SITE TERMINATION
 ..................................................................................................................................... [ADDRESS_495573]/Independent Ethics Committee .................................. [ADDRESS_495574] Confidentiality ........................................................................................... 72 
16 P UBLICATION OF STUDY RESULTS ................................ ...................................  72 
17 R EFERENCES ............................................................................................................  73 
APP
ENDIX A:  SCHEDULE OF ACTIVITIES ................................................................... 75 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 8 of 80 APPENDIX B:  CKD-EPI [INVESTIGATOR_245881] ...................................................... 79 
APP
ENDIX C:  ACTH (COSYNTROPIN) STIMULATION TEST FOR ADRENAL 
FUNCTION MONITORING ...................................................................................... 80 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 9 of 80 2 PROTOCOL SYNOPSIS 
Study Title  Phase 3, Randomized, Open -Label, Active -Controlled Study Evaluating the Effica cy 
and Safety of Oral Vadadustat  for the Maintenance Treatment  of Anemia in Subjects 
with Non -Dialysis -Dependent Chronic Kidney Disease (NDD -CKD) 
(PRO 2TECT  - CONVERSION)  
Protocol Number  AKB -[ADDRESS_495575]  Vadadustat ; [ADDRESS_495576]  Darbepoetin alfa (Aranesp™) ; [COMPANY_010] Inc. 
Study Population  The study population will consist of subjects ≥18  years of age with NDD -CKD , 
estimated glomerular filtration rate (eGFR) <60 mL/min/1.73  m2, and hemoglobin 
(HGB ) between 8.0 and 11 .0 g/dL (inclusive)  in the [LOCATION_002] ( US) and between 
9.0 and 12.0  g/dL (inclusive) outside of the US , who are currently treated with an 
erythropoiesis -stimulating agent (ESA) for anemia.  
Investigative Sites  Approximately 450 investigative sites  in North America, Latin America, Europe, and 
Asia Pacific . 
Planned Number of 
Subjects  Approximately 2100 subjects . 
Primary Objective  Demonstrate the efficacy and safety of vadadustat  compared with darbepoetin alfa for 
the maintenance treatment of anemia in subjects with NDD -CKD  after conversion 
from current ESA therapy . 
Study Design 
Overview  Phase 3, randomized, open -label, active -controlled study of the efficacy and safety of 
vadadu stat versus darbepoetin alfa for the maintenance treatment of anemia after 
conversion from cur rent ESA therapy.  Following a S creening period of up to 4  weeks, 
subjects who meet all inclusion and no exclusion criteria will be randomized 1:1 to  
vadadustat  or darbepoetin alfa.  
Randomization will be stratified by:  
Geographic region (US versus European Union [EU] versus Rest of World
[ROW])
[LOCATION_001] Heart Association  congestive heart failure (CHF ) Class 0 or I
versus II or III
Study entry HGB  (<10.0 versus ≥1 0.0 g/dL) .
Following randomization, there will be 3 periods during the study:  
Conversion and Maintenance Period (Weeks 0 -52):  conversion to study
treatment for maintaining HGB  (Weeks 0 -23), primar y efficacy evaluation
(Weeks 24 -36), and secondary efficacy evaluation (Weeks 40 -52)
Long -Term Treatment Period (Weeks 53 -End of Treatment  [EOT] ):
continued study medication  to assess long -term safety
Follow -Up Period (EOT  + 4 weeks):   post-treatment visit (either in person or
via telephone)  for safety .

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 10 of 80 Study Duration  Estimated time to full enrollment  of approximately 2100 randomized subjects is 
20 months, and average follow -up duration is expected to be 1.8  years.  All subjects 
will remain in the study until approximately 631  major adverse cardiovascular events 
(MACE) occur across 2  separate NDD -CKD studies, at which time subjects will be 
scheduled for a final visit and the study will close.  Sites  will be notified of the global 
study  end date approximately 3  months prior to study closure (based on accrual of 
MACE  across the 2  studies) and should inform active subjects of the global study end 
date thereafter.  
Inclusion Criteria  1.≥18 years of age
2.Diagnosis of CKD with an eGFR ≤60  mL/min /1.73  m2 using the 2009
Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD -EPI) creatinine
equation at Screening and not expected to start dialysis within [ADDRESS_495577] dose received  within
8 weeks prior to Screening
4.Mean  Screening  HGB  between 8.0 and 11 .0 g/dL (inclusive)  in the US and
between 9.0 and 12.0  g/dL (inclusive) outside of the US,  as de termined by [CONTACT_394647] 2 HGB  values measured by  [CONTACT_394648] S creen ing
5.Serum ferritin ≥100  ng/mL and transferrin saturation (TSAT) ≥20% at
Screening
6.Folate and vitamin B 12 measurement s ≥lower limit of normal at Screening
7.Understands the procedures and requirements of the study and provides
written informed consent and aut horization for protected health information
disclosure .
Exclusion Criteria  1.Anemia due to a  cause other than CKD  or subjects with active bleeding or
recent blood loss
2.Subjects with sickle cell disease, myelodysplastic syndromes, bone marrow
fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia,
or pure red cell aplasia
3.Red blood cell  (RBC)  transfusion within 4 weeks prior to or during Screening
4.Aspartate aminotrans ferase (AST) /serum glutamic oxaloacetic transaminase
(SGOT),  alanine aminotransferase (ALT) /serum glutamic pyruvic
transaminase (SGPT), or total bilirubin >2.0 x upper limit of normal (ULN) at
Screening.  Subjects with a history of Gilbert’s syndrome are n ot excluded.
5.Uncontrolled hypertension (confirmed diastolic blood pressure >110 mmHg
or systolic blood pressure >180 mmHg) at  Screening
6.Severe heart failure at Screening ( [LOCATION_001] Heart Association  Class IV)
7.Acute coronary syndrome (hosp italization for uns table angina or  myocardial
infarction), urgent coronary revascularization, hospi[INVESTIGATOR_245045], or
stroke within 12  weeks prior to S creening
8.History of active malignancy within 2  years prior to Screening, except for
curatively resected basal cell carcinoma of skin, squamous cell carcinoma of
skin, cervical carcinoma in situ, or resected benign colonic polyps
9.History of deep vein thrombosis (DVT) or pulmonary embolism (PE)
requiring active treatment within 8  weeks prior to Screening
10.History of hemos iderosis or hemochromatosis
11.History of prior organ transplantation or scheduled organ transplant (subjects
on kidney transplant wait -list are not excluded), or prior stem cell or bone
marrow transplant (corneal transplants are not excluded)
12.Use of an inves tigational medication or participation in an investigational

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 11 of 80 study within 30  days or 5  half-lives of the investigational medication 
(whichever is longer), prior to the Screening visit  
13.Previous participation in this study, receipt of vadadustat in another s tudy, or
previous participation in a study with another hypoxia -inducible factor
prolyl -hydroxylase inhibitor (HIF -PHI)
14.Females who are pregnant or breast -feeding.  Women of childbearing
potential who are unable or unwilling to use an acceptable method of
contraception
15.Non-vasectomized male subjects who are unable or unwilling to use an
acceptable method of c ontraception
16.Any other rea son that in the opi[INVESTIGATOR_2511] I nvestigator would make the
subject not suitable for participation in the study .
Retesting/ Rescreening  Subjects who initially fail to qualify for the study based on laboratory test results may 
be retested once within the [ADDRESS_495578]’s status has progressed and that the subject may now qualify for the 
study.  Additionally, subjects who fail to qualify for the study  based on low TSAT, 
ferritin, folate, or B 12 values may be considered for rescreening after receiving 
replacement therapy.  Screening is limited to 3 attempts (initial Screening and 
2 additional rescreening attempts).  
Efficacy Endpoints  Primary  
Mean change in HGB between B aseline (mean pretreatment HGB ) and the
primary evaluation  period (mean HGB from Weeks  24-36)
Key Secondary  
Mean change in HGB value between B aseline (mean pretreatment HGB ) and
the secondar y evaluation period (Weeks 40 -52)
Proportion of subjects with mean HGB  within the target range  during the
primar y evaluation period (Weeks 24 -36)
Mean weekly  dose of  intravenous (IV) elemental iron adm inistered from
Baseline to Week  52
Proportion of subjects receiving RBC transfusion(s) fr om B aseline to
Week  52.
Other Secondary  
Progression of CKD
Proportion of HGB  values within the target range  during the maintenanc e
period (Weeks 24-52)
Confirmed HGB  values <10.0 or > 12.0 g/dL
ESA rescue
Dose adjustments
Maintenance of iron sufficiency (defined as ferritin ≥ 100 ng/mL and
TSAT  ≥20%)
Receiving IV iron therapy .

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 12 of 80 Safety Endpoints  MACE, defined as all -cause mortality, non -fatal myocardial i nfarction, or
non-fatal stroke
Individual components of MACE:
oAll-cause mortality
oNon-fatal myocardial infarction
oNon-fatal stroke
Thromboembolic events:  arterial thrombosis, DVT, PE , or vascular access
thrombosis
HGB  >12.0  g/dL, >13.0  g/dL, or >14.0  g/dL
HGB  increase >1.0  g/dL wi thin any 2 -week interval or >2.0  g/dL within any
4-week interval
Adverse even ts (AEs) and serious adverse events (SAEs)
Vital signs and clinical laboratory values .
Study Procedures and 
Assessments  See Appendix A:  Schedule of Activities . 
Dosage and Regimens  Subjects will be randomized 1:1 to either:  
Vadadustat  starting dose :  2 tablets once daily (300  mg/day)  
Darbepoetin alfa subcutaneous ( SC):  initial  dose as follows  
For subjects already on darbepoetin, the initial dosing regimen in the study
should be based on the prior dosing regimen .
For subjects taking other ESAs, the initial dose of  darbepoetin should be
based on the  approved  local product label .
For all subjects, it is recommended that no additional ESA doses b e administered after 
Screening v isit 2 (SV2) and prior to the Randomization visit.  
Dose Adjustment Guidelines  – All Treatment Groups  
Dosing will be initiated at the Baseline visit, and the first dose of study medication  
(vadadustat or darbepoetin alfa)  will be administered at the investigative site after other 
Baseline procedures have been completed .  For all sub jects, it is recommended that no 
additional ESA doses be administered after SV2 and prior to the Randomization visit.  
Hemoglobin will be monitored via HemoCue® point of care  device  throughout the 
study to determine if the dose of study medication (vadadustat or darbepoetin alfa) will 
be adjusted  or suspended .  From Week s 0 to 12, HGB  will be measured via HemoCu e® 
every 2  weeks for monitoring for dose adjustment.  From Week  12 to Week  52, HGB  
via HemoCue® will be monitored every 4  weeks .  From Week 53 through the end of 
the study , HGB  will continue to be monitored via HemoCue® to determine if the dose 
of study medication will be adjusted or suspended .  Hemoglobin will also be assessed 
with a complete blood count (CBC) through the central laboratory for efficacy and 
safety evaluations; however, dose adjustments should be based  on the local HemoCue® 
HGB  value.  
The aim is to maintain a  HGB  level of 10 -11 g/dL in the US and 10 -12 g/dL outside 
the US throughout the study.  
Adjustments to doses will be guided by [CONTACT_252605] (IWR) system 
based on HGB concentration and programmed Dose Adjustment Algorithms.  The 
programmed Dose Adjustment Algorithm for vadadustat will follow the Dose 
Adjustment Guidelines (see b elow).  The programmed Dose Adjustment  Algorithm for 
darbepoetin alfa will be based on the local product label.  
When adjusting therapy, consider HGB rate of rise, rate of decline, and variability as 
well as the subject’s clinical condition (ie, recent illn ess, volume depletion, volume 
overload, etc).  In cases of extenuating clinical circumstances, the Investigator may 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495579]’s record and collected in the case report form  (CRF) . 
Vadadustat  
Vadadustat  should be dosed according to the following Dose Adjustment  Guidelines . 
US 
Do not increase the dose more frequently than once every 4 weeks.  Decreases
in dose can occur more frequently.  Avoid frequent dose adjustments.
If a dose adjustment is required to maintain HGB  at the desired level, the
vadadustat  dose is adjusted by 1  tablet ( minimum dose of vadadustat is
150 mg/day [1  tablet] ; maximum dose of vadadustat is 600  mg/day
[4 tablets] ).
If the HGB  rises rapi[INVESTIGATOR_375] (eg, > 1 g/dL in any 2 -week period), reduce the dose
of vadadustat  by 1 tablet.
If the HGB  falls below 10 .0 g/dL, increase the dose of vadadustat  by 1 tablet.
If the HGB  excee ds 11.0  g/dL, interrupt vadadustat until HGB decreases to
10.5 g/dL or less  then resume dosing of vadadustat with 1  fewer tablet .
Non-US 
Do not increase the dose more frequently than once every 4  weeks.  Decreases
in dose can occur more frequently.  Avoid  frequent dose adjustments.
If a dose adjustment is required to maintain HGB  at the desired level, the
vadadustat  dose is adjusted by 1  tablet ( minimum dose of vadadustat is
150 mg/day [1  tablet]; maximum dose of vadadustat is 600  mg/day
[4 tablets] ).
If the HGB  rises rapi[INVESTIGATOR_375] (eg, > 1 g/dL in any 2 -week period), reduce the dose
of vadadustat  by 1 tablet.
If the HGB  falls below 10 .0 g/dL, increase  the dose of vadadustat by 1 tablet.
If the HGB  level exceeds 12.0  g/dL, reduce the dose of vadadustat  by 1 tablet.
If the HGB  level exceeds 13.0  g/dL, interrupt vadadustat  until HGB  decreases
to 12.5  g/dL or less  then resume dosing of vadadustat  with 1  fewer tablet.
Darbepoetin alfa  
For subjects randomized to darbepoetin alfa, the initial dose will be d etermined as 
follows:  
For subjects already on darbepoetin, the initial dosing regimen in the study
should be based on the prior dosing regimen .
For subjects taking other ESAs, the initial dose of  darbepoetin should be
based on the  approved  local produc t label.
Following the dose conversion, darbepoetin alfa will be dosed SC, with dose 
adjustment s guided by [CONTACT_394649] a Dose Adjustment Algorithm 
based on the approved darbepoetin alfa  local product label .  Darbepoetin alfa dosing is 
independent of the visit schedule, and the dosing schedule may shift per local standard 
of care and country -specific darbepoetin dosing guidelines.  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 14 of 80 Dosing Instructions  Vadadustat  
All subjects will start with 2 tablets daily ( 300 mg/day).  Dose levels of vadadustat  
include 150, 300, 450, and 600  mg (available tablet strength is 150  mg).  Each subject 
will take his/her  first dose of vadadustat  at the investigative site  at the Baseline visit.  
Thereafter, vadadustat  will be taken  once daily on an outpatient basis.  Subjects may 
take vadadustat with or without food .  The dose should be taken at approximately the 
same time each day, preferably between [ADDRESS_495580] label.  
Iron Supplementation  Investigators should prescribe iron supplementation as needed during the study to 
maintain ferritin ≥100  ng/mL and TSAT ≥20%.  In general, only oral iron should be 
used for therapy.  Intravenous iron use is restricted and should only be administered to  
subjects who have documented intoleranc e to oral iron and iron deficiency (eg, ferritin 
<100  ng/mL and/or TSAT <20%).  Discontinuation of IV iron is required once the  
subject is no longer iron deficient (ferritin ≥100  ng/mL and TSAT ≥20%).  
Important :  Because of the potential for oral iron to r educe the bioavailability of 
vadadustat, the study medication should not be administered concurrently with an oral 
iron supplement (including multivitamins containing iron).  The subject should be 
instructed to take any oral iron supplements at least 2  hours before or 2  hours after the 
dose of vadadustat.  
Rescue Therapy 
Guidelines  To ensure the safety of study subjects and to standardize the use of rescue in the study, 
rescue therapy guidelines are provided.  
1.ESA Rescue:   Starting at Week  6, subjects in both treatment arm s will be allowed
(although will not be required) to have their HGB  rescued with ESA therapy , per the
local standard of care .  When possible, a  subject on vadadustat should be on the
maximum dose of vadadustat  for [ADDRESS_495581] fulfill ALL of the following:
The subject has experienced a clinically significant worsening of their anemia
or symptoms of anemia (eg, fatigue, weakness, shortness of breath, chest
pain, confusion, or dizziness) compared with Baseline
The subject’s HGB  is <9.0  g/dL
Reducing the risk of alloimmunization and/or other RBC transfusion -related
risks is a goal .
The ESA rescue therapy should be administered as per the local institution’s guidelines 
and per the approved local product label .  While receiving ESA rescue therapy, 
subjects must temporarily discontinue taking study medication  (vadadustat or 
darbepoeti n alfa) .  Hemoglobin will be monitored throughout the study at scheduled 
visits as defined in the Schedule of Activities using a HemoCue® point of care device, 
and ESA rescue treatment should be stopped when HGB  is ≥9 .0 g/dL.  A minimum 
interval must be ob served prior to restarting vadadustat after the last dose of rescue 
medication, and t reatment may be resumed after the following intervals:  
[ADDRESS_495582] dose of epoetin rescue
[ADDRESS_495583] dose of darbepoetin alfa  rescue
[ADDRESS_495584] dose o f methoxy polyethylene glycol -epoetin beta  rescue.
Following ESA rescue, the study medication should be resumed and adjusted 
according to the Dose Adjustment Guidelines.  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 15 of 80 2.RBC  Transfusion:   Investigators should use their local institution’s transfusion
guidelines when determining whether to transfuse a study subject.  In general, in the
event of an acute or severe loss of blood, a RBC transfusion should be administered as
clinically indicat ed.  In less severe instances but where there may be worsening of
anemia or moderate to severe symptoms of anemia, RBC transfusions are permitted at
the discretion of the Investigator  given the medical necessity.  Study medication
(vadadustat or darbepoeti n alfa)  may be continued during the transfusion period .
Phlebotomy  If a subject’s HGB  exceeds 14.0  g/dL or the rate of rise of HGB  raises concern to the 
Investigator , the subject may be phlebotomized based on  the Investigator ’s judgment.  
The method of phlebotomy will be in accordance with the investigative site’s standard 
clinical practice.  
Subject Completion, 
Premature 
Termination of Study 
Medication, or 
Withdrawal from the 
Study  Subject Completion  
A subject will be conside red as having completed the study, regardless of whether the  
subject is on or off study medication, if the  subject is followed until the global study 
end date as determin ed by [CONTACT_245935].  Subj ects who continue on the study 
medication up to the gl obal study end date will continue receiving vadadustat  or 
darbepoetin alfa until the EOT  visit.  A post -treatment follow -up either in person or via 
telep hone will occur approximately [ADDRESS_495585] withdrawal from the study  or study medication  (vadadustat  
or darbepoetin alfa).  
Discontinuation  of Study Medication Treatment  
During the course of this long -term stu dy, it is anticipated that  subjects may 
temporarily interrupt or permanently discontinue study medication (vadadustat or 
darbepoetin alfa) for any of the following reasons:  
Unacceptable toxicity or drug intolerability
Investigator discretion
Subject withdrawal of consent
Subject becomes pregnant
Development of end -stage kidney disease and initiation of ongoing chronic
hemodialysis or peritoneal dialysis or receipt of a kidney transplant .  (Note
that a subject who receives transient acute  dialysis may still continue study
medication per Investigator discretion.)
Other reasons .
Subjects who either temporarily interrupt or permanently discontinue study 
medication (vadadustat or darbepoetin alfa)  after randomization and prior  to 
completion of the study sh ould  continue with study visits and assessments through 
Week  52 and should be followed for safety assessments after Week  52 (see 
“Procedures to Avoid Withdrawal or Los t to Follow -Up” below).   Unless 
contraindicated, treatment should be resumed wherever pos sible and routinely 
considered at every visit following study medication  interruption/ discontinuation.  
Receipt of rescue therapy is not a reason for permanent study  medication 
discontinuation.  While receiving ESA rescue, subjects must temporarily disconti nue 
study medication, but should resume study medication following the end of rescue 
therapy.  
Complete  Withdrawal from Study Visits /Assessments  
Subjects may request to be withdrawn or may be withdrawn from the study  prior to 
completion only for  the followi ng reasons:  
Death

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 16 of 80 Withdrawal of informed consent (complete withdrawal of consent requires a
subject’s refusal of ALL methods of follow -up noted in the informed consent
form:  procedures, participation in reduced procedures/study visits, telephone
contact [CONTACT_245936], source document or designated
alternative contact, or access to medical records from alternative sources)
Lost to follow -up (detailed procedures to prevent  subjects from becoming
“lost to follow -up” are provided below and these procedures must be followed
by [CONTACT_32366], their staff, and all designated study personnel).
Procedures to Avoid 
Withdrawal or Los t to 
Follow -Up Avoiding Study Discontinuation  
As part of the informed consent process, only  subjects who fully understand and agree 
to full participation and long -term follow -up shoul d be consented to participate.  
In all cases of  impending study medication discontinuation , subject request for 
withdrawal from study visits , or consent withdrawal, Investigator s should  discuss with 
the subject their options of continuing in the study.  
The Investigator  should ensure understanding and documentation of the reasons for a  
subject’s desire to stop study proced ures or stop study medication.  
Minimizing Los t to Follow -Up 
The Investigator  must make every effort to contact  [CONTACT_245991] “lost to follow -up.”  These actions 
must include, but are not limited to, the following : 
1.Contact [CONTACT_245938]/her listed contacts (to be
collected in the source at the  subject’s entry into the study) , as applicable .  This
includes making phone calls after normal business hours or on holidays or  week ends.
2.Contact [CONTACT_19578]’s primary care physi cian, referring specialist, pharmacist, or
other healthcare professional , as applicable .
3.Send email, text, and postal mail with certified letters to all of the subject’s
addresses and contacts , as applicable .
4.Review available medical records /notes for details of hospi[INVESTIGATOR_602], clinic visits,
or other procedures that may indicate the status of the  subject, as applicable .
5.Utilize the internet to search for additional contact [CONTACT_3031] , as applicable .
6.Check local, regional, and national public records to locate the  subject or search for
mortality status as allowed by [CONTACT_2371] , as applicable .
Once all of these actions have been exhausted and documented then the Sponsor  or 
Sponsor  representative should be contact[CONTACT_245939].  
Stud y Termination/  
Individual Study Site 
Termination  The entire study may be suspended or terminated by [CONTACT_245993].  If this occurs, prompt 
notification will be given to Investig ators, Institutional Review Boards 
(IRBs)/ Institutional Ethics Committees (IECs), and regulatory authorities in 
accordance with regulatory requirements.  
The Investigator must notify the Sponsor if the study is terminated by [CONTACT_394650]/IEC at the investigative site.  If the Investigator, IRB/IEC, or Sponsor 
decides to terminate or suspend the study conducted at a particular investigative site for 
safety, non -enrollment, non -compliance with the protocol, or other unanticipated 
reasons, the ab ove parties will be promptly notified.  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 17 of 80 Statistical 
Considerations  Primary Efficacy Endpoint Analysis  
The primary efficacy endpoint is defined as the mean HGB  change from Baseline  
(mean pretreatment HGB ) to the mean  HGB  from Weeks 24 -36 (inclusive) . 
The primary analysis will use an analysis of variance (ANOVA), stratified by [CONTACT_252608].  
A 2-sided, 95% confidence interval will be calculated for the difference between the 
vadadustat  group and control  group.  Noninferiority of vadadustat will be established if 
the lower limit of this confidence interval is ≥-0.5 g/dL.  
MACE Analysis  
The MACE endpoint (adjudicated result) wil l be analyzed as the time from first dose of 
study medication  to first MACE .  Subjects who have not experienced an adjudi cated 
MACE  by [CONTACT_245943].  
Major adverse  cardiovascular events will be analyzed using a stratified Cox 
proportional hazards model with a model containing treatme nt group.  The 
randomization strata will be used in this analysis.  The primary MACE analysis will 
take place at study conclusion and will be based upon all subjects in the safety 
population.  The hazard ratio ( vadadustat/c ontrol) will be estimated, togeth er with its 
95% confidence interval.  As this individual study has not been powered to provide a 
stand -alone estimate of the hazard ratio for MACE, this interval will be considered as 
descriptive.  T he time to first MACE will also be graphically presented using 
Kaplan -Meier curves.  
The primary analysis for MACE will be performed using the safety population .  These 
analyses will be repeated with censoring occurring  4 weeks following early 
discontinuation of study medication . 
An independent statistical analys is center will perform an alyses in support of the 
Independent Data Monitoring Committee (IDMC) . 
Sample Size 
Estimation  For the primary efficacy analysis  in this study , it will be assumed that the difference in 
mean change in HGB  for vadadustat  will be the  same as the active control, darbepoetin  
alfa, and the common standard deviation for the mean c hange will be assumed to be 
1.5 g/dL.  The noninferiority margin of  -0.5 g/dL will be used.  With these assumptions 
and approxima tely [ADDRESS_495586] >99% power.  
The primary MACE analysis will be based upon all events that accrue over 
2 separately planned NDD -CKD studies  (Studies AKB -6548 -CI-0014 and 
AKB -6548 -CI-0015 ).  It has been calculated that [ADDRESS_495587] 80 % power to establish noninferiority wit h a margin of 1.25 , and >90% power to 
establish noninferiority with a margin of 1.3,  evaluated with a 2 -sided 95% confidence 
interval assuming no difference between the treatm ents.  The power is >90% to 
establish a noninferiority margin of 1.[ADDRESS_495588] ratio  is 0.95 favoring vadadustat .  
A MACE rate of 10% annually is anticipated in both treatment arms based on a 
comprehensive review of available epi[INVESTIGATOR_394622].  W ith 1050  subjects per treatment group enrolled in this study, approximately  
20 months for accrual , and up to 36  months of follow -up, approximately 68% of the 
needed MACE (429) would be captured.  
Independent D ata 
Monitoring 
Committee  An IDMC will be established to review and discuss the available study safety data as  
subjects are enrolled and followed.  The team will meet approximately twice per year 
throughout the course of the study.  The IDMC will be unblinded and will include, at a 
minimum, a nephrologist, a cardiologist, and a biostatistician.  The discussions of the 
IDMC will include a review of key safety data (ie, AEs, vital signs measurements, and  
laboratory assessments).  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 18 of 80 Endpoint 
Adjudication 
Committee ( EAC)  An independent safety EAC, blinded to treatment group, will be formed prior to study 
commencement to adjudicate the components of the primary safety endpoints (eg, 
death, myocardial infarction, and stroke) .  Thromboembolic events will also be 
adjudica ted by [CONTACT_131461].  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495589] OF ABBREVIATIONS 
ACTH adrenocorticotropic hormone 
AE adverse event 
ALT alanine aminotransferase (SGPT) 
ANOVA  a
nalysis of variance 
AST aspartate aminotransferase (SGOT) 
B
UN blood urea nitrogen 
C Celsius 
CBC complete blood count 
CHF congestive heart failure 
CKD chronic kidney disease 
CKD-EPI [INVESTIGATOR_394623] C ochran-Mantel-Haenszel 
CPK c reatine phosphokinase 
CRF  case report form 
CRO  contract research organization 
CS clinically significant 
CV cardiovascular 
CVD cardiovascular disease 
dL deciliter 
DVT  deep venous thrombosis 
EA
C Endpoint Adjudication Committee 
ECG e lectrocardiogram 
EDC electronic data capture 
eGFR estimated glomerular filtration rate 
EOT end of treatment 
EPO erythropoietin 
ESA erythropoiesis-stimulating agent 
ESRD end-stage renal disease 
EU Eur
opean Union 
F Fahrenheit 
FDA Food and Drug Administration 
g g ram 
GCP Good Clinical Practice 
GFR glomerular filtration rate 
GMP Good Manufacturing Practice 
HA health authority 
HDL  high-density lipoprotein 
HGB  he
moglobin 
HIF hypoxia-inducible factor 
H
IFPH hypoxia-inducible factor prolyl-hydroxylase 
H
IF-PHI hypoxia -inducible factor prolyl-hydroxylase inhibitor 
IC50 50% inhibitory concentration 
ICH International Conference on Harmonization 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495590] 
IV intravenous(ly) 
IWR interactive web response 
JSDT Japanese Society for Dialysis Therapy 
JSN Japanese Society of Nephrology 
KDIGO Kidney Disease:  Improving Global Outcomes 
kg kil ogram 
LDH lactate dehydrogenase  
LDL low-density lipoprotein 
LLN lower limit of normal 
MACE major adverse cardiovascular events 
MC
H mean corpuscular (cell) hemoglobin 
MCHC mean corpuscular (cell) hemoglobin concentration 
MCV mean corpuscular (cell) volume 
Me
dDRA Medical Dictionary for Regulatory Activities 
µM micromolar 
mg milligram 
mL milliliter 
mRNA messenger ribonucleic acid  
MTD maximum tolerated dose 
NDD-CKD non-dialysis dependent chronic kidney disease 
ng na nogram 
PD pharmacodynamics(s) 
PE pulmonary embolism 
PHD prolyl 4-hydroxylase domain 
PK pharmacokinetic(s) 
PP per protocol 
PT prothrombin time 
PTT partial thromboplastin time 
QA qua lity assurance 
QC quality control 
RBC red blood cell 
RDW red cell distribution width 
ROW rest of world 
SAE serious adverse event 
SAP Statistical Analysis Plan 
SC subcutaneous(ly) 
SGOT serum glutamic oxaloacetic transaminase (AST) 
S
GPT serum glutamic pyruvic transaminase (ALT) 
SmPC summary of product characteristics 
SV Screening visit 
TIBC total iron binding capacity 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495591] upper limit of normal 
US [LOCATION_002] 
VE
GF vascular endothelial growth factor 
WBC white blood cell 
WHO World Health Organization 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 22 of 80 4 
BACKGROUND INFORMATI ON 
Chronic kidney disease (CKD), defined as the presence of kidney damage or a decreased level of 
kidney function, is a major public health problem worldwide.  Globally, CKD is estimated to 
a
ffect between 8-16% of the population ( Jha et al. 2013; KDIGO 2013 ).  At the most advanced 
stages of CKD, end-stage renal disease (ESRD), patients require chronic dialysis or kidney 
transplantation to sustain life.  Chronic kidney disease is not only a cause of ESR D, but is also a 
significant risk factor for cardiovascular disease (CVD), infection, cancer, and mortality ( Iseki 
and Kohagura 2007). 
R
enal anemia often develops during the progression of CKD and is present in almost all patients 
with ESRD.  Anemia is defined as a decrease in circulating red blood cell (RBC) mass that is 
usually detected by [CONTACT_245944] (HGB) concentration.  The causes of anemia in CKD 
include blood loss, shortened RBC lifespan, iron deficiency, erythropoietin (EPO) deficiency, 
and inflammation ( Nurko 2006).  Although many factors contribute to anemia in CKD, it occurs 
prima
rily due to an inadequate synthesis of EPO by [CONTACT_8212], leading to a deficiency in the 
production of RBC progenitor cells by [CONTACT_245945].  Also contributing to anemia in CKD 
are impaired iron homeostasis and iron loss, which often necessitate iron supplementation 
(Nurko 2006).  Anemia in CKD patients usually occurs when the glomerular filtration rate 
(GFR) fa
lls below 60 mL/min/1.73 m2, a nd is present in >90% of the patients undergoing 
dialysis (CKD Stage 5) ( Goodkin et al. 2011). 
The
 main impact of anemia on organ function is reduced oxygen delivery to tissues leading to a 
constellation of symptoms including fatigue, shortness of breath, and exercise intolerance 
(Stauffer and Fan 2014 ) .  In patients with anemia related to CKD, compensatory changes occur 
in ca
rdiac structure and function, including an increase in cardiac output, the development of left 
ve
ntricular hypertrophy, and, eventually, the development of heart failure ( Me tivier et al.  2000 ).  
Risk of stroke also increases with anemia, which may be an underlying mechanism leading to 
stroke in CKD ( Abramson et al., 2003;  I seki and Kohagura 2007 ).  Other consequences from 
anemia in CKD patients include impaired cognitive function, sleep disorders, and depressed 
immune function, which can impact the quality of life in these patients ( Ise ki and 
Kohagura 2007; NICE 2011 ) .  Overall, anemia contributes to a poorer prognosis in patients with 
CKD ( Nurko 2006; I seki and Kohagura 2007). 
Er
ythropoiesis-stimulating agents (ESAs) a dministered either intravenously (IV) or 
subc
utaneously (SC), along with oral or IV  iron therapy,  are currently the cornerstones for 
tre
ating anemia in patients with CKD.  Treatment with exogenous recombinant ESAs can raise 
HG
B levels, relieve symptoms, and reduce the complications of anemia, including RBC 
tra
nsfusions which carry the risks of infection, iron overload, and impact candidacy for kidney 
transplantation. 
Clinical practice guidelines and prescribing information for approved ESAs and guidelines 
provide
d by [CONTACT_24623] (US) Food and Drug Administration (FDA), the European Union 
(EU), the Japanese Society of Nephrology, and the Japanese Society for Dialysis Therapy 
Guideline Committee differ slightly in their recommendations for treatment of renal anemia, as 
summarized in Table 1. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 23 of 80 T
able 1 Treatment Guidelines and Prescribing Information for Renal Anemia in 
NDD-CKD 
KDIGO guidelines  Treatment should occur in symptomatic patients  and when HGB generally falls below 
10 g/dL (Kidney Disease :  Improving Global Outcomes [K DIGO ] 2012 ). 
US darbepoetin alfa 
label  Same as other approved ESAs , but also recommend  that if HGB exceeds 10  g/dL  in adults 
not on dialysis , the dose of ESA  should be reduced or interrupted (Aranesp® US Package 
Insert 2015 ). 
EU practice 
guidelines  Recommend that in high -risk patients with NDD -CKD, treatment with ESAs should be 
initiated when the HGB levels are between 9  g/dL and 10  g/dL, although in low -risk 
patients and those in whom a clear benefit of quality of life can be foreseen, the initiation 
of ESA therapy could be considered at higher HGB levels ( Locatelli 2013 ). 
Japan practice 
guidelines  JSDT recommends that ESA treatment be initiated when HGB is below 11  g/dL following 
a diagnosis of renal anemia in NDD -CKD.  JSN 2013 does not provide a clear 
recommendation or maintenance range for HGB.  Both guidelines recommend that if the 
HGB exceeds 13  g/dL, the dose of ESA should be reduced or interrupted.  I n patients with 
CVD  or complications, ESA treatment should be reduced or interrupted if the HGB 
exceeds 12  g/dL ( Tsubakihara  2010 ; Japanese Society of Nephrology  2014 ). 
Abbreviations:  CVD  = cardiovascular disease; ESA  = erythropoietin stimulating agent; EU = European Union; 
HGB  = hemoglobin; JSDT  = Japanese Society for Dialysis Therapy; JSN  = Japanese Society of Nephrology; 
KDIGO  = Kidney Disease Improving Global Outcomes; NDD -CKD  = non-dialysis dependent chronic kidney disease; 
US = [LOCATION_002].  
The majority of patients with CKD currently receives interventional therapy in the form of iron 
ther
apy, and may initiate therapy with an ESA if other interventions fail and HGB levels fall 
be
low 9 to 11 g/dL, dependent upon local clinical practice guidelines. 
A numbe
r of large, prospective, randomized controlled trials in CKD (Stages 3 to 5) have 
e
xplored the potenti
al benefit of ESAs in patients with CKD with respect to overall mortality, 
c
ardiovascular ( CV) events, and progression of CKD with higher HGB targets (≥13 g/dL) 
(B
esarab et al. 1998; Dr ü eke et al. 2006; S ingh et al. 2006; P feffer et al. 2009a ; Pfeffer 
et al. 2009b).  These trials did not demonstrate the expected beneficial effects of correcting 
a
nemia on these outcom
es, but suggested an increased risk of death and CV events when 
targeting higher HGB levels ( Besarab et al. 1998 ; Drüeke et al.  2006 ; Singh et al. 2006; Pfeffer 
et al. 2009a ; P feffer et al. 2009b ).  Additional analyses from these trials suggest that the risk of 
de
ath or CV events appears to be highest in CKD patients who fail to respond to ESAs, as 
indi
cated by [CONTACT_394651] ( S zczech 
et al. 2008; S olomon et al.  2010 ).  This suggests that in some subjects the ESAs themselves, and 
not the HGB  level, may be causative of the increase in events.  This is supported by [CONTACT_394652] 
C
KD patients on dialysis with naturally high HGB levels and no increase in CV events ( Goodkin  
et al.  2011). 
The risks identified with ES
As from these trials have led to changes in prescribing information 
and practice guidelines in the US, the EU, and Japan that guide clinicians toward more cautious 
use of ESAs and targeting lower HGB levels.  In the US, the mortality and CV risks associated 
with ES
As are outlined in a black-box warning in the prescribing information of ESAs with a 
recommendation to use the lowest dose possible to avoid transfusions.  While no similar major 
wa
rnings exist in the EU Summary of Product Characteristics (SmPC) or on the approved 
labeling for ESAs in Japan, the EU SmPCs for ESAs do suggest caution with the use of these 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 24 of 80 drug
s, with a recommendation to keep HGB levels below 12 g/dL, while the Japanese practice 
g
uidelines recommend ESA treatment be reduced or interrupted if the HGB exceeds 12 g/dL in 
pa
tients with CVD or complications.  Further, recent EU clinical practice guidelines ( L ocatelli et 
al. 2013) recommend that risk factors for stroke (including a past history of stroke) and the 
pre
sence of a
ctive malignancy or a past history of malignancy should be taken into account when 
making decisions to use ESAs for the treatment of anemia. 
The
 risks associated with ESAs, including an increased risk of death and CV events, highlight 
the ne
ed for additional ther
api[INVESTIGATOR_245888]-based ESAs.  Therefore, the unmet medical need for the 
tre
atment of anemia in non-dialysis dependent CKD ( NDD - CKD) patients remains high, 
especially from a CV safety perspective.  To fulfill this unmet need, the vadadustat clinical 
program is focused on developi[INVESTIGATOR_245889]. 
4.1 Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors 
Please see the vadadustat Investigator Brochure for additional discussion and information for 
the foll
owing section.  
Vadadustat is a novel, synthetic, orally bioavailable, small molecule being developed as an 
inhi
bitor of hypoxia-inducible factor prolyl-hydroxylases (HIFPHs) for the treatment of anemia 
associated with CKD.  Hypoxia-inducible factor prolyl-hydroxylase enzymes are also referred to 
as prolyl 4-hydroxylase domains (PHDs), of which the [ADDRESS_495592] commonly expressed are PHD2 
a
nd PHD3.  Vadadustat is a slightly more potent inhibitor of PHD3 (50% inhibitory 
c
oncentration [ IC50] = 0.08 µM) than of PHD2 (IC 50 = 0.19 µM).  The inhibition of PHD3 and 
PHD2 stabilizes hypoxia-inducible factor (HIF)-2α and HIF-1α, which in turn stimulates the 
produ
ction of EPO.  In vivo animal efficacy and messenger ribonucleic acid (mRNA) data 
indicate that va
dadustat induces the production of EPO from both renal and extra-renal sites 
(
liver and brain), and this increase in EPO results in an increase in RBC production in the bone 
m
arrow.  In clinical trials, vadadustat has been shown to facilitate iron homeostasis by 
[CONTACT_394653].  This enables iron transport mechanisms that should enhance the 
ter
minal steps of erythropoiesis.  Vadadustat offers the potential of flexible oral dosing that 
provide
s a more gradual and reliable means of titration than injectable hormones.  Therefore, 
va
dadustat is being developed as an alternative to the existing protein hormone ESAs. 
4
.2 Summary of Clinical Experience 
Please see the vadadustat Investigator Brochure for additional discussion and information for 
the 
following section.  
To date, the safety, tolerability, pharmacokinetic ( PK) , and pharmacodynamic ( PD) pr ofiles of 
vadadustat have been characterized in 6 completed Phase 1 studies in healthy volunteers, 
1 completed Phase 1 study in subjects undergoing chronic hemodialysis, 3 completed Phase 2a 
studi
es in NDD-CKD subjects, and 1 completed Phase 2b study in NDD-CKD subjects.  The 
P
hase 2a studies evaluated Stages 3, 4, and 5 CKD (not on dialysis) subjects in a single-dose PK 
study, a multi
-dose, 28-day, open-label, dose escalation pi[INVESTIGATOR_799], and a randomized, 
placebo-controlled study with 5 different dose groups dosed for 42 days.  The Phase 2b study 
evaluated Sta
ges 3, 4, and 5 CKD (pre-dialysis).  A total of [ADDRESS_495593] received 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 25 of 80 va
dadustat, including 125 healthy volunteers and 254 subjects with CKD ([ADDRESS_495594] or Stage 5 on dialysis).  An additional 
[ADDRESS_495595] been accompanied by [CONTACT_245949] (increased total 
iron binding capacity [TIBC] and transferrin and decreased hepcidin and ferritin).  Together, 
these
 effects have stimulated an increase in reticulocytes and HGB.  Vadadustat has generally 
been well-tolerated with limited adverse events (AEs) and serious adverse events (SAEs) 
observed to date.  The urinary excretion of the compound has been shown to be less than 50% in 
he
althy human volunteers, which makes the compound appropriate for use in subjects with CKD. 
A recently completed Phase 2b, randomized, double-blind, placebo-controlled study to assess the 
he
matologic PD response, safety, and tolerability of oral vadadustat for 20 weeks was performed 
in 210 subjects with anemia associated with NDD-CKD.  Subjects were assigned to a study 
g
roup based on their ESA status at Screening (naïve, previously treated, or actively treated) and 
were randomized 2:1 to receive either vadadustat at a starting dose of 450 mg/day or placebo.  
The dose of vadadustat was adjusted based on HGB levels and changes in HGB.  A significantly 
higher proportion of subjects with a successful HGB response at the end of treatment was 
observed with vadadustat treatment when compared with placebo.  The dosing algorithm was 
effective in minimizing excessive HGB levels (>13.0 g/dL) and a consistent and sustained 
im
provement in iron mobilization was observed with treatment with vadadustat.  The safety 
profile of vadadustat in this study was generally consistent with that observed in prior studies. 
Based on the Phase 1 and Phase 2 study results, vadadustat appears to be a suitable candidate for 
c
ontinued development as a treatment for anemia in patients with CKD. 
4.3 Potential Benefits and Risks 
Please see the vadadustat Investigator Brochure for additional discussion and information for 
the foll
owing section. 
Vadadustat offers the potential of flexible oral dosing that is easier to titrate than injectable 
hormone
 ESAs.  This alternate the
rapeutic approach may avoid the overshoots and fluctuations 
in HGB  levels seen with currently available injectable ESAs and provide for a controlled, steady 
rise
 in HGB  concentration.  This less aggressive approach to modifying the HGB  concentration 
may be of benefit based on the FDA’s suggestion that fluctuations in HGB  concentrations, 
rapi[INVESTIGATOR_245890], and overshoots of the target level are associated with an 
incr
eased risk of
 CV events ( Unger 2007; Un ger et al. 2010). 
I
n addition, since HIFs downregulate the iron absorption regulator hepcidin, and upregulate the 
iron
-mobilizing regulators ferroportin and transferrin (and its receptor) ( Peyssonnaux et al. 
2007), vadadustat will likely enhance iron metabolism and transport, thereby [CONTACT_394654]
.  In the Phase 1b multiple ascending dose  study, a prominent effect on iron 
meta
bolism w as noted with the dosing of vadadustat, including a rapid increase in iron uptake, a 
dose responsive increase in TIBC, decreases in hepcidin and ferritin, and an increase in 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 26 of 80 tra
nsferrin.  A similar pattern was observed in the Phase 2a and 2b studies, with dose responsive 
increa
ses in TIBC and decreases in ferritin and hepcidin. 
To da
te, all of the acute findings observed at doses less than the maximum tolerated dose (MTD) 
in animals have been shown to be reversible and dose-related.  In addition, most of the findings 
have followed a pattern that would have been predicted based on the known HIF and HIFPH 
biochemistry, pharmacology, and human genetic variations (Chuvash polycythemia, etc).  In the 
completed clinical studies, vadadustat has been generally well-tolerated. 
5 STUDY OBJECTIVES AND ENDPOINTS 
5.1 Primary Objective 
The primary objective of this study is to demonstrate the efficacy and safety of vadadustat 
compared with darbepoetin alfa for the maintenance treatment of anemia in subjects with 
NDD-CKD a
fter conversion from current ESA therapy. 
5.2 Primary Efficacy Endpoint 
The primary endpoint used to assess the efficacy objective will be the mean change in HGB 
between Baseline (mean pretreatment HGB ) and the primary evaluation period (mean HGB from 
W
eeks 24-36). 
5
.3 Secondary Efficacy Endpoints 
Key secondary efficacy endpoints include the following: 
Mean change in HGB value between Baseline (mean pretreatment HGB) and the
se
condary evaluation period (Weeks 40-52)
Proportion of subjects with mean HGB within the target range during the primary
e
valuation period (Weeks 24-36)
Mean weekly dose of IV elemental iron administered from Baseline to Week 52
P
roportion of subjects receiving RBC transfusion(s) from Baseline to Week 52.
Othe
r second
ary efficacy endpoints include: 
P
rogression of CKD
Proportion of HGB  values within the target range during the maintenance period
(W
eeks 24-52)
C
onfirmed HGB  values <10.0 or >12.0 g/dL
ES
A rescue
Dose adjustments
Maintenance of iron sufficiency (defined as ferritin ≥100 ng/mL and transferrin
sa
turation [TSAT] ≥20%)
R
eceiving
 IV iron therapy.

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 27 of 80 5
.4 Safety Endpoints 
Safety endpoints in this study include the following: 
Ma
jor adverse cardiovascular events (MACE), defined as all-cause mortality, non-fatal
m
yocardial infarction, or non-fatal stroke
I
ndividual components of MACE:
All-cause mortality
N
on-fatal myocardial infarction
N
on-fatal stroke
Thr
omboembolic events:  arterial thrombosis, deep vein thrombosis (DVT), pulmonary
e
mbolism (PE), or vascular access thrombosis
HGB  >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL
HGB  increase >1.0 g/dL within any 2-week interval or >2.0 g/dL within any 4-week
int
erval
AEs and SAEs
Vital signs and clinical laboratory values
Adrenal function assessment in a subset of subjects (see Appendix C :  ACTH
(Cos
yntropin) Stimulation Test for Adrenal Function Monitoring ).
6 STUDY DESIGN 
6.1 Study Design 
This is a Phase 3, randomized, open-label, active-controlled study of the efficacy and safety of 
va
dadustat versus darbepoetin alfa for maintenance treatment of anemia after conversion from 
c
urrent ESA therapy in subjects with NDD-CKD.  Target enrollment in this study is 
a
pproximately 2100 subjects at approximately 450  investigative sites in North America, Latin 
Ame
rica, Europe, and Asia Pacific. 
Subjects will be randomized at the Baseline visit using an Interactive Web Response (IWR) 
s
ystem to receive either vadadustat or darbepoetin alfa.  For all subjects, it is recommended that 
no a
dditional ESA doses be
 administered after Screening visit 2 (SV2) and prior to the 
R
andomization visit. 
To monitor adrenal function, a subset of 100 subjects per treatment arm (200 subjects total) in 
the E
U will also undergo sequential adrenocorticotropic hormone (ACTH [cosyntropin])  adrenal 
stimulation tests at Baseline (predose), as well as at the Week 12 and Week 52 study visits, or at 
the
 end of treatment (EOT ) visit if the subject permanently discontinues study medication early 
prior
 to the Week 52 study visit (Appen dix C :  ACTH (Cosyntropin) Stimulation Test for 
Adrenal F
unction Monitoring ). 
Randomization will be stratified by [CONTACT_1617] (US versus EU versus rest of world 
[
ROW]), [LOCATION_001] Heart Association congestive heart failure (CHF ) C lass 0 or I versus II or 
III, and study entry HGB level (< 10.0 g/dL versus ≥10.0 g/dL based on the most recent central 
labor
atory HGB measurement prior to the Baseline/Randomization visit).  Following 
ra
ndomization, there will be 3 periods during the study: 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 28 of 80 C
onversion and Maintenance Period (Weeks 0-52):  conversion to study medication for
maintaining
 HGB (Weeks 0-23), primary efficacy evaluation (Weeks 24-36), and
se
condary efficacy evaluation (Weeks 40-52)
L
ong-term Treatment Period (Week 53-EOT):  continued study medication to assess
long
-term safety
Follow-up Period (EOT + 4 weeks):  post-treatment visit for safety (either in person or
via te
lephone).
A HemoCue® point of care device will be used throughout the study to monitor HGB to 
de
termine if the dose of study medication (vadadustat or darbepoetin alfa) will be adjusted.  
From Weeks 0 to 12, HemoCue® will be used to monitor HGB  every 2 weeks for dose 
adjustment.  From Week 12 to Week 52, HGB  will be monitored via HemoCue® every 4 weeks.  
From Week 53 through the end of study, HGB will continue to be monitored via HemoCue® to 
de
termine if the dose of study medication will be adjusted or suspended.  Hemoglobin will also 
be
 assessed with a complete blood count (CBC) through the central laboratory for efficacy and 
safety evaluations; however, dose adjustments should be based on the HemoCue® HGB value. 
The aim of the dosing strategy is to maintain HGB levels of 10.0  g/dL to 11.0 g/dL in the US 
and 10.0  g/dL to 12.0 g/dL outside of the US throughout the study. 
Subjects assigned to vadadustat will initiate dosing at [ADDRESS_495596]
ments to doses for vadadustat will be guided by [CONTACT_394655] 
c
oncentration and a programmed Dose Adjustment Algorithm (Section [IP_ADDRESS] , Vadadustat 
Dosing and Dose Adjustment Guidelines ).  Dosing will be suspended if HGB rises to >11.0 g/dL 
(U
S investigative sites) or >13.0 g/dL (non-US investigative sites), and will not be restarted until 
HG
B levels are reduced to ≤10.5 g/dL (US investigative sites) or ≤12.5 g/dL (non-US 
investi
gative sites) (see Section [IP_ADDRESS], Vadadustat Dosing and Dose Adjustment Guidelines  for 
details regarding dose suspension). 
S
ubjects assigned to darbepoetin alfa will be dosed SC at the Baseline visit and the initial dose 
will be determi
ned based on the approved local product labe l.  Dose adjustments will be guided 
b
y an IWR system implementing a programmed Dose Adjustment Algorithm based on the local 
product label (Section [IP_ADDRESS], Darbepoetin Alfa Dosing and Dose Adjustment Guidelines ).  
Da
rbepoetin alfa dosing is independent of the visit schedule, and the dosing schedule may shift 
per local standard of care and country specific dosing guidelines. 
Investigators should prescribe iron supplementation as needed during the study to maintain 
ferritin ≥100 ng/mL and TSAT ≥20% (see Section 8.4.6, I ron Supplementation  for details 
regarding iron supplementation during the study). 
Clinical and safety assessments (including laboratory assays, PK evaluations [both vadadustat 
pa
rent compound and metabolites], MACE endpoint data, vital sign measurements, and AEs) 
will be performed as indicated at Screening, during the Conversion and Maintenance Period 
(Weeks 
0-52), during the Long-term Treatment Period  (visits approximately every 3 months), 
a
nd during the Follow-up Period (4 weeks after the EOT).  Refer to Section 9, Study Procedures 
a
nd Schedule of Activities  and Appendix A:  Schedule of Activities  for additional details. 
All subjects will remain in the study until approximately 631 MACE occur across 2 separately 
planne
d NDD -CKD studies (Studies AKB - 6548- CI-0014 and AKB-6548- CI- 0015), at which 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 29 of 80 time subjects will be scheduled for a final visit and the study will close (see Section 11.1.2, 
S
ample Size for the Primary Safety Endpoint ). 
6.[ADDRESS_495597] been accompanied by [CONTACT_245949] 
(increased TIBC and transferrin and decreased hepcidin and ferritin).  Together, these effects 
ha
ve stimulated an increase in reticulocytes and HGB.  Vadadustat has generally been 
well-tolerated with limited AEs.  Finally, the urinary excretion of vadadustat has been shown to 
be
 less than 50% in humans which makes the compound appropriate for evaluation in subjects 
with C
KD.  B a sed on the Phase  [ADDRESS_495598] caution with the use of these 
drug
s, with a recommendation to keep HGB levels below 12 g/dL.  Recent clinical practice 
g
uidelines ( L ocatelli et al. 2013 ) recommend that risk factors for stroke and  malignancy should 
also be taken into account when making treatment decisions to use ESAs for the treatment of 
a
nemia. 
G
iven the concerns associated with marketed ESAs, a goal of this study will be to evaluate the 
C
V events during the treatment of anemia with vadadustat.  The inclusion of a MACE endpoint 
in this study will allow for a statistical comparison of the rates of CV events between vadadustat 
and darbepoetin alfa treatment groups when used to treat anemia associated with NDD-CKD.  
While the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)  (P feffer et 
al 2009b) compared different HGB targets, the present study will have similar HGB targets 
be
tween trea
tment arms.  Importantly, the HGB goals for this study are lower than those used in 
TREAT and are consistent with practice guidelines and prescribing information for approved 
ESAs. 
This s
tudy will be performed as an open-label study.  Because HGB values are objective and will 
be measured via a central laboratory for all efficacy endpoints, efficacy assessments are not 
considered to be subject to bias with an open-label design.  Blinding of this study presented 
inherent practical problems, including potential dosing errors, inappropriate dose adjustments, 
and delays in dosing, which may also increase the safety risk to study participants.  Given the 
differing dosing regimens and routes for vadadustat (oral) and darbepoetin alfa (SC injection), a 
double-dummy design would have been required which also created ethical concerns and 
required extensive coordination to maintain the blind.  The Sponsor and contract research 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 30 of 80 orga
nization ( CRO ) study teams will remain blinded to the randomization codes.  In addition, the 
study will involve blinded adjudication of MACE, the use of an independent data monitoring 
committee (IDMC), and an identical schedule of visits, procedures, and assessments for both 
treatment groups in order to reduce the potential for bias.  However, certain personnel directly 
involved in medical oversight of the study, regulatory reporting of safety information, and 
on-site monitoring activities may become unblinded to the treatment assignments of individual 
subj
ects during the course of the study. 
6.3 Dose Justification 
The starting dose and the proposed dosing algorithm in this study are designed to increase and 
maintain HGB in a predictable and controlled manner while minimizing abrupt increases or 
excessive rises in HGB levels.  Based on plasma concentrations and PD measures from 
previously conducted clinical studies with vadadustat, a population PK/PD model was 
developed.  Using this model and the proposed dosing algorithm, simulations were carried out to 
evaluate the effects of different starting doses and the resulting HGB responses to support the 
dosing rationale.  Results of the simulations indicated that a starting dose regimen of 300 mg 
onc
e daily along with the proposed dosing algorithm are optimal to increase and maintain HGB 
levels of 10.0 to 11.0 g/dL in the US and 10.0 to 12.0 g/dL outside of the US while minimizing 
e
xcessive rises. 
6.[ADDRESS_495599], and 
a biostatistician.  The discussions of the IDMC will include a review of key safety data (ie, AEs, 
vital signs, and laboratory assessments).  Written records of the IDMC meetings, the materials 
re
viewed, and the decisions made will be maintained.  Details on the roles and responsibilities of 
the IDMC and guidelines for monitoring study safety data will be described further in the IDMC 
charter. 
6.5 Endpoint Adjudication Committee 
An independent safety endpoin t adjudication committee (EAC) will be formed prior to study 
commencement to adjudicate the primary safety endpoints (death, myocardial infarction, and 
stroke).  Thromboembolic events will also be adjudicated by [CONTACT_131461].  The committee will be 
blinded throughout the course of the study.  The EAC will be composed of independent experts 
with experience and training appropriate for adjudication of MACE and thromboembolic events. 
Details on the responsibilities of the EAC will be described further in the EAC charter. 
[ADDRESS_495600] meet all of the following criteria.  No study procedures 
(inc
luding Screening tests) may be performed until after the informed consent has been legally 
signed. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495601] should progress to full Screening procedures.  
A separate Pre-Screen informed consent (distinct from the full protocol informed consent) will 
be implemented for the Pre-Screen visit.  To be eligible for the Pre-Screen HGB measurement, a 
study subject or their legally acceptable representative must provide valid informed consent prior 
to t
he Pre-Screen procedure.  For a better understanding of the P re- Screening visit, please se e 
Section 9.3.1, Pre-Screening Vis it. 
[ADDRESS_495602] meet all of the following inclusion criteria to be eligible: 
1.
At least 18 years of age
2. Diagnosis of CKD with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m2
using
 the 2009 Chronic Kidney Disease Epi[INVESTIGATOR_10444] (C KD-EPI) creatinine
equation at Screening (see Appendix B:  CKD-EPI [INVESTIGATOR_91258] ) a nd not expected to
start dialysis within [ADDRESS_495603] dose received within 8 weeks prior to
S
creening
4. Mean Screening HGB between 8.0 and 11.0 g/dL (inclusive) in the US and between 9.0 and
12.0 g
/dL (inclusive) outside of the US, as  determined by [CONTACT_144372] 2 HGB  values
mea
sured by [CONTACT_245933]
5. Serum ferritin ≥100 ng/mL and TSAT ≥20% at Screening
6. Folate and vitamin B 12 measurements ≥lower limit of normal (LLN) at  Screening
7.
Understands the procedures and requirements of the study and provides written informed
consent and authorization for protected health information disclosure.
7.3 Exclusion Criteria 
Subjects presenting with any of the following will not qualify for entry into the study: 
1. Anemia due to a cause other than CKD or subjects with active bleeding or recent blood loss
2. Subjects with 
sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis,
hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
3. RBC transfusion within 4 weeks prior to or during Screening
4.
Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine
a
minotransferase (ALT )/serum glutamic pyruvic transaminase (SGPT), or total bilirubin
>2.0 x upper limit of normal (ULN) at Screening.  Subjects with a history o f Gilbert’s
syndrome are not excluded.
5. Uncontrolled hypertension (confirmed diastolic blood pressure >110 mmHg or systolic blood
pressure >180 mmHg) at Screening
6.
Severe heart failure at Screening ([LOCATION_001] Heart Association Class IV)
7. Acute coronary syndrome (hospi[INVESTIGATOR_252587]),
urgent coronary revascularization, hospi[INVESTIGATOR_245045], or stroke within 12 weeks prior to
S
creening
8. History of active malignancy within 2 years prior to Screening, except for curatively resected
basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or
resected benign colonic polyps
9. History of DVT or PE requiring active treatment within 8 weeks prior to Screening

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 32 of 80 10.
History of hemosiderosis or hemochromatosis
11. History of prior organ transplantation or scheduled organ transplant (subjects on kidney
tra
nsplant wait-list are not excluded), or prior stem cell or bone marrow transplant (cornea l
transplants are not excluded)
12. Use of an investigational medication or participation in an investigational study within
30 days or 5 half-lives of the investigational medication (whichever is longer), prior to the
Screening
 visit
13. Previous participation in this study, receipt of vadadust at in another study, or previous
pa
rticipation in a study with another hypoxia-inducible factor prolyl-hydroxylase inhibitor
(HIF-PHI)
14. Females who are pregnant or breast-feeding.  Women of childbearing potential who are
unable or unwilling to use an acceptable method of contraception (refer to Section 9.1.3,
C
ontraception and Pregnancy Avoidance Measures )
15. Non-vasectomized male subjects who are unable or unwilling to use an acceptable method of
contraception (refer to Section 9.1.3, Contraception and Pregnancy Avoidance Measures )
16.
Any other reason that in the opi[INVESTIGATOR_394624].
7.4 Retesting and Rescreening 
Subjects who fail to qualify for the study based on certain laboratory parameters may be retested 
and/or rescreened at the discretion of the Investigator. 
7.4.[ADDRESS_495604] their 
laboratory value retested 1 time within the 28-day Screening period at the discretion of the 
Investigator.  Retesting within the 28-day Screening period does not constitute rescreening; 
however, if retesting falls outside of the [ADDRESS_495605] qualifying 
re
peat measurement and the Baseline visit. 
F
or eligibility purposes, if HGB at SV1 is 11.1-11.5 g/dL in the US or 12.1-12.5 g/dL outside of 
the U
S, [ADDRESS_495606] HGB is >11.0 g/dL in the US 
or >
12.0 g/dL outside the US, the subject should not proceed with SV2.  If the HGB at SV1 is 
>11.5 g/dL in the US or >12.5 g/dL outside of the US, the subject should not proceed with any
fur
ther Scre
ening at this time.
7.4.[ADDRESS_495607]’s status has progressed and that the subject may now qualify for the study.  Additionally, 
subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B 12 va lues may 
be considered for rescreening after receiving replacement therapy. 
Screening is limited to 3 attempts (Screening and 2 additional rescreening attempts).  If IV iron 
is used to replete iron stores, the last dose of IV iron must be administered at least 4 weeks prior 
to rescreening. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495608] will be considered as having completed the study, regardless of whether they are on or 
off
 study medication (vadadustat or darbepoetin alfa), if the subject is followed until the global 
study end date as determined by [CONTACT_245935] (see Section 11.1.2 , S ample Size for the 
Primary Safety Endpoint ).  A post-treatment follow-up either in person or via telephone should 
oc
cur approximately [ADDRESS_495609] withdrawal from the study or study medication (vadadustat or darbepoetin alfa). 
7.5.[ADDRESS_495610] Discontinuation 
During the course of this long-term study, it is anticipated that subjects may temporarily interrupt 
or permanently discontinue study medication (vadadustat or darbepoetin alfa) or study 
participation for any of the following reasons: 
Unacceptable toxicity or drug intolerability
Investigator discretion
Subject withdrawal of consent
Subject becomes pregnant
Development of end-stage kidney disease and initiation of ongoing chronic hemodialysis,
peritoneal dialysis, or receipt of a kidney transplant.  (Note that a subject who receives
transient acute  dialysis may still continue study medication per Investigator discretion.)
Othe
r reasons.
Subjects who temporarily interrupt or permanently discontinue study medication (vadadustat or 
darbepoetin alfa) early or are withdrawn from the study prior to Week 52 should continue with 
the Schedule of Activities and safety assessments through Week 52 and should be followed for 
safety assessments only after Week 52.  Subjects who stop study medication after Week 52 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 34 of 80 should be followed for safety assessments only for the remainder of the study (See 
Sections [IP_ADDRESS] , Temporary Interruption of Study Medication  and [IP_ADDRESS] , Permanent 
Discontinuation of Study Medication , and Appendix A:  Schedule of Activities ). 
R
eceipt of rescue therapy is not a reason for permanent study medication discontinuation.  While 
re
ceiving ESA rescue, subjects must temporarily discontinue study medication (vadadustat or 
darbepoetin alfa), but should resume study medication once rescue therapy has ended, as detailed 
in S
ection 8.4.7, Rescue Therapy .  
As part of the informed consent process, only subjects who fully understand and agree to full 
participation and long-term follow-up should be consented to participate. 
[IP_ADDRESS]
 Temporary Interruption of Study Medication 
Subjects who temporarily interrupt study medication (vadadustat or darbepoetin alfa) treatment 
after the first dose and prior to completion of the study will continue with study visits and 
assessments.  Unless contraindicated, treatment should be resumed wherever possible and 
routinely considered at every visit following study medication discontinuation.  If a subject does 
not return for a scheduled visit, every effort should be made to contact [CONTACT_423]. 
[IP_ADDRESS] Permanent Discontinuation of Study Medication 
If a subject wishes to discontinue study medication (vadadustat or darbepoetin alfa) or withdraw 
from the study, the Investigator should encourage continued study participation, as described in 
Section [IP_ADDRESS], Procedures to Encourage Continued Study Participation .  A subject who 
permanently discontinues treatment will be recorded as a discontinuation on the case report form 
(CRF), and the Investigator must document the primary reason for the discontinuation. 
Subjects who permanently discontinue study medication early or are withdrawn from the study 
prior to Week 52 should continue with the Schedule of Activities and safety assessments through 
Week 52 and should be followed for safety assessments only after Week 52.  Subjects who stop 
study medication after Week 52 should be followed for safety assessments only for the 
remainder of the study (See Appendix A:  Schedule of Activities ). 
For subjects who permanently discontinue study medication, the Investigator should resume 
standard of care treatment, including ESAs and iron therapy, as deemed appropriate. 
[IP_ADDRESS] Complete Withdrawal from Further Study Visits/Assessments 
Subjects may request to be withdrawn from the study or may be withdrawn prior to completion 
only for the following reasons of: 
Death
Withdrawal of informed consent (complete withdrawal of consent requires a subject’s
refusal of ALL methods of follow-up noted in the informed consent form:  procedures,
participation in reduced procedures/study visits, telephone contact [CONTACT_245953], source document or designated alternative contact, or access to medical
records from alternative sources)
Lost to follow-up (detailed procedures to prevent subjects from becoming lost to
follow-up are provided in Section [IP_ADDRESS] , Procedures to Prevent “Lost to Follow-up” ,

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495611] be followed by [CONTACT_32366], their staff, and all designated 
study personnel). 
[IP_ADDRESS] Procedures to Encourage Continued Study Participation 
In all cases of impending study drug discontinuation or subject request for withdrawal, the 
Investigator should discuss with the subject their options of continuing in the study.  If a subject 
wishes to discontinue study medication (vadadustat or darbepoetin alfa) or to withdraw from the 
study, the following procedures should take place: 
1. The Investigator should understand the subject’s motivation to discontinue or withdraw ( eg,
study visit fatigue, study medication intolerability, etc) and wherever possible make
accommodations to prevent treatment discontinuation or complete withdrawal of consent and
to maintain the fullest compliance with the protocol assessments (eg, provide necessary
travel reimbursement, in-home visits, alternate visit scheduling, including during weekends).
If the subject’s wish is to discontinue study medication only, proceed to Step 2.
2. Ask the subject, “Would you be willing to continue if your dose of medication was
lowered?”  If the answer is “Yes”, titrate the subject’s dose down [ADDRESS_495612] withdrawal of consent.  If the answer is “No” or if, once the lowest dose
is reached, the subject continues to request discontinuation from study medication, proceed to
Step 3.
3. Ask the subject, “If we temporarily interrupt your study medication would you be willing to
later resume medication and continue with all visits and sample collections?”  If the answer
is “Yes”, interrupt study medication but continue to follow all other study procedures for the
subject until they restart treatment.  If the answer is “No”, proceed to Step 4.
4. Ask the subject, “If we discontinue your study medication permanently, would you continue
with all visits and sample collections?”  If the answer is “Yes”, discontinue study medication,
continue with all other assessments until Week 52, and then continue with safety assessments
onl
y for the remainder of the study after Week 52.  If the answer is “No”, proceed to Step 5.
5.
If further study support, interruption, or permanent discontinuation of study medication does
not resolve the subject’s issues, further accommodations such as less frequent visits or blood
draws may be used, so long as adequate safety monitoring can be ensured for those
continuing study medication treatments.  Less frequent visits or procedures should be offered
only if they are required to maintain access to the subject’s medical information and/or to
encourage the subject to continue in the study.  For subjects who are no longer on study
medication after Week 52, study visits can be reduced to every 24 weeks for safety
assessments only either in person or via telephone.
[IP_ADDRESS] Procedures to Prevent “Lost to Follow-up” 
The Investigator must make every effort to contact [CONTACT_394656] “lost to follow-up.”  These actions must include, but are 
not limited to, the following: 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495613] and their listed contacts (to be collected in source at the
subject’s entry into the study), as applicable.  This includes making calls after normal
busi
ness hours or on holidays and weekends.
2.
Contact [CONTACT_423]’s primary care physician, referring specialist, pharmacist, and/or other
he
althcare professional (using the contacts provided by [CONTACT_245956]), as
a
pplicab le
3. Send a text, email, and postal mail with certified (return- receipt requested) letters to the
subject’s addresses and all contacts, as applicable
4. Review available medical records/notes for details of hospi[INVESTIGATOR_602], clinic visits, or other
procedures which may indicate the status of the subject (as allowed through release of
medical record f
orms to be completed by [CONTACT_245957]), as applicable
5. Utilize the internet to search for additional contact [CONTACT_3031] (eg, reverse directory for
phone numbers or new address information, Facebook, LinkedIn, or other social media for
status update
s), as applicable
6. Check local, regional, and national public records to locate the subject or search for mortality
status as allowed by [CONTACT_2371], as applicable.
Once these actions have been exhausted and documented, the Sponsor’s clinical research 
associate or Medical Monitor should be contact[CONTACT_245939]. 
[ADDRESS_495614], Supplies, and Storage 
Oral vadadustat and darbepoetin alfa for injection will be provided and shipped by [CONTACT_394657]/distributor.  Both vadadustat and darbepoetin alfa will be supplied as 
open-label supplies.  All study medication supplies must be kept in a temperature-controlled, 
locke
d facility, accessible only to authorized study personnel. 
Cosyntropin for the adrenal function substudy will be sourced by [CONTACT_3878]. 
The
 Investigator or designated study personnel will be responsible for preparing study 
medication for dispensing to the subject (Section 8.2, Dispensing Procedures )  and for study 
medic
ation supply accountability (Section 8.[ADDRESS_495615] Accountability and Destruction ). 
8.1.1 Va dadustat 
Vadadustat will be provided as 150 mg white to off-white, round, bi-convex film-coated tablets 
for
 oral administration
.  The tablets will be packaged in high-density polyethylene bottles with 
c
hild-resistant closures, polypropylene liner, and induction seal.  Labeling will be in accordance 
with current Good Manufacturing Practices (GMP) and local regulatory requirements. 
Dose
 levels utilized in this study will include:  150 mg (1 tablet), 300 mg (2 tablets), 450 mg 
(3 tablets), and 600 mg  (4 tablets) per day. 
Vadadustat should be stored at a controlled room temperature of 15°-30°C (59°-86°F). 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495616] during the study.  Subjects will receive either 
vadadustat ta
blets or darbepoetin alfa according to the randomization assignments provided via 
the IWR system (see Section 8.4.2, Randomization ). 
8.2.[ADDRESS_495617]’s current vadadustat supply at a given study visit 
(Section [IP_ADDRESS], Vadadustat Dosing and Dose Adjustment Guidelines ).  Subj ects will be 
instructed to finish 1 bottle before opening a new bottle. 
At the Baseline visit, study subjects will be provided with 1 bottle of vadadustat.  Each bottle of 
va
dadustat will contain 100 tablets of vadadustat (150 mg tablets). 
S
ubjects should be instructed to bring unused vadadustat and empty bottles to each study visit for 
produ
ct accountability.  Empty bottles will be collected at these study visits.  Previously 
dispensed bottles (whether opened or unopened) with remaining tablets may be redispensed to 
the subject during the dosing phase of the study. 
8.2.2 Dispe nsing of Darbepoetin Alfa 
The initial darbepoetin alfa dose will be determined as follows: 
F
or subjects already on darbepoetin, the initial dosing regimen in the study should be
based on the prior dosing regimen.
For subjects taking other ESAs, the initial dose of darbepoetin should be based on the
approved local product label.
Dispe
nsing of additional darbepoetin alfa at subsequent dosing visits will be managed by [CONTACT_245959] (Section [IP_ADDRESS], Darbepoetin Alfa Dosing and Dose Adjustment Guidelines ). 
[ADDRESS_495618] accountability should be an ongoing process throughout the study.  All study medication 
(vadadustat and darbepoetin alfa) must be accounted for and any discrepancies explained.  The 
I
nvestigator or designated study personnel are responsible for keepi[INVESTIGATOR_394625] 
c
linical supplies received from the Sponsor, all supplies retained in inventory at the investigative 
site, and study medication dispensed to or returned from each subject.  Records will be 
maintained that accurately reflect the drug accountability of vadadustat and darbepoetin alfa at 
all times. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 38 of 80 P
roper drug accountability includes, but is not limited to: 
Continuously monitoring expi[INVESTIGATOR_394626]
I
nvestigator
Frequently verifying that actual inventory matches documented inventory
Verifying that the log is completed for all drug received and that all required fields are
complete, accurate, and legible.
If any dispensing errors or discrepancies are discovered, the Sponsor must be notified 
im
mediately. 
During the study, the Investigator will be notified of any expi[INVESTIGATOR_394627].  If an expi[INVESTIGATOR_113982], the 
investigative site must complete all instructions outlined in the notification, including 
se
gregation of expi[INVESTIGATOR_245894]. 
Prior to investigative site closure and at appropriate intervals during the study, a representative 
fr
om the Sponsor will perform clinical study material accountability and reconciliation. 
At the end of the study, the Investigator will retain a ll original documentation regarding clinical 
stud
y material accountability, return, and/or destruction, and copi[INVESTIGATOR_245895]. 
All unused and/or partially used vadadustat or darbepoetin alfa should be returned to the Sponsor 
or de
stroyed at the investigational site, as specified by [CONTACT_1034].  Appropriate records of the 
disposal will be documented and maintained.  No unused vadadustat or darbepoetin alfa may be 
dispo
sed of until fully accounted for by [CONTACT_1034] ’s monitor (or designee).  Empty containers 
ma
y be disposed of according to local procedures. 
8.4 Treatment of Subjects 
8.4.1 Tr eatment Group Assignments 
Subjects will be randomized in a 1:1 ratio via the IWR system to either: 
Va
dadustat (starting dose of 2 tablets once daily [300 mg/day])
Da
rbepoetin alfa (starting dose based on the approved local product label)
F
or all subjects, it is recommended that no additional ESA doses be administered after SV2 and 
prior to the Randomization visit. 
Target enrollment for each treatment group is approximately 1050 subjects. 
8.4.2 R andomization 
This study will be open to approximately 2100 subjects with NDD-CKD with an eGFR 
≤60
 mL/min/1.73 m2 (pre-dialysis). 
Using an  IWR system, eligible subjects will be assigned using permuted block randomization 
a
nd a 1:[ADDRESS_495619] to:  1) geographic region (US versus EU versu s 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 39 of 80 R
OW); 2) [LOCATION_001] Heart Association CHF Class (0 or I versus II or III); and 3) study entry 
HGB  lev
el (<10.0 versus ≥10.0 g/dL, based on the most recent central laboratory HGB 
mea
surement prior to the Baseline/Randomization visit ). 
8.4.3 B linding 
This will be an open-label study.  Treatment assignment will be done through the IWR system 
a
nd the Investigator will not be aware of which treatment will be assigned next.  Treatments will 
be
 administered in an open-label fashion; however, the Sponsor and CRO study teams will be 
blinded to the randomization codes.  In addition, the study will involve blinded adjudication of 
MACE, the use of an IDMC, and an identical schedule of visits, procedures, and assessments for 
both treatment groups in order to reduce the potential for bias.  However, certain personnel 
directly involved in medical oversight of the study, regulatory reporting of safety information, 
and on-site monitoring activities may become unblinded to the treatment assignments of 
individual subjects during the course of the study. 
In geographies where regulatory approval does not require a formal analysis of MACE, efficacy 
and safety analyses may be performed upon the completion of [ADDRESS_495620]-randomization 
follow-up in a sufficient number of subjects to support registration in that geography.  The 
unblinding of the treatment assignments for this analysis will be detailed in the Statistical 
Analysis Plan (SAP).  The EAC will remain blinded throughout the full course of the study. 
8.4.[ADDRESS_495621] dose of study medication (vadadustat 
or darbepoetin alfa) will be administered at the investigative site after other Baseline visit 
procedures have been completed.  For all subjects, it is recommended that no additional ESA 
dose
s be administered after SV2 and prior to the Randomization visit. 
Hemoglobin will be monitored via HemoCue® throughout the study to determine if the dose of 
study medication (vadadustat or darbepoetin alfa) will be adjusted.  From Weeks 0 to 12, HGB 
will
 be obtained via HemoCue® every 2 weeks for monitoring for dose adjustment.  From 
W
eek 12 to Week 52, HGB will be monitored every 4 weeks via HemoCue®.  From Wee k 53 
throug
h the study end, HGB will continue to be monitored via HemoCue® to determine if the 
dose of study medication will be adjusted or suspended.  Hemoglobin will also be assessed with 
a
 CBC through the central laboratory for efficacy and safety evaluations; however, dose 
a
djustments should be based on the HemoCue® HGB value. 
The aim is to maintain a HGB level of 10-11 g/dL in the US and 10 -12 g/dL outside of the US 
throughout the study. 
Adjustments to doses for vadadustat and darbepoetin alfa will be guided by [CONTACT_394658].  The programmed 
Dose Adjustment Algorithm for vadadustat will follow the Dose Adjustment Guidelines (see 
below).  The programmed Dose Adjustment Algorithm for darbepoetin alfa will be based on the 
local product label. 
When adjusting therapy, consider HGB rate of rise, rate of decline, and variability, as well as the 
subject’s clinical condition (ie, recent illness, volume depletion, volume overload, etc).  In cases 
of extenuating clinical circumstances, the Investigator may elect to dose outside the IWR system 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495622]’s record and collected in the CRF. 
[IP_ADDRESS] Vadadustat Dosing and Dose Adjustment Guidelines 
Subjects assigned to vadadustat will initiate dosing at 2 tablets once daily (300 mg/day).  Dose 
leve
ls of vadadustat utilized in this study include 150, 300, 450, and 600 mg (available tablet 
strength is 150 mg). 
Dosing
 will be initiated at the Baseline visit and the first dose of vadadustat will be administered 
a
t the investigative site (study physician’s clinic) after other Baseline visit procedures have been 
c
ompleted.  Thereafter, vadadustat will be taken once daily on an outpatient basis.  Subjects may 
take
 vadadustat with or without food and should be instructed to swallow the tablet(s) whole.  
S
ubjects should be instructed to take vadadustat at roughly the same time each day, preferably 
be
tween 7 AM and 2 PM. 
During the study, vadadustat should be dosed according to the following Dose Adjustment 
Guide
lines. 
F
or subjects enrolled in a US i nvestigative site , the following guidelines should be followed: 
Do not incr
ease the dose more frequently than once every 4 weeks.  Decreases in dose
can occur more frequently.  Avoid frequent dose adjustments.
If a dose adjustment is required to maintain HGB at the desired level, the vadadustat dose
is adjusted by 1 tablet (minimum dose of vadadustat is 150 mg/day [1 tablet]; maximum
dose
 of vadadustat is 600 mg/day [4 tablets]).
I
f the HGB rises rapi[INVESTIGATOR_375] (eg, > 1.0 g/dL  in any 2-week period), reduce the dose of
va
dadustat by 1 tablet.
I
f the HGB falls below 10.0 g/dL , incr ease the dose of vadadustat by 1 tablet.
I
f the HGB level exceeds 11.0 g/dL , int errupt vadadustat until the HGB decreases to
10.5 g/dL or less then resume dosing of vadadustat with 1 fewer tablet.
F
or subjects enrolled in in vestigative sites outside of the US  (non-US), the following guidelines 
shoul
d be followed: 
Do not increase the dose more frequently than once every 4 weeks.  Decreases in dose
can occur more frequently.  Avoid frequent dose adjustments.
If a dose adjustment is required to maintain HGB  at the desired level, the vadadustat dose
is adjusted by 1 tablet (minimum dose of vadadustat is 150 mg/day [1 tablet]; maximum
dose
 of vadadustat is 600 mg/day [4 tablets]).
I
f the HGB rises rapi[INVESTIGATOR_375] (eg, > 1.0 g/dL  in any 2-week period), reduce the dose of
va
dadustat by 1 tablet.
I
f the HGB falls below 10.0 g/dL , incr ease the dose of vadadustat by 1 tablet.
I
f the HGB level exceeds 12.0 g/dL , reduce the dose of vadadustat by 1 tablet.  If the
HGB  level exceeds 13.0 g/dL , int errupt vadadustat until the HGB  decreases to 12.5 g/dL
or le
ss then resume dosing of vadadustat with 1 fewer tablet.

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 41 of 80 [IP_ADDRESS]
 Darbepoetin Alfa Dosing and Dose Adjustment Guidelines 
F
or subjects randomized to receive darbepoetin alfa, the initial dose will be determined as 
follows:
 
For subjects already on darbepoetin, the initial dosing regimen in the study should be
based on the prior dosing regimen.
For subjects taking other ESAs, the initial dose of darbepoetin should be based on the
approved local product label.
Ea
ch subject will receive their first dose of darbepoetin alfa at the Baseline visit.  Subsequent 
a
dministration of darbepoetin alfa may occur at the clinic or may be self-administered at home 
per regional standard of care.  Darbepoetin alfa dosing is independent of the visit schedule, and 
the dosing
 schedule may shift per local standard of care and country-specific darbepoetin alfa 
dosing guidelines. 
8.4.[ADDRESS_495623] experienced any problems related to the dosing of study medication (vadadustat or 
da
rbepoetin alfa). 
8.4.6 I ron Supplementation 
Investigators should prescribe iron supplementation as needed during the study to maintain 
ferritin ≥100 ng/mL and TSAT ≥20%.  In general, only oral iron should be used for therapy.  
I
ntravenous iron use is restricted and should only be administered to subjects who have 
doc
umented intolerance to oral iron and are iron deficient (eg, ferritin <100 ng/mL and/or 
TSAT <20%).  Discontinuation of IV iron is required once the subject is no longer iron deficient 
(ie
, ferritin ≥100 ng/mL and TSAT ≥20%). 
Important:  Because of the potential for iron to reduce the bioavailability of vadadustat, the 
study medication should not be administered concurrently with an oral iron supplement 
(including multivitamins containing iron).  The subject should be instructed to take any oral iron 
supplement at least 2 hours before or 2 hours after the dose of vadadustat. 
8.4.7 Rescue Therapy 
To ensure the safety of study subjects and to standardize the use of rescue in the study, rescue 
therapy guidelines are provided. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 42 of 80 [IP_ADDRESS]
 ESA Rescue (Optional) 
Starting at Week 6, subjects in both treatment arms will be allowed (although will not be 
re
quired) to have their HGB rescued with ESA therapy per the local standard of care.  Drug 
produ
ct and supplies for ESA rescue will not be provided by [CONTACT_1034]. 
If possible, a subj ect on vadadustat should be on a maximum dose of vadadustat for [ADDRESS_495624] fulfill ALL of the following: 
The
 subject has experienced a clinically significant worsening of their anemia or
s
ymptoms of anemia (eg, fatigue, weakness, shortness of breath, chest pain, confusion, or
diz
ziness) compared with Baseline
The subject’s HGB is <9.0 g/dL
Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a
goal.
The ESA rescue therapy should be administered as per the local institution’s guidelines and per 
the approved local product label.  While receiving ESA rescue therapy, subjects must 
temporaril y discontinue taking study medication (vadadustat or darbepoetin alfa).   Hemoglobin 
will be monitored throughout the study at scheduled visits as defined in the Schedule of 
Activities using HemoCue®, and ESA rescue treatment should be stopped when HGB is 
≥
9.0 g/dL.  A minimum interval must be observed prior to restarting vadadustat after the last 
dose
 of rescue medication, and treatment may be resumed after the following intervals: 
[ADDRESS_495625] dose of epoetin rescue
[ADDRESS_495626] dose of darbepoetin alfa rescue
[ADDRESS_495627] dose of methoxy polyethylene glycol-epoetin beta rescue.
F
ollowing ESA rescue, the study medication should be resumed at the same dose as previously 
used and adjusted according to the Dose Adjustment Guidelines (Section 8.4.4, Dosing and Dose 
Adjust
ment Guidelines ). 
[IP_ADDRESS] Red Blood Cell Transfusion 
Investigators should use their local institution’s transfusion guidelines when determining whether 
to transfuse a study subject.  In general, in the event of an acute or severe loss of blood, a RBC 
tra
nsfusion should be administered as clinically indicated.  In less severe instances but where 
there may be worsening of anemia or moderate to severe symptoms of anemia, RBC transfusions 
are permitted at the discretion of the Investigator given the medical necessity.  Study medication 
(vadadustat or darbepoetin alfa) may be continued during the RBC transfusion period. 
8.4.[ADDRESS_495628]’s HGB exceeds 14.0 g/dL or the rate of rise of HGB raises concern to the 
I
nvestigator, the subject may be phlebotomized based on the Investigator’s judgment.  The 
method of phlebotomy will be in accordance with the local institution’s guidelines and standard 
c
linical practice. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495629] experienced any problems related to the dosing of study medication (vadadustat or 
da
rbepoetin alfa).  The Investigator will also maintain drug accountability logs itemizing all 
study medications dispensed to and returned from each subject during the study.  Treatment 
compliance will
 be determined from these forms along with the subject questioning and the study 
medic
ation dispensing CRFs. 
Subjects who miss doses will be counseled on the importance of compliance. 
S
ubjects will also be questioned regarding the timing of their last dose of vadadustat prior to the 
P
K samples at the Week 4, 12, 28, and 52 study visits.  The date and time of these doses will be 
re
corded on the CRF. 
8.4.10 Continuation of Treatment 
Subjects may receive study medication (vadadustat or darbepoetin alfa) up until the EOT visit. 
8.[ADDRESS_495630] participated in a 
study with another HIF-PHI. 
Additionally, subjects should not take another investigational medication while participating in 
this study. 
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITI ES 
Please see Appendix A:  Schedule of Activities  for a detailed table of the Schedule of Activities.  
This s
tudy includes the following visits: 
Optional Pre-Screening
Two Screening visits (SV1 and SV2)
Baseline/Randomization visit (Week 0/ Day  1)
Year 1 Treatment Period Study Visits/Evaluations while receiving study medication:
Weeks 2, 4, 6, 8, 10, 12, and every 4 weeks thereafter until Week 52
Year 2 Treatment Period Study Visits/Evaluations while receiving study medication:
Weeks 64, 76, 88, and 104

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 44 of 80 Ye
ar 3 Treatment Period Study Visits/Evaluations while receiving study medication:
Weeks 116, 128, 140, and 156
Year 4 Treatment Period Study Visits/Evaluations while receiving study medication:
Weeks 168, 180, 192, and 208
EOT visit
F
ollow-u p visit:  [ADDRESS_495631] entering into the study and before any 
protoc
ol-directed procedures are performed (including Screening activities).  Subjects 
pa
rticipating in the optional Pre-Screening visit must sign an abbreviated consent form or full 
consent form prior to Pre-Screening and, if eligible, may proceed with the Screening visit after 
full consent has been obtained (see Section 9.3.[ADDRESS_495632] 
I
nformation and Consent  for additional details).  Additionally, subjects may be asked to provide 
a
 separate, optional consent to obtain and store a blood sample(s) for future genetic analyses. 
A subset of 200 subjects (100 subjects per treatment arm) in the EU will be selected to undergo 
se
quential ACTH (cosyntropin) stimulation testing to monitor adrenal function (see Appendix C : 
ACTH
 (Cosyntropin) Stimulation Test for Adrenal Function Monitoring ) .  A separate optional 
infor
med consent form must be signed at SV1 prior to participation in this substudy. 
9.1.[ADDRESS_495633] is found not to be 
e
ligible for randomization, the reason(s) for ineligibility must be documented by [CONTACT_737]. 
S
creening numbers assigned to subjects who fail Screening will not be re-used. 
9.1.[ADDRESS_495634] dose tested of 160 mg/kg/day.  
Peri-postnatal development studies have not yet been conducted with vadadustat, and there are 
no data on the transmission of vadadustat in breast milk or the effect of vadadustat on infants. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495635] dose of study medication. 
Ade
quate contraception is defined as follows: 
Female subjects must be surgically sterile, postmenopausal (no menses for at least one year), or 
have negative pregnancy test results at Screening (serum). 
Female subjects not surgically sterile or postmenopausal (no menses for at least one year) and 
non-vasectomized male subjects must practice at least 1 of the following methods of birth 
c
ontrol: 
Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior
to Screening visit, throughout the study, and for [ADDRESS_495636] dose of study
medic
ation)
A vasectomized partner
H
ormonal contraceptives (oral, parenteral, or transdermal) for at least 3 months prior to
stud
y drug administration or intrauterine contraception/device
Double-barrier method (such as male condom, female condom, diaphragm, sponge, or
cervical cap together with  spermicidal foam/gel/film/suppository).
9.1.4 Laboratory Accreditation and Reference Ranges 
The Investigator and the Sponsor will maintain a copy of the laboratory accreditation and the 
reference ranges for the central laboratory used for clinical laboratory evaluations.  Additionally, 
other accreditation(s) will be collected as required. 
9.2 Study Procedures and Evaluations 
9.2.1 C linical Evaluations 
The following clinical evaluations will be conducted during the course of the study: 
Medical history, demographics, and physical examination:  Medical history, demographic
information, and physical examination (including height) will be collected at SV2.
R
elevant medical history (with particular emphasis on previous medical conditions that
may lead to exclusion) and significant ongoing medical conditions or diseases should be
documented.  After SV2, an abbreviated, symptom-directed physical examination should
be
 performed at the discretion of the Investigator as clinically indicated.
Vital signs:  Vital signs will include heart rate and blood pressure.  Heart rate and blood
pressure will be assessed in the seated position after [ADDRESS_495637].  Vital signs will be
collected at SV1, SV2, Baseline, during study visits, and EOT and should be taken prior
to bl
ood draws when possible.
Weight:  Weight will be collected for all subjects at SV2, at Weeks 12, 24, 36, and 52,
yearly thereafter, and at the EOT visit.  For subjects on darbepoetin alfa, subjects will be
we
ighed for dosing as per the local standard of care.

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 46 of 80 12-Lead electrocardiogram (ECG):  A standard 12-lead ECG will be performed at
Baseline.  The ECG should be obtained after the subject has been resting comfortably in a
supi
[INVESTIGATOR_73414] [ADDRESS_495638] of the tracing(s) will be made and
retained with other source documents.
Completion of MACE Endpoint Questionnaire:  At each post-randomization study visit,
the subject must specifically be questioned regarding the occurrence of any potential
MACE endpoint event since the last study visit.  IMPORTANT:  The endpoint
questionnaire electronic CRF must be completed in full at each visit even if no
potential MACE endpoints have occurred.   If a potential endpoint event is reported,
the da
te of the event should be recorded and the appropriate source documents should be
collected according to the endpoint packet checklist.
AE Assessments:  Beginning with the first dose of study medication (vadadustat or
darbepoetin alfa) and through the global study end (Follow-up visit), the Investigator and
stud
y personnel will review each subject’s laboratory and clinical evaluation findings and
que
ry the subject directly regarding AEs (see Section 10, Adverse Events ).  Subjects
must be followed for AEs until the final required protocol visit (global study end date) or
until all drug-related toxicities and SAEs have resolved (or are considered
chronic/stable), whichever is later.
Concomitant Medication Recording:  All medications (both prescription and
non-prescription, and including vitamins, herbals, topi[INVESTIGATOR_8593], inhaled, and intranasal) taken
within 30 days prior to the start of study medication (vadadustat or darbepoetin alfa) and
throug
h the EOT visit should be recorded on the appropriate CRF.  At each study visit,
subjects will be a
sked whether they have started or discontinued any medication since
their previous study visit.  This includes single-use or as-needed medication use.  All
medic
ations and treatments, including vitamin supplements, over-the-counter
medications, and oral herbal preparations must be recorded in the CRFs.  In addition, the
ESA and iron treatment regimen prior to randomization and date of last dose will be
re
corded.
9.2.[ADDRESS_495639]
ructions for the collection, processing, and shipment of laboratory samples will be provided 
by [CONTACT_245962].  The Investigator is responsible for reviewing 
labor
atory results for clinical significance. 
The following laboratory evaluations will be conducted during the course of the study: 
Pregnancy test:  A serum pregnancy test will be performed at SV2 for females of
childbearing potential.  Additional serum or local urine pregnancy tests may be
conducted throughout the study in sufficient number, as determined by [CONTACT_245963], to establish the absence of pregnancy during the study.  The
SV2 results must be available and must be negative before the subject takes the first dose
of study medication.

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 47 of 80 CBC:  A CBC with differential will be performed at Baseline and twice annually at
Weeks 28, 52, 76, 104, 128, 156, 180, 208.  At all other noted visits in Appendix A:
Schedule of Activities , including SV1 and SV2, a CBC without differential will be
performed.  The CBC with differential will include:  HGB, hematocrit, RBCs, mean
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), red cell distribution width (RDW), white blood cell
(WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils,
basophils), and platelets.
Hemoglobin assessed by [CONTACT_245964], but should not be used for dose adjustments.  Rather, HGB levels assessed by
[CONTACT_245965]® should be used for dose adjustments, as described in Section 8.4.4, Dosing
a
nd Dose Adjustment Guidelines .
For eligibili ty purposes, if HGB at SV1 is 11.1-11.5  g/dL in the US or 12.1-12.5 g/dL
outsi
de of the US, [ADDRESS_495640] HGB is
>11.0 g/dL in the US or >12.0 g/dL outside the US, the subject should not proceed with
S
V2.  If the HGB at SV1 is >11.5 g/dL in the US or >12.5 g/dL outside of the US, the
subj
ect should not proceed with any further Screening at this time.  Refer to
S
ections 7.4.1 , Retesting  and 7.4.2 , Rescreening  for further details regarding repeating
labor
atory measurements during the Screening period.
Point of care HGB:  Using HemoCue®, HGB will be monitored throughout the study to
determine if the dose of study medication (vadadustat or darbepoetin alfa) will be
adjusted or suspended as described in Section 8.4.4 , Dosing and Dose Adjustment
Guide
lines .
Reticulocyte count:  An automated reticulocyte count (both absolute and percent) will be
performed at Baseline and at Weeks 4, 12, 28, and 52.
Coagulation tests:  Blood samples will be drawn at Baseline to assess the prothrombin
time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR).
Folate and Vitamin B 12:  A blood sample will be drawn at SV2 to assess the folate and
Vitamin B12 levels. 
Urine albumin- to-creatinine ratio (uACR):  A random urine spot sample should be
collected at the investigative site during the Baseline visit to provide the uACR.  Subjects
should refrain from heavy exercise [ADDRESS_495641].
C-reactive protein:  A blood sample for C-reactive protein will be collected at the
Baseline visit. 
Serum Chemistry:  Blood samples to assess serum chemistry will be collected at SV2,
Baseline, and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208.  At all other
noted visi
ts in Appendix A:  Schedule of Activities , serum creatinine and eGFR will be
performed.  The serum chemistry will include the following assays:  sodium, potassium,
bicarbonate, chloride, calcium, magnesium, phosphorus, glucose, creatinine, blood urea
nitrogen (BUN), creatine phosphokinase (CPK), uric acid, albumin, and total protein.

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 48 of 80 Note:  When a ≥50% decline in eGFR from the Baseline value is observed, a repeat 
central laboratory measure should be performed within 30 to 60 days. 
Liver Function Tests:  Blood samples to assess liver function will be collected at SV2,
Baseline, every 4 weeks through Week 28, every 8 weeks from Week 28 to Week 52, and
twice annually from Week 53 through the end of the study.  Blood samples will also be
c
ollected at the EOT visit.  Liver function tests will include: total bilirubin, alkaline
phosphatase, ALT/SGPT, AST/SGOT, and lactate dehydrogenase (LDH).
Iron indices:  Blood samples to assess the iron indices will be collected at SV1, Baseline,
every 4 weeks through Week 12, every 8 weeks from Week 12 to Week 52, and every
12 weeks from Week 53 through the end of the study.  Blood samples will also be
c
ollected at the EOT visit.  Assessments will include the following indices:  ferritin, iron,
TIBC, and TSAT.
Lipid Profile:  Blood samples will be collected at the Baseline, Week 28, and Week 52
visits to assess the cholesterol levels and will be tested for the following types of lipi[INVESTIGATOR_805]:
total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and
triglycerides.
Biomarkers (hepcidin, vascular endothelial growth factor [VEGF]):  Samples for
biomarker analysis will be drawn at the Baseline, Week 12, Week 28, and EOT visits.
EPO:  Blood samples for EPO analysis will be obtained at Baseline and at Weeks 4, 12,
28, and  52.
PK Evaluations (samples to be drawn only for subjects randomized to vadadustat):
Plasma samples for PK evaluation will be collected to analyze for both the parent
compound (vadadustat) and its metabolites.  Collection time points for PK will include
Weeks 4, 12, 28, and 52.
Samples should be collected along with the other laboratory samples being collected at
the study visit.  Subjects will be questioned regarding the timing of their last dose of
vadadustat prior to the collection of PK samples.  The date and time of these doses will
be
 recorded by [CONTACT_30107].
Exploratory Samples:  Additional blood and urine samples will be collected at Baseline
and Week 28 which may be used for exploratory measurement of biomarkers (eg, factors
re
lating to the activation of the HIF pathway).  Subjects will also be asked to provide
optional consent to obtain and store a blood sample for future genetic analyses (eg, DNA,
mRNA).
ACTH (Cosyntropin) Stimulation Test:  An ACTH (cosyntropin) stimulation test will be
performed at Baseline and at Weeks 12 and 52 (or at the EOT visit if the subject
permanently discontinues study medication early prior to the Week 52 study visit) in a
subset of
 [ADDRESS_495642], serum cortisol will be
measured prior to cosyntropin administration, and again 30 and 60 minutes after
cosyntropin administration.  Cosyntropin will be administered 0.25 mg (full vial) IV
push.  Depending on the results of the test, early morning cortisol and ACTH
measurements may be required to confirm the clinical significance of the results in

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 49 of 80 indi
vidual subjects (see Appe ndix C :  ACTH (Cosyntropin) Stimulation Test for Adrenal 
F
unction Monitoring ). 
9
.3 Schedule of Activities 
The Schedule of Activities (see Appe ndix A:  Schedule of Activities ) shows the timing of 
planned study procedures.  Every effort should be made to adhere to this procedure schedule and 
a
ll assessments should be completed at each study visit. 
9.3.[ADDRESS_495643] a HemoCue® HGB prior to proceeding with full Screening.  Subjects will need to 
sig
n an abbreviated Pre-Screening informed consent form or full consent form prior to 
Pre-
Screening.  If the Pre-Screen HemoCue® HGB is between 8.0 and 11.0 g/dL (inclusive) in 
the U
S or between 9.0 and 12.0 g/dL (inclusive) outside the US, the investigative site may 
proc
eed with SV1, which preferably will occur on the same day as Pre-Screening. 
9.3.2 S creening Visits 
Subjects will need to sign a full consent form prior to Screening.  The Screening period is a 
maximum of 28 days in duration.  Two Screening visits (SV1 and SV2) must be performed 
within 28 days prior to dosing (Baseline visit or Day 1).  There must be a minimum of 4 days 
be
tween the 2 Screening visits and a minimum of 4 days between SV2 and the Baseline visit. 
The
 Investigator will maintain a log of subjects (both Pre-Screened and S cre ened) and indicate 
who of the Pre-Screened subjects were brought in for informed consent and Screening and who 
of the
 Screened subjects were enrolled or excluded and the reason for exclusion. 
Af
ter obtaining informed consent and receiving a unique subject identification number, subjects 
will
 undergo a number of Screening activities. 
[IP_ADDRESS] Screening Visit 1 (SV1) 
At SV1, the following activities/procedures will be performed: 
I
nformed consent (including an additional optional consent for blood samples for future
g
enetic analyses.  Also includes an additional optional consent for a substudy of adrenal
func
tion in a subset of 200 subjects in the EU.)
R
eview of eligibility criteria
Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495644] and prior to blood draws)
L
aboratory procedures:
oCBC (without differential)
oIron indices.
If the HGB at SV1 is 11.1-11.5 g/dL in the US or 12.1-12.5 g/dL outside of the US, [ADDRESS_495645] HGB is >11.0 g/dL in the US or >12.0 g/dL 
outsi
de the US, the subject should not proceed with SV2.  If the HGB at SV1 is >11.5 g/dL in the 
US or >
12.5 g/dL outside of the US, the subject should not proceed with any further Screening at 
this time.  Refer to Sections 7.4.1, Retesting  and 7. 4.2 , Rescreening  for further details regarding 
repeating laboratory measurements during the Screening period. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 50 of 80 [IP_ADDRESS]
 Screening Visit 2 (SV2) 
At SV2, the following activities/procedures will be performed: 
Review of eligibility criteria
Physical examination
Demographics and medical history
Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495646] and prior to blood draws), as well as height and weight
L
aboratory procedures:
oFolate and vitamin B 12 levels
oC
BC (without differential)
oS
erum chemistry including serum creatinine and eGFR
oL
iver function tests
oSerum pregnancy test for females of childbearing potential (eligible subjects will
be
 advised to use an adequate contraceptive method)
Prior and current medication use.
The mean of [ADDRESS_495647] be between 8.0 and 11.0 g/dL 
(inc
lusive) in the US or between 9.0 and 12.0 g/dL (inclusive) outside the US to qualify for 
inclusi
on into the trial.  If the subject’s HGB does not qualify after SV1 and/or SV2 +/- [ADDRESS_495648] should be considered a Screen failure. 
[IP_ADDRESS] Subject Retesting 
Subjects who initially fail to qualify for the study based on laboratory test results may be retested 
once within the 28-day Screening period, per Investigator discretion (Section 7.4.1, Retesting ) . 
9.3.[ADDRESS_495649]’s status has progressed and that the subject may now qualify for the study.  Additionally, 
subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B 12 va lues may 
be considered for rescreening after receiving replacement therapy.  Screening is limited to 
3 attempts (Screening and 2 additional rescreening attempts) (Section 7.4.2, Rescreening ). 
9.3.4 B aseline Visit (Day 1) 
The Baseline visit must be performed within 28  days of the 2 Screening visits (SV1 and SV2) 
and a minimum of [ADDRESS_495650] Screening visit (SV2) and the Baseline 
visit. 
At the B
aseline visit, the following activities/procedures will be performed: 
Randomization
12-lead ECG (prior to vital sign assessments and blood draws)
Vital si
gns including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495651] and prior to blood draws)
L
aboratory Procedures:
oRandom spot urine sample for uACR

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 51 of 80 oC
oagulation Tests
oC-reactive protein
oCBC (including differential)
oReticulocyte count
oSerum chemistry including serum creatinine and eGFR
oL
iver function tests
oIron indices
oLipid profile
oEPO
oBiomarkers (hepcidin, VEGF)
oExploratory samples
oACTH (cosyntropin) stimulation test (for a subset of subjects in the EU)
R
eview of medical history for new conditions since Screening visit
Medication use since Screening visit
Study medication assessments and procedures:
oSubject will take their first dose of study medication at the investigative site
during the Baseline visit
oHGB by [CONTACT_245965]® for dose initiation
oVadadustat dispensing
oDa
rbepoetin alfa dispensing (per local product label)
oOral iron supplementation as needed to maintain ferritin ≥100 ng/mL and
TS
AT ≥20% (per local product label; see Section 8.4.6 , I ron Supplementation )
AE assessment as needed (after receiving the first dose of study medication).
9.3.5 Ye ar 1 Treatment Period Visits (Day 2 through Week 52) 
Dur
ing the Year 1 Treatment Period visits at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 
44, 48, a
nd 52, the following activities/procedures will be performed: 
Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495652] and prior to blood draws)
W
eight (Weeks 12, 24, 36, and 52)
Laboratory procedures:
oCBC (Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ;
diff
erential at Weeks 28 and 52)
oReticulocyte count (Weeks 4, 12, 28, and 52)
oSerum chemistry (Weeks 28 and 52)
oSerum creatinine and eGFR (Weeks 4, 8, 12, 20, 36, and 44; also at Weeks 28
and 52 as part of the serum chemistry)
oL
iver function tests (Weeks 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52 )
oIron indices (Weeks 4, 8, 12, 20, 28, 36, 44, and 52)
oL
ipid profile (Weeks 28 and 52)
oEPO (Weeks 4, 12, 28, and 52)
oBiomarkers (Weeks 12 and 28)
oPK (Weeks 4, 12, 28, and 52; see Section 9.2.2, La boratory Evaluations ; samples
to be drawn only for subjects randomized to vadadustat)
oExploratory samples (Week 28)

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 52 of 80 oACTH (
cosyntropin) stimulation test (Weeks 12 and 52 for a subset of subjects in
the E
U)
Record date and time of subject’s last dose of vadadustat prior to the PK sample
(Weeks 4, 12, 28, and 52)
S
afety assessments:
oAE assessment
oRBC transfusions and ESA rescue collection
oTherapeutic phlebotomy collection
oMACE endpoint questionnaire
Medication assessments and procedures:
oReview of concomitant medications
oHGB  by [CONTACT_245965]® fo r dose adjustment
oDrug reconciliation:  Study medication (vadadustat or darbepoetin alfa)
reconciliation will be conducted per the pharmacy manual instructions.
oVadadustat dispensing as needed per Section 8.2.1 , Dispensing of Vadadustat
oDa
rbepoe
tin alfa dispensing (per local product label)
oIron supplementation as needed to maintain ferritin ≥100 ng/mL and TSAT ≥20%
(pe
r local product label; see Section 8.4.6, I ron Supplementation )
oQuestion subject regarding dosing compliance and whether they have questions or
ha
ve experienced any problems related to the dosing of study medication
(vadadustat or darbepoetin alfa).
9.3.6 Ye ar 2 Treatment Period Visits (Weeks 53 through 104) 
Dur
ing the Year 2 Treatment Period visits at Weeks 64, 76, 88, and 104, the following 
a
ctivities/procedures will be performed: 
Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495653] and prior to blood draws)
W
eight (Week 104)
Laboratory Procedures:
oCBC (Weeks 64, 76, 88, and 104 ; differential at Weeks 76 and 104)
oSerum chemistry including serum creatinine and eGFR (Weeks 76 and 104)
oL
iver function tests (Weeks 76 and 104)
oIron indices (Weeks 64, 76, 88, and 104)
S
afety assessments:
oAE assessment
oRBC transfusions and ESA rescue collection
oTherapeutic phlebotomy collection
oMACE endpoint questionnaire
Medication assessments and procedures:
oReview of concomitant medications
oHGB  by [CONTACT_245965]® for dose adjustment
oDrug reconciliation:  Study medication (vadadustat or darbepoetin alfa)
reconciliation will be conducted per the pharmacy manual instructions.
oVadadustat dispensing as needed per Section 8.2.1 , Dispensing of Vadadustat
oDarbepoe
tin alfa dispensing (per local product label)

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 53 of 80 oI
ron supplementation to maintain ferritin ≥100 ng/mL and TSAT ≥20% (per local
produ
ct label; see Section 8.4.6 , I ron Supplementation )
oQuestion subject regarding dosing compliance and whether they have questions or
ha
ve experienced any problems related to the dosing of study medication
(vadadustat or darbepoetin alfa).
9.3.7 Ye ar 3/4 Treatment Period Visits (Weeks 116 through 208) 
During the Year 3/4 Treatment Period visits at Weeks 116, 128, 140, 156, 168, 180, 192, 
a
nd 208, the following activities/procedures will be performed: 
Vital si
gns including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495654] and prior to blood draws)
W
eight (Weeks 156 and 208)
Laboratory Procedures:
oCBC (Weeks 116, 128, 140, 156, 168, 180, 192, and 208 ; differential at
Weeks 128, 156, 180, and 208)
oS
erum chemistry including serum creatinine and eGFR (Weeks 128, 156, 180,
and 208)
oLiver function tests (Weeks 128, 156, 180, and 208)
oI
ron indices (Weeks 116, 128, 140, 156, 168, 180, 192, and 208)
S
afety assessments:
oAE assessment
oRBC transfusions and ESA rescue collection
oTherapeutic phlebotomy collection
oMACE endpoint questionnaire
Medication assessments and procedures:
oReview of concomitant medications
oHGB  by [CONTACT_245965]® for dose adjustment
oDrug reconciliation:  Study medication (vadadustat or darbepoetin alfa)
reconciliation will be conducted per the pharmacy manual instructions.
oVadadustat dispensing as needed per Section 8.2.1 , Dispensing of Vadadustat
oDa
rbepoe
tin alfa dispensing (per local product label)
oIron supplementation to maintain ferritin ≥100 ng/mL and TSAT ≥20% (per local
produ
ct label; see Section 8.4.6 , I ron Supplementation )
oQuestion subject regarding dosing compliance and whether they have questions or
ha
ve experienced any problems related to the dosing of study medication
(vadadustat or darbepoetin alfa).
9.3.8 End of  Treatment Visit 
E
nd of treatment evaluations will be performed when the study is ended.  Subjects who 
prematurely 
discontinue study medication for any reason should attend all subsequent 
protoc
ol-defined study visits and be continually monitored according to the Schedule of 
Ac
tivities for the duration of the study. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 54 of 80 At the E
OT visit, the following activities/procedures will be performed: 
Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495655] and prior to blood draws), as well as weight
L
aboratory Procedures:
oCBC (without differential)
oSerum creatinine and eGFR
oLiver function tests
oIron indices
oBiomarkers (hepcidin, VEGF)
oACTH (cosyntropin) stimulation test (the test will only be performed at the EOT
visi
t for subjects who are part of the adrenal function substudy and who have
permanently discontinued study medication early prior to the Week 52 study
visi
t.)
Safety assessments:
oAE assessment
oRBC transfusions and ESA rescue collection
oTherapeutic phlebotomy collection
oMACE endpoint questionnaire
Recording of concomitant medications
Drug reconciliation:  Study medication (vadadustat or darbepoetin alfa) reconciliation
will be conducted per the pharmacy manual instructions.
Question subject regarding dosing compliance and whether they have experienced any
proble
ms related to the dosing of study medication (vadadustat or darbepoetin alfa).
9.3.9 F ollow-Up Visit 
The Follow-up visit will be conducted in person or via the telephone 4 weeks after the EOT visit. 
T
he following activities/procedures will be performed: 
AE assessment
RBC transfusions and ESA rescue collection
Therapeutic phlebotomy collection
MACE endpoint questionnaire.
[ADDRESS_495656] medical occurrence that occurs in the 
protocol-
specified AE reporting period; the event does not necessarily have a causal relationship 
with that treatment or usage.  
An AE includes medical conditions, signs, and symptoms not previously observed in the subject 
that emerge during the protocol-specified AE reporting period, including signs or symptoms 
associated with pre-existing underlying conditions that were not present prior to the AE reporting 
pe
riod. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 55 of 80 Adve
rse events therefore include the following: 
All AEs, whether suspected to be causally related to study drug or otherwise
All AEs secondary to any medication overdose, abuse, withdrawal, sensitivity, or toxicity
Illnesses apparently unrelated to study drug, including the worsening of a pre-existing
il
lness (see paragraph below on Pre-existing Conditions)
Injury or accidents.  Note that if a medical condition is known to have caused the injury
or a
ccident (eg, a fall secondary to dizziness), the medical condition (dizziness) and the
a
ccident (fall) should be reported as 2 separate AEs.
Abnor
malities in physiological testing or physical examination findings that require
clinical intervention or further investigation (beyond ordering a repeat [confirmatory]
test)
Laboratory abnormalities that require clinical intervention or further investigation
(beyond ordering a repeat [confirmatory] test) unless they are associated with an already
reported clinical event.  Laboratory abnormalities associated with a clinical event
reported as an AE (eg, elevated liver enzymes in a subject with jaundice) should be
de
scribed under ‘Comments’ on the report of the clinical event rather than reported as
se
parate AEs.
The following guidelines are to be used when reporting AEs for this study: 
M
edical Diagnoses  – Whenever possible, a medical diagnosis term should be used to report AEs 
instea
d of signs and symptoms due to a common etiology, as determined by [CONTACT_245966].  For example, pneumonia should be the reported AE term, instead of fever, dyspnea, 
etc, when the diagnosis has been established.  Signs and symptoms should be reported as event 
terms only when the medical diagnosis remains unknown, and revised to a medical diagnosis 
term once it has been established. 
Procedures  – Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, 
shoul
d not be reported as AEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an AE.  For example, an acute 
a
ppendicitis that begins during the AE reporting period should be reported as the AE and the 
resulting appendectomy noted under ‘Comments’. 
P
re-planned therapeutic procedures not associated with a new medical condition or worsening 
pre-existing condition should not be reported as AEs (with the exception of kidney transplant, 
see below). 
Pre-existing Conditions  – In this study, a pre-existing condition (ie, a disorder present before 
the A
E reporting period started and noted on the pretreatment medical history/physical 
e
xamination form) should not be reported as an AE unless the condition worsens or epi[INVESTIGATOR_245897]. 
Abn
ormal Test Findings – All laboratory test results will be reviewed by [CONTACT_737].  The 
I
nvestigator will utilize his/her judgment in determining if out of range laboratory values are 
clinically significant and will denote this using the abbreviation “CS” on the laboratory report for 
source documentation.  Laboratory tests that are labeled as clinically significant should be 
re
ported as AEs, either separately or as part of a description of a symptomatic AE.  If there are 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 56 of 80 sig
nificant changes in a laboratory report from a previous visit that are determined to be 
clinically significant, these should also be reported as AEs.  Any abnormal laboratory value 
which requires treatment or further diagnostic testing and/or results in discontinuation from study 
should be reported as an AE.  An expected laboratory abnormality from a condition that is part of 
the me
dical history is not considered clinically significant for the purposes of the study unless it 
represents a worsening of the condition. 
Worsening of Anemia  – In this study, it is possible that some subjects may experience a 
wor
sening of anemia.  As the primary endpoint of this study assesses HGB response, worsening 
of anemia is captured as part of this efficacy parameter.  Worsening of anemia should not be 
considered an AE unless the worsening of anemia is associated with a cause other than  the 
subj
ect’s CKD. 
Renal-Related Events  - Some subjects will experience a progression of their CKD over the 
c
ourse of this study as part of the natural course of  the disease.  In addition, the study population 
is prone
 to experience acute, transient loss of kidney function of different etiologies, sometimes 
c
oncomitantly complicated by [CONTACT_245967]. 
To e
nsure valid and consistent reporting of renal events, the following guidelines are to be used 
whe
n reporting a renal-related AE: 
Acute kidney injury – If a decline and recovery of renal function has occurred, the
reported AE term should reflect whether the renal event was of a prerenal, intrarenal, or
postrenal etiology (see below).  Non-specific terms such as decreased eGFR or increased
c
reatinine should be avoided whenever the underlying etiology is known.
oExamples of AE terms for a prerenal etiology include:  hypovolemia, hepatorenal
syndrome, and heart failure
oExamples of AE terms for an intrarenal etiology include:  acute tubular necrosis,
a
cute interstitial nephritis, and glomerulonephritis
oExamples of AE terms for a postrenal etiology include:  hydronephrosis,
pelvicaliectasis, and urinary tract obstruction.
Progression of CKD – If permanent loss of renal function due to underlying CKD has
occurred, the reported AE term should reflect the underlying etiology of the pre-existing
CKD.  Non-specific terms such as decreased eGFR or increased creatinine should be
avoided whenever the underlying etiology is known.
oExamples of AE terms include:  lupus nephritis, diabetic kidney disease, and
glomerulonephritis
Progression of CKD Associated with Chronic Dialysis – Subjects who undergo transition
to chronic maintenance dialysis should have the event recorded as an AE and classified as
serious (re
fer to Section 10.1.2, Serious Adverse Events ); the v erbatim AE term should be
“progression of CKD”  with the outcome denoted as “Chronic Dialysis”.
Transient Acute Dialysis - Subjects who undergo transient acute dialysis should have the
event recorded as an AE and classified as serious (refer to Section 10.1.2 , Serious
Adverse Events ); the verbatim AE term should reflect the indication requiring dialysis
(eg, hyperkalemia, volume overload, acute kidney injury, etc.).

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 57 of 80 Transplantation – During this long-term study, it is possible that some subjects may
receive a kidney transplant.  Subjects should have these events recorded as AEs  and
classified as serious (refer to Section 10.1.2 , Serious Adverse Events ).  The verbatim AE
term should be “progression of CKD” with the outcome denoted as “Kidne y
Transplantation”.
Medical conditions related to kidney disease but without loss of renal function – In these
cases the complication should be reported instead of progression of CKD or acute kidney
injury.
oExamples of AE terms include:  edema and hyperkalemia.
10.1.2
 Serious Adverse Events 
Each AE is to be classified by [CONTACT_28135].  An AE that 
mee
ts 1 or more of the following criteria/outcomes is classified as serious: 
De
ath
Life-threatening (see paragraph below on life-threatening)
In-patient hospi[INVESTIGATOR_1081] (see paragraph below
on hospi[INVESTIGATOR_059])
Persistent or significant disability/incapacity (see paragraph below on disability)
C
ongenital anomaly/birth defect
Is considered a medically important event not meeting the above criteria, but which may
jeopardize a subject, or may require medical or surgical intervention to prevent one of the
criteria listed in this definition.
In addition to the above criteria for classifying AEs as serious, the following situations will also 
be classified as serious for purposes of this study: 
Dialysis or Transplantation-Events requiring transition to chronic, ongoing dialysis, or
re
quiring an acute transient course of dialysis, or requiring an immediate kidney
transplantation (ie, not pre-planned) will be classified as serious.  Guidance for the
reporting of these events is provided in Section 10.1.1, Adverse Events .
S
erious also includes any other event that the Investigator or Sponsor judges to be serious.  If 
ther
e is any doubt whether the information constitutes an AE or SAE, the information is to be 
tre
ated as an SAE. 
Life-threatening – Any AE that places the subject at immediate risk of death from the event as 
it
 occurred.  A life-threatening event does not include an event that might have caused death had 
it occurred in a more severe form but that did not create an immediate risk of death as it actually 
occurred.  For example, drug-induced hepatitis that resolved without evidence of hepatic failure 
would not be c
onsidered life threatening, even though drug-induced hepatitis of a more severe 
nature can be fatal. 
Hospi[INVESTIGATOR_059] – Hospi[INVESTIGATOR_225938] a 
mi
nimum of [ADDRESS_495657] event occurs 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 58 of 80 re
lated to the procedure (e g , elective hospi[INVESTIGATOR_272] a total knee replacement due to a 
pre
existing condition of osteoarthritis of the knee that has not worsened during the course of the 
stud
y). 
Disability  – Defined as a substantial disruption in a person’s ability to conduct normal life 
func
tions. 
10.[ADDRESS_495658]
 be reported, whether or not the event is considered related to study medication (vadadustat 
or da
rbepoetin alfa). 
10.3.[ADDRESS_495659] dose of study medication 
(vadadustat or darbepoetin alfa) and ends at the final protocol-required visit. 
I
n addition, any AE that occurs subsequent to the AE reporting period that the Investigator 
assesses as possibly or probably related to the study medication should also be reported as an 
AE. 
10.3.[ADDRESS_495660] be reported to the Sponsor’s Medical Monitor 
or CRO  designee within 24 hours after the Investigator becomes aware of the SAE.  Compliance 
with t
his time requirement is essential so that the Sponsor may comply with its regulatory 
obligations. 
The initial SAE report should be completed as fully as possible but should contain, at a 
minimum: 
Subject number/ID, sex, and age/date of birth
The date of report
Name [CONTACT_225982]
A description of the event, including event term(s), seriousness criteria, and a clinical
summary of the event
Causality assessment.

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 59 of 80 I
nformation about all SAEs (either initial or follow-up information) should be collected and 
recorded in English on the electronic SAE Report Form within the electronic data capture (EDC ) 
system.  The Investigator must assess the relationship to each specific component of the study 
treatment.  When the form is completed, CRO personnel will be notified electronically and will 
retrieve the form.  If the event meets serious criteria and it is not possible to access the internet, a 
paper SAE Report Form should be sent to the CRO via email or fax or the Investigator should 
c
all the CRO SAE hotline within 24 hours of being made aware of the SAE (reference the site 
manual for contact [CONTACT_3031]).  When the EDC system becomes available, the SAE 
information must be entered within [ADDRESS_495661] be reported to the Sponsor’s Medical Monitor or 
C
RO designee within [ADDRESS_495662] should be observed and monitored carefully until the condition 
re
solves or stabilizes. 
All deaths are to be thoroughly investigated and reported.  Autopsy reports and death certificates 
a
re to be obtained, if possible. 
The Sponsor and/or its designee are responsible for reporting SAEs to all applicable regulatory 
a
gencies and the central ethics committees within the required timeline. 
The Investigators are responsible for submitting required safety information to their local 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC).  This information 
includes, but is not limited to, any safety alert letter received from the Sponsor and any SAEs 
oc
curring at their investigative site. 
10.3.4 Reporting Study Endpoints 
Investigators will be counseled to report any event that they assess as potentially being a study 
endpoint requiring adjudication (death, myocardial infarction, stroke, and thromboembolic 
events).  All study endpoint events will be submitted blinded to the EAC for adjudication.  To 
prote
ct the integrity of the trial, these events that are adjudicated will not be unblinded or 
reported to either Health Authorities (HAs) or Investigators as safety reports unless otherwise 
re
quested by [CONTACT_245969].  After study completion, these events will be included 
in t
he final analysis which will be unblinded and submitted to HAs with the study report. 
10.3.5 Relationship to Study Medication 
The causal relationship of the AE to study medication (vadadustat or darbepoetin alfa) will be 
a
ssessed by [CONTACT_29548].   
The
 assessment of causal relationship to study drug should be evidence-based, and not based on 
the premise that all AEs are possibly causally related to study medication until proven otherwise.  
Examples of evidence that would suggest a causal relationship between the study medication and 
the AE include the occurrence of an AE that is uncommon and known to be strongly associated 
with drug exposure (eg, angioedema, hepatic injury, Stevens-Johnson syndrome) or an AE that is 
uncommon in the population exposed to the drug. 
The following definitions will be used for the assessment of relationship to study medication: 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 60 of 80 Probably Related:  There is strong evidence to support a causal association between the AE and 
study medication (eg, the event occurred after the first dose, the characteristics of the AE are 
typi[INVESTIGATOR_12340] a drug toxicity, and there is recurrence after rechallenge) and the AE cannot be 
reasonably explained by [CONTACT_1605]’s clinical state, therapeutic 
interventions, or concomitant drugs. 
Possibly Related:  There is some evidence to support a causal association between the AE and 
the study medication (eg, the AE resolved after study medication interruption and the 
characteristics of the AE are unusual for the study population) and alternative explanations, such 
as the subject’s clinical state, other therapeutic interventions, or concomitant drugs, are less 
likely than study medication. 
Unrelated:  There is currently no evidence to support a causal association with study medication 
and the AE is clearly related to other factors such as the subject’s clinical state, other therapeutic 
int
erventions, or concomitant drugs administered to the subject. 
Default assessments using the “possibly related” category without supportive evidence for a 
causal relationship to study medication are generally uninformative and do not contribute 
meaningfully to the development of the safety profile of the drug or to subject protection. 
10.3.6 Severity 
The Investigator will assess each AE as either MILD, MODERATE, or SEVERE using the 
following guidelines to describe the maximum severity of the AE: 
MILD:  Does not interfere with subject's usual function 
MODERATE:  Interferes to some extent with subject's usual function 
SEVERE:  Interferes significantly with subject's usual function 
Note that a severe  AE is not necessarily a s erious  AE.  For example, a headache may be severe 
in intensity, but would not be classified as serious unless it met [ADDRESS_495663]’s participation in the trial ends (ie, until a final report is completed for 
that subject). 
I
n addition, all SAEs and those nonserious events assessed by [CONTACT_245970]'s 
participation in the trial is over.  Such events should be followed until they resolve or until the 
Investigator assesses them as “chronic” or “stable”.  Resolution of such events is to be 
documented on the appropriate CRF. 
10.[ADDRESS_495664] be confirmed by a positive serum β human chorionic 
g
onadotropin (β-HCG) test. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 61 of 80 I
f any study participant becomes or is found to be pregnant while receiving a study medication 
(va
dadustat or darbepoetin alfa) or within [ADDRESS_495665] be recorded on the Pregnancy Reporting Form/Exposure in Utero Form in the 
EDC within [ADDRESS_495666] should also be reported. 
The
 Pregnancy Reporting Form/Exposure in Utero Form must be completed with all known 
information regarding the pregnancy at the time of reporting.  Investigative site personnel will 
upda
te the form with additional information regarding the pregnancy and the outcome of the 
pregnancy as it becomes available until the outcome of the pregnancy is reported. 
The study medication should be immediately discontinued once the pregnancy of a female study 
pa
rticipant has been confirmed. 
The Investigator will follow the subject (or female partner of a male subject) until completion of 
the pr
egnancy.  If the outcome of the pregnancy meets the criteria for classification as a SAE (ie, 
spontaneous abortion, stillbirth, neonatal death within 1 month of birth, or congenital anomaly 
[
including that in an aborted fetus]), the Investigator should also follow the procedures for 
reporting a SAE within 24 hours of awareness.  A pregnancy in itself is not considered an AE; 
howe
ver, unexpected complications are considered AEs. 
Additional information about pregnancy outcomes follows: 
Note that “spontaneous abortion” includes miscarriage and missed abortion.
All neonatal deaths that occur within [ADDRESS_495667]
to ca
usality, as SAEs.  In addition, any infant death after 1 month that the Investigator
a
ssesses as possibly or probably related to the in utero exposure to the study medication
shoul
d also be reported.
In the case of a live birth, the “normality” of the newborn can be assessed at time of birth.
The “normality” of an aborted fetus can be assessed by [CONTACT_245971]-abortion laboratory findings suggestive of a congenital anomaly.
10.5 Special Situations 
Certain safety events, called ‘Special Situations’, th a t occur in association with study 
medic
ation(s) may require reporting.  These Special Situations include, but are not limited to, the 
following
: 
Overdose of the medicinal product
Suspected abuse/misuse of the medicinal product
Inadvertent or accidental exposure to the medicinal product
Medication error involving the medicinal product (with or without subject/patient
exposure to the Sponsor medicinal product, eg, name [CONTACT_2976])
Drug-drug interaction.
The Investigator should follow SAE criteria reporting guidelines for reporting Special Situations. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495668] deviation, median, minimum, and maximum.  For categorical variables, the 
number and percentage of subjects in each category will be tabulated.  Summaries will be 
provided by [CONTACT_245972] (as defined in Section 11.2 , 
S
tudy Analysis Populations ) and by [CONTACT_7206]/time period as appropriate. 
For HGB, Baseline will be defined as the mean of all qualifying HGB values collected prior to 
the first dose of study medication (vadadustat or darbepoetin alfa).  For subjects rescreened, only 
values for the last Screening period will be used for establishing the Baseline.  For othe r 
parameters, unless otherwise specified, Baseline will be defined as the last available value prior 
to the first dose of study medication. 
Hemoglobin values as assessed through the central laboratory will be used for efficacy and safety 
evaluations; local HemoCue® HGB values will be used only for dose adjustments. 
I
n geographies where regulatory approval does not require a formal analysis of MACE, efficacy 
and safety analyses may be performed upon the completion of [ADDRESS_495669]-randomization 
follow
-up in a sufficient number of subjects to support registration in that geography.  Such 
a
nalysis will be documented in a geography-specific SAP. 
11.1 Sample Size Determination 
The goal of this study is to demonstrate the efficacy and safety of vadadustat compared with 
da
rbepoetin alfa for the maintenance treatment of anemia in subjects with anemia secondary to 
NDD-CKD after conversion from current ESA therapy.  The sample size is calculated to ensure 
sufficient power for testing both efficacy in this trial and the primary safety endpoints as part of a 
pooled a
nalysis. 
11.1.1
 Sample Size for the Primary Efficacy Endpoint 
The primary efficacy endpoint is defined as the mean change in HGB from Baseline (mean 
pre
treatment HGB ) to the average HGB over the primary evaluation period (mean HGB from 
W
eeks 24-36). 
The
 primary efficacy objective of this study is to show that vadadustat is noninferior to 
darbepoetin alfa within the noninferiority margin.  Noninferiority will be established based on a 
mar
gin of -0.5  g/dL (for vadadustat minus darbepoetin alfa). 
For the primary efficacy analysis in this study, it is assumed that the mean change from Baseline 
in HGB  for vadadustat will be the same as for darbepoetin alfa, and the common standard 
de
viation for the mean change from Baseline is assumed to be 1.5 g/dL.  Noninferiority will be 
e
stablished based on a 2-sided 95% confidence interval for the difference between the vadadustat 
group and darbepoetin alfa and using a noninferiority margin of -0.5 g/dL.  With these 
a
ssumptions and approximately [ADDRESS_495670] >99% power. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495671] 
(a
djudicated) MACE (defined as all-cause mortality, non-fatal myocardial infarction, or non-fatal 
stroke). 
The
 primary safety analysis will be based upon all events that accrue over 2 planned NDD-CKD 
studi
es (Studies AKB -6548- CI-0014 and AKB-6548- CI- 0015).  The sample size with respect to 
the MACE endpoint has been determined based on the number of events needed to demonstrate 
noninferiority of the 2-sided 95% confidence interval for the hazard ratio 
(va
dadustat/darbepoetin alfa).  It has been calculated that 631 events will be required overall to 
ha
ve 80% power to establish noninferiority with a margin of 1.25, and >90% power to establish 
noninferiority with a ma
rgin of 1.3, assuming no difference between treatment groups.  The 
powe
r is >90% to establish a noninferiority margin of 1.[ADDRESS_495672] ratio is 0.95 favoring 
vadadustat.  A MACE rate of 10% annually is anticipated in both treatment arms based on a 
comprehensive review of available epi[INVESTIGATOR_245898].  
W
ith 1050 subjects per treatment group enrolled in this study, approximately 20 months for 
accrual
, and up to 36 month s of f ollow-up, approximately 68% of the needed MACE would be 
c
aptured, assuming the dropout rate is negligible.   The remaining 32% of the needed MACE 
would be capture
d in Study AKB-6548- CI-0014. 
11.2 Study Analysis Populations 
The following analysis populations will be used in this study: 
Randomized population:  defined as all randomized subjects
F
ull analysis population:  defined as randomized subjects receiving 1 or more doses of
ther
apy
Per protocol (PP) population:  defined as all randomized subjects who received study
medic
ation (vadadustat or darbepoetin alfa) during the primary evaluation period, had at
lea
st 2 HGB  assessments during the primary evaluation period, and received no rescue
ther
apy in the 8 weeks prior to the evaluation period
S
afety population:  defined as all subjects who received at least 1 dose of study
medication
Efficacy analyses will utilize the randomized, full analysis, and PP populations while safety 
analyses will utilize the safety population. 
11.3 Analysis of Demographic and Pretreatment Variables 
Descriptive statistics will be generated for demographic and pretreatment variables for each 
a
nalysis population defined in Section 11.2, Study Analysis Populations . 
Me
dical history terms will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) and summarized by [CONTACT_245973]. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495673] listing. 
The number of randomized subjects who completed each period of study medication treatment 
(maintenance and long-term treatment), discontinued from study medication early, and 
completed or discontinued from the study and reasons for discontinuation will be summarized by 
[CONTACT_6654]. 
11.[ADDRESS_495674] of rescue therapy on study conclusions. 
In the primary analysis of the primary efficacy endpoint, all available qualifying HGB 
measurements during the pretreatment period and during the primary evaluation period 
(Weeks 24-36) will be used to calculate an average HGB during each period respectively.  For 
a
ny subject with no available HGB measurements during the primary evaluation period, th e 
va
lue (central laboratory data only) closest in time to the evaluation period will be used for the 
change from Baseline.  Given the design of this study where the subjects will continue to be 
assessed after early study medication discontinuation, it is expected that only a minimal amount 
of missing data will be present and the primary analysis should not be substantially affected by 
[CONTACT_245974]. 
All data pertaining to the MACE endpoint collected at any point during the study, both during 
study medication treatment and post study medication treatment discontinuation, and regardless 
of the rescue therapy, will be used for the primary analysis of the MACE endpoint and its 
individual components. 
Unless stated otherwise, missing data for all other secondary efficacy and safety endpoints will 
not be imputed and the analysis will be based on observed data.  For certain responder-type 
binary endpoints, subjects with no available data will be classified into one of the categories as 
described in the relevant sections below. 
11.6 Efficacy Analyses 
The primary efficacy endpoint as well as all key and other secondary endpoints will be 
summarized using descriptive statistics by [CONTACT_1570], as well as by [CONTACT_245975]/or 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 65 of 80 a
nalysis period as appropriate.  Mean values o f HGB as well as selected other efficacy 
pa
rameters will be plotted across study visits/periods by [CONTACT_1570]. 
11.6.1 Analysis of Primary Efficacy Endpoint 
The primary efficacy endpoint is defined as the mean HGB change from Baseline (mean 
pre
treatment HGB ) to the mean HGB from Weeks 24-36 (inclusive). 
[IP_ADDRESS]
 Primary Analysis of Primary Efficacy Endpoint 
The primary analysis will use an analysis of variance (ANOVA) stratified by [CONTACT_394659].  Within this model the strata-specific differences between the treatments will be combined 
using weights proportionate to the stratum size.  A 2-sided 95% confidence interval for the 
diff
erence between the vadadustat group and the darbepoetin alf a group will be obtained from 
this model. 
Noninf
eriority of vadadustat to darbepoetin alfa will be established by [CONTACT_245976]
 95% confidence interval for the difference between treatment groups (vadadustat minus 
da
rbepoetin alfa) obtained from this model to th e noninferiority margin of -0.5 g/dL. 
The
 primary analysis will be performed using the full analysis population and the assigned 
treatment as described in Section 11.2, Study Analysis Populations .  All data collected during the 
stud
y for subjects included in the full analysis population at the time of analysis, including data 
collected at any point after the initiation of rescue therapy as well as after early discontinuation 
of study medication treatment, will be used for the primary analysis.  Missing data will be 
ha
ndled by [CONTACT_394660], as described in Section 11.5, 
Mis
sing Data . 
I
n geographies where regulatory approval does not require a formal analysis of MACE, efficacy 
a
nd safety analyses may be performed upon the completion of [ADDRESS_495675]-randomization 
follow-up in a sufficient number of subjects to support registration in that geography.  Details 
will be provided in a geography-specific SAP. 
[IP_ADDRESS] Sensitivity Analyses of Primary Efficacy Endpoint 
The following sensitivity analyses will be conducted to investigate the impact of missing data 
and rescue treatment. 
Primary analysis will be repeated with change from Baseline to the primary evaluation
period in HGB  based upon the last HGB value before rescue for subjects receiving any
for
m of rescue (transfusion or ESA) prior to the primary evaluation period (ie, during the
conversion period Weeks 0-23).
Primary analysis will be repeated using all randomized subjects.
Primary analysis will be repeated using only subjects with available HGB data during the
prima
ry evaluation period, ie, excluding subjects with no available data during the
primary evaluation period.
Primary analysis will be repeated using the PP population with the actual treatment
re
ceived.

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 66 of 80 11.6.2
 Analysis of Key Secondary Efficacy Endpoints 
Secondary efficacy endpoints analyses will be performed using the randomized and full analysis 
populations and the assigned treatment as described in Section 11.2, Study Analysis Populations .  
Ana
lysis for the key secondary efficacy endpoints will be repeated using the PP population with 
the actual treatment received. 
In order to control the overall Type I error rate, hierarchical testing procedures will be applied to 
the primary and secondary efficacy endpoints, and details will be provided in the SAP. 
[IP_ADDRESS] Analysis of Mean Change in HGB Value between Baseline (Mean Pretreatment HGB) 
a
nd the Seconda
ry Evaluation Period (Weeks 40-52) 
This endpoint will be analyzed using the same methodology as specified for the primary efficacy 
endpoint, including the same method of imputation in absence of any measurements during the 
se
condary evaluation period (Weeks 40-52). 
Sensitivity analyses similar to those of the primary efficacy endpoint will be performed and 
de
tails will be provided in the SAP. 
[IP_ADDRESS] Analysis of Proportion of Subjects with Mean HGB within the Target Range during the 
P
rimary Evaluation Period (Weeks 24-36) 
Each subject will be classified using a binary variable (“yes”/”no”) for the analysis of this 
e
ndpoint.  A classification of “yes” will be assigned to any subject with a mean HGB within the 
tar
get range during the primary evaluation period (Weeks 24-36).  All other subjects, including 
those with no available values during the primary evaluation period, will be classified to the “no” 
category.  The between-treatment difference will be summarized with a confidence interval 
which uses Cochran-Mantel-Haenszel (CMH) weighting. 
[IP_ADDRESS] Analysis of Mean Weekly Dose of IV Elemental Iron Administered from Baseline to 
W
eek [ADDRESS_495676] a mean weekly dose (mg) of IV elemental iron administered at any time starting 
on Day 1 through Week 52 will be calculated based upon observed data.  It will be calculated as 
a
 total cumulative dose (mg) of IV elemental iron administered from Day [ADDRESS_495677] remained in the study up to the Week 52 visit.  The 
be
tween-treatment difference will be summarized with a confidence interval similar to those 
used for the primary endpoint. 
[IP_ADDRESS] Analysis of Proportion of Subjects Receiving RBC Transfusion(s) from Baseline to 
Week [ADDRESS_495678] will be classified using a binary variable (“yes”/”no”) for the analysis of this 
endpoint.  A classification of “yes” will be assigned to any subject receiving RBC transfusion(s) 
at any time starting on Day 1 through Week 52.  All other subjects will be c lassified to the “no” 
category.  The between-treatment difference will be summarized with a confidence interval 
which uses CMH weighting.  Time to first RBC transfusion will also be summarized. 
11.6.[ADDRESS_495679] of the presentation of descriptive statistics by 

[CONTACT_54125].  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 67 of 80 tre
atment group along with the presentation of 2-sided 95% confidence intervals for the 
treatment differences.  The descriptive summaries of the secondary endpoints will be made 
without stratification. 
11.[ADDRESS_495680] adjudicated MACE, will be analyzed as [date of the 
first MACE – the date of first dose of study medication].  A MACE is defined as all-cause 
morta
lity, non-fatal myocardial infarction, or non-fatal stroke.  Subjects who have not 
experienced a MACE by [CONTACT_245978].  The hazard ratio (vadadustat/darbepoetin alfa) and its 95% confidence interval will 
be obtained from a stratified Cox proportional hazards model.  As this study has not been 
designed to provide a stand-alone assessment of MACE, this analysis will be considered a 
descriptive analysis.  A similar analysis as described for the primary analysis of the MACE 
endpoint will be performed with censoring of subjects [ADDRESS_495681] a MACE prior to that time. 
The primary MACE analysis will be based upon all events that accrue over 2 separately planned 
NDD
-CKD studies (Studies AKB -6548- CI- 0014 and AKB -6548- CI-0015) (see Section 11.1.2 , 
Sample Size for the Primary Safety Endpoint ). 
11.7.[ADDRESS_495682]-treatment AEs will be 
summarized by [CONTACT_245979].  Adverse 
events will also be summarized by [CONTACT_225974]. 
Summaries will also be provided for the following types of AEs: 
SAEs
Related AEs (including all categories for relationship to study medication other than
“Unrelated”, as determined by [CONTACT_737])
AEs leading to early discontinuation of study medication.
11.7.3 Remaining Safety Endpoints 
The following safety endpoints will be analyzed using time to event methods: 
1) Individual components (death, myocardial infarction, stroke) of MACE
2)
Thromboembolic events (defined as arterial thrombosis, DVT, PE, or vascular access
thrombosis).
For these endpoints the incidence ("yes"/"no") of the endpoint will be presented for each 
treatment arm.  Kaplan-Meier curves will be presented for each endpoint as the time of endpoint 
free survival (ie, time until endpoint or death). 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 68 of 80 The
 analysis of proportion of subjects with HGB >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL 
post
-Baseline will classify a subject as a “yes” if: 
An
y value HGB >12.0 g/dL at any time after Day 1
An
y confirmed value HGB >12.0 g/dL at any time after Day 1
An
y value HGB >13.0 g/dL at any time after Day 1
An
y confirmed value HGB >13.0 g/dL at any time after Day 1
An
y value HGB >14.0 g/dL at any time after Day 1
An
y confirmed value HGB >14.0 g/dL at any time after Day 1.
A H
GB value above a set threshold will be considered as confirmed if there are [ADDRESS_495683]-Baseline will be 
e
xcluded from this analysis.  All other subjects will be classified to the “no” category. 
The
 analysis of proportion of subjects with any HGB increase >1.0 g/dL within any 2-week 
int
erval or >2.0 g/dL within any 4-week interval post-Baseline will classify a subject as a “yes” 
if at lea
st 1 of the following criteria at any point after Day 1 is met: 
HG
B increase >1.0 g/dL within any 2-week interval
HGB increase >2.0 g/dL within any 4-week interval.
Subjects with no available data post-Baseline will be excluded from this analysis.  All 
other subjects will be classified to the “no” category. 
Obse
rved values of continuous and categorical parameters and changes from Baseline for 
continuous parameters to each study visit will be summarized descriptively for vital signs and 
clinical laboratory results.  Graphical displays of selected laboratory parameters will also be 
provided. 
11.8 Additional Assessments 
11.8.1 Concomitant Medications 
Prior and concomitant medications will be coded using World Health Organization (WHO) Drug 
dictionary. 
Prior medications will be defined as any medications that were taken before the date of the first 
dose of study medication.  Concomitant medications will be defined as any medications taken at 
any time from the date of the first dose of study medication through the date of the last dose of 
the study medication. 
The total number of transfusions, ESA rescue therapi[INVESTIGATOR_014], and therapeutic phlebotomy collections 
will be summarized by [CONTACT_252628]-Baseline overall. 
11.8.2 Biomarkers 
Biomarkers (hepcidin and VEGF) will be summarized descriptively at Baseline and by [CONTACT_245980]
-Baseline.  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495684] KEEPI[INVESTIGATOR_1645] 
12.1 Case Report Forms/Electronic Data Capture 
This study will utilize an EDC system to manage data collection during this trial.  The system is 
fully Code of Federal Regulations [ADDRESS_495685]’s chart at the hospi[INVESTIGATOR_394628]'s office.  In these cases, data collected on the CRFs must match the data in those 
charts. 
12.[ADDRESS_495686] Re
tention 
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator 
agrees to keep records, including the identity of all participating subjects (sufficient information 
to l
ink records, eg, CRFs and hospi[INVESTIGATOR_1097]), all original signed informed consent forms, 
c
opi[INVESTIGATOR_4600], SAE forms, source documents, detailed records of drug disposition, and 
adequate documentation of relevant correspondence (eg, letters, meeting minutes, telephone calls 
re
ports).  The records should be retained by [CONTACT_394661] 
C
onference on Harmonization (ICH), local regulations, or as specified in the Clinical Study 
Agr
eement, whichever is longer. 
If the Investigator becomes unable for any reason to continue to retain study records for the 
re
quired period (eg, retirement, relocation), the Sponsor should be prospectively notified.  The 
stud
y records must be transferred to a designee acceptable to the Sponsor, such as another 
Investigator, another institution, or to the Sponsor.  The Investigator must obtain Sponsor’s 
wr
itten permission before disposing of any records, even if retention requirements have been 
met. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 70 of 80 13
 QUALITY CONTROL (QC) AND QUALITY ASSURANCE (QA) 
13.[ADDRESS_495687] periodic monitoring visits to ensure 
that the protocol and Good Clinical Practice (GCP) are being followed.  The monitors will 
re
view source documents to confirm that the data recorded on the CRFs is accurate.  The 
I
nvestigator/institution will allow the Sponsor’s monitors or designees and appropriate regulatory 
authorities direct access to source documents to perform this verification. 
The investigative site may also be subject to QA audits performed by [CONTACT_394662], and/or review by [CONTACT_1201]/IEC, and/or to inspection by 
[CONTACT_4708]. 
I
t is important that the Investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process. 
13.[ADDRESS_495688] to study subj ects.  Should other unexpected circumstances arise that will 
re
quire deviation from protocol-specified procedures, the Investigator should consult with the 
Sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action. 
The investigative site should document all protocol deviations in the subject’s source documents.  
I
n the event of a significant deviation, the investigative site should notify the Sponsor or its 
de
signee (and IRB or IEC, as required).  Significant deviations include, but are not limited to, 
those tha
t involve fraud or misconduct, increase the health risk to the subject, or confound 
interpretation of primary study assessments. 
14 STUDY DISCONTINUATION/INVESTIGATIVE STUDY SITE 
TERMINATION 
The Sponsor reserves the right to discontinue the study prior to inclusion of the intended number 
of
 subjects, but intends only to exercise this right for valid scientific or administrative reasons.  
Af
ter such a decision, the Investigator must contact [CONTACT_27936] a time period 
spe
cified by [CONTACT_245983]. 
14.1 Criteria for Premature Termination or Suspension of the Study 
The following criteria may result in either temporary suspension or early termination of the 
study: 
New information regarding the safety or efficacy of the study medication that indicates a
change in the known risk/benefit profile for the compound, such that the risk/benefit is no
longer acceptable for subjects participating in the study
S
ignificant violation of GCP that compromises the ability to achieve the primary study
objectives or compromises subject safety.
The Sponsor reserves the right to discontinue the study for other valid administrative reasons. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 71 of 80 1
4.2 Criteria for Premature Termination or Suspension of Investigational Study 
Sites 
A study site may be terminated prematurely or suspended if the study site (including the 
I
nvestigator) is found to be in significant violation of GCP, protocol, contractual agreement, or is 
unable to ensure adequate performance of the study. 
14.3 Procedures for Premature Termination or Suspension of the Study or 
Investigational Sites 
In the event that the Sponsor elects to terminate or suspend the study or the participation of an 
investigational study site, a study-specific procedure for early termination or suspension will be 
provided by [CONTACT_1034]; the procedure will be followed by [CONTACT_245984]. 
[ADDRESS_495689] of the Study 
The study will be conducted in accordance with the Declaration of Helsinki on Ethical Principles 
for
 Medical Research Involving Human Subjects, adopted by [CONTACT_394663] (1996). 
In addition, the study will be conducted in accordance with the protocol, the ICH guideline on 
GCP, and applicable local regulatory requirements and laws. 
15.[ADDRESS_495690]/Independent Ethics Committee 
It is the responsibility of the Investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent forms, and other relevant documents, (eg, recruitment 
a
dvertisements, if applicable) from the IRB/IEC.  All correspondence with the IRB/IEC should 
be retained in the Investigator File.  Copi[INVESTIGATOR_1099]/IEC approvals should be forwarded to the 
S
ponsor or its designee. 
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that 
e
vent, the Investigator must notify the IRB/IEC and the Sponsor in writing immediately after the 
implementation. 
15.[ADDRESS_495691] (or the subject’s acceptable 
re
presentative), prior to inclusion in the study, full and adequate verbal and written information 
re
garding the objective and procedures of the study and the possible risks involved.  The subjects 
must
 be informed about their right to withdraw from the study at any time. 
F
urthermore, it is the responsibility of the Investigator, or a person designated by [CONTACT_3786], to obtain signed informed consent from each subject or the subject’s legally 
a
cceptable representative prior to inclusion in the study.  The Investigator will retain the original 
of each subject's signed consent form. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page [ADDRESS_495692] be prospectively approved by [CONTACT_28150]/IEC and the 
Sponsor before use. 
15.4 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP 
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_394664] 
C
ompetent Authority, or if the Investigator is aware of any new information which might 
influence the evaluation of the benefits and risks of the investigational product, the Sponsor 
should be informed immediately. 
In addition, the Investigator will inform the Sponsor immediately of any urgent safety measures 
taken by [CONTACT_167630], and of any 
se
rious breaches of this protocol or of ICH GCP, defined as a breach that will likely affect the 
safety or physical or mental integrity of subjects or the scientific value of the trial, that comes to 
the a
ttention of the Investigator. 
15.[ADDRESS_495693]’s right to protection 
against invasion of priva
cy.  Throughout this study, a subject’s source data will only be linked to 
the Spons
or’s clinical study database or documentation via a unique identification number.  As  
pe
rmitted by [CONTACT_1763], limited subject attributes, such as sex, age, or 
da
te of birth, and subject initials may be used to verify the subject and accuracy of the subject’s 
unique identifica
tion number. 
To comply with ICH guidelines for GCP and to verify compliance with this protocol, the 
Sponsor requires the Investigator to permit its monitor or designee’s monitor, representatives 
from any regulatory authority (eg, FDA), the Sponsor’s designated auditors, and the appropriate 
I
RBs and IECs to review the subject’s original medical records (source data or documents), 
including
, but not limited to, laboratory test result reports, ECG reports, admission and discharge 
summaries for hospi[INVESTIGATOR_1684] a subject’s study participation, and autopsy 
re
ports.  Access to a subject’s original medical records requires the specific authorization of 
the subject as part of the informed consent process. 
C
opi[INVESTIGATOR_394629] (ie, subject name, address, and other identifier fields 
not collec
ted on the subject’s CRF). 
16
 PUBLICATION OF STUDY RESULTS 
No publication or disclosure of study results will be permitted, except under the terms and 
conditions of a separate, written agreement between Sponsor and the Investigator and/or the 
Investigator’s institution.  The Sponsor must have the opportunity to review and approve all 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 73 of 80 propo
sed abstracts, manuscripts, or presentations regarding this study prior to submission for 
publication/prese
ntation.  Any information identified by [CONTACT_394665]. 
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publications and authorship, including:  Section II - “Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship , 
established by [CONTACT_4717]. 
[ADDRESS_495694], Vaccarino V et al. Chronic kidney disease , anemia, and incident 
stroke in a middle -aged, community -based population: the ARIC study.  Kidney Int (2003) 
64(2): 610 -615. 
Ar
anesp (package insert). Thousand Oaks, CA: [COMPANY_010], Inc.; 2015. 
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al.  The effects 
of no
rmal as compared with low hematocrit values in patients with cardiac disease who are 
receiving hemodialysis and epoetin.  N Engl J Med (1998) 339(9):584-590. 
Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al.  Normalization 
of he
moglobin level in patients with chronic kidney disease and anemia.  N Engl J Med (2006) 
355(20):2071-2084. 
G
oodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, et al.  Naturally 
oc
curring higher hemoglobin concentration does not increase mortality among hemodialysis 
patients.  J Am Soc Nephrol (2011) 22(2):358-365. 
I
seki K and Kohagura K.  Anemia as a risk factor for chronic kidney disease.  Kidney Int (2007) 
S
uppl 72:S4-9. 
J
apanese Society of Nephrology.  Evidence-based clinical practice guideline for CKD 2013. Clin 
Exp Nephrol (2014) 18(3):346 -423. 
J
ha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and 
pe
rspectives. Lancet (2013) 382(9888): [ADDRESS_495695] (2013) 3(1): 1-150. 
KDIGO.  KDIGO clinical practice guideline for anemia in chronic kidney disease.  Kidney Int 
(
2012) 2(4) :1-64.  Available at: 
htt
p://www2.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm 
Levey AS, Stevens LA, Schmid CH, et al.  A new equation to estimate glomerular filtration rate.  
Ann Intern Med (2009) 150(9):604-612. 
L
ocatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al.  Kidney 
Dise
ase: Improving Global Outcomes guidelines on anaemia management in chronic kidney 
disease: a European Renal Best Practice position statement.  Nephrol Dial Transplant (2013) 
28(6)
:1346-1359. 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 74 of 80 Me
tivier F, Marchais SJ, Guerin AP, Pannier B, London GM.  Pathophysiology of anaemia: 
foc
us on the heart and blood vessels.  Nephrol Dial Transplant (2000) [ADDRESS_495696] 3: 14-18. 
Na
tional Institute for Health and Care Excellence (NICE).  Anaemia management in people with 
c
hronic kidney disease.  NICE clinical guideline (2011) 114 :1-39. 
Nur
ko S.  Anemia in chronic kidney disease: causes, diagnosis, treatment.  Cleve Clin J Med 
(2006
) 73(3):289-297. 
Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, and 
Johnson RS.  Regulation of iron homeostasis by [CONTACT_245985]-inducible transcription factors 
(H
IFs).  J Clin Invest (2007) 117(7):1926-1932. 
P
feffer MA, Burdmann EA, Chen CY, et al.  A trial of darbepoetin alfa in type 2 diabetes and 
c
hronic kidney disease.  N Engl J M ed (2009a) 361(21):2019-2032. 
P
feffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al.  Baseline 
c
haracteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).  
Am J Kidney Dis (2009b ) 54(1):59-69. 
S
ingh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al.  Correction of anemia 
with epoe
tin alfa in chronic kidney disease.  N Engl J Med (2006) 355(20):2085-2098. 
S
olomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al.  Erythropoietic 
response and outcomes in kidney disease and type 2 diabetes.  N Engl J Med (2010) 363(12): 
1146-1155. 
S
tauffer ME and Fan T.  Prevalence of anemia in chronic kidney disease in the [LOCATION_002].  
P
LoS One (2014) 9(1): e84943. 
Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al.  Secondary analysis 
of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.  Kidney Int (2008) 
74(6):791-798. 
Tsuba
kihara Y, Nishi S, Akiba T, et al.  2008 Japanese Society for Dialysis Therapy:  Guidelines 
for renal anemia in chronic kidney disease.  Ther Apher and Dial (2010) 14(3):240-275. 
Unger EF.  FDA perspectives on erythropoiesis-stimulating agents (ESAs) for anemia of chronic 
renal failure: Hemoglobin target and dose optimization (Slide presentation from the Sep 11, 2007 
Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety 
and Risk Management Advisory Committee).  Retrieved from 
http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4315s1-10-FDA-Unger.ppt . 
Unger EF, Thompson AM, Blank MJ, and Temple R.  Erythropoiesis-stimulating agents - Time 
for a reevaluation.  N Engl J Med (2010) 362(3):189-92. 

Protocol No.  AKB- 6548- CI- 0015  
Akebia — Company Confidential 
Page 75 of 80 APPENDIX A:  SCHEDULE OF ACTIVITIES 
Study Period  Optional 
Pre-
Screen  Screening  Treatment Period  
Post  
Treatment  BL/ 
rand . [a] Year 1  Year 2  Year 3/Year 4  
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtm t Follow -
up [b] 
Week  -4 to 0 0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c ] EOT 
+4
wks
Procedures/Assessments  
Informed Consent  X [d] X [d] 
Pre-Screening Local 
HGB [e]  X 
I/E Criteria [f ] X X X 
Vital Signs [g]  X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Demographics, Med 
History  X 
Physical Exam [h ] X 
12-Lead ECG [i ] X 
Randomization  X 
Laboratory Procedures  
Pregnancy Test [j ] X 
Folate and Vitamin B 12 X [k] 
Coagulation Tests [l ] X 
C-Reactive Protein X 
Urine Albumin: 
Creatinine (uACR)  X 
CBC [m ] with periodic  
diff  X 
[k,n] X [k] X X X X X X X X X X X X X X X X X X X X X X X X X X 
Iron Indices [o]  X [k] X X X X X X X X X X X X X X X X X X 
Serum Chem and  
eGFR [p ] X [k] X X X X X X X X X X X X X X 
Liver Function Tests [q ] X [k] X X X X X X X X X X X X X X X X 
Lipid Panel [r]  X X X 

Protocol No.  AKB- 6548- CI- 0015  
Akebia — Company Confidential 
Page [ADDRESS_495697]  
Treatment  BL/ 
rand . [a] Year 1  Year 2  Year 3/Year 4  
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtm t Follow -
up [b] 
Week  -4 to 0 0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c ] EOT 
+4
wks
Biomarkers [s]  X X X X 
Reticulocyte Count  X X X X X 
Erythropoietin  X X X X X 
PK [t ] X X X X 
Exploratory Samples [u]  X X 
ACTH (C osyntropin ) 
Stimulation Test  [v] X X X X [w] 
Safety Assessments  
MACE Endpoint 
Questionnaire [x ] X X X X X X X X X X X X X X X X X X X X X X X X X X 
Adverse Event 
Assessment [y ] X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Transfusions and ESA 
Rescue C ollection  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Therapeutic 
Phlebotomy Collection  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Medication Assessments and Procedures  
Concomitant Med 
Review [z ] X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Vadadustat  Medicat ion 
Dispensing [aa ] X X X X X X X X X X X X X X X X X X X X X X X X X 
Drug Reconciliation  X X X X X X X X X X X X X X X X X X X X X X X X X 
Visit Registration in 
IWR X X X X X X X X X X X X X X X X X X X X X X X X X X 
HGB  via HemoCue® for 
Dose Adjustment [ bb] X X X X X X X X X X X X X X X X X X X X X X X X X 
Darbepoetin A lfa Dosing per approved local product label [cc ] 
Vadadustat  Dose 
Adjustments [ dd] Start at [ADDRESS_495698] dose as per  Dose Adjustment Guidelines  

Protocol No.  AKB- 6548- CI- 0015  
Akebia — Company Confidential 
Page [ADDRESS_495699]  
Treatment  BL/ 
rand . [a] Year 1  Year 2  Year 3/Year 4  
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtm t Follow -
up [b] 
Week  -4 to 0 0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c ] EOT 
+4
wks
Oral Iron 
Supplementation [ ee] As needed to maintain ferritin ≥100 ng/mL  and TSAT ≥20%  
Abbreviations:  ACTH  = adrenocorticotropic hormone; AE = adverse event; ALT/SGPT  = alanine aminotransferase /serum glutamic -pyruvic transaminase; AST/SGOT  = aspartate 
aminotransferase /serum glutamic oxaloacetic transaminase; BUN  = blood urea nitrogen; CBC  = complete blood count; CPK  = creatine phosphokinase; CRF  = case report form; diff  = differential; 
ECG  = electrocardiogram; eGFR  = estimated glomerular filtration rate; EOT  = end of treatment; ESA  = erythropoiesis -stimulating agent; HDL  = high density lipoprotein; HGB  = hemoglobin;  
HIF = hypoxia inducible factor;  ICF = informed consent fo rm; I/E = inclusion/exclusion; INR = international normalized ratio; IWR  = interactive web response; LDH  = lactate dehydrogenase; 
LDL  = low density lipoprotein; MACE  = major adverse cardiovascular event; MCH  = mean corpuscular hemoglobin; MCHC  = mean corpu scular hemoglobin concentration; MCV  = mean corpuscular 
volume; med  = medicati on; PK  = pharmacokinetic; PS  = Pre-Screening; PT  = prothrombin time; PTT  = partial thromboplastin time; RBC  = red blood cell; RDW  = red cell distribution width; 
SV1 = Screening v isit 1; SV2  = Screening visit 2; TIBC  = total iron binding capacity; Trtmt  = treatment; TSAT  = transferrin saturation; uACR  = urine albumin to creatinine ratio; VEGF  = vascular 
endothelial growth factor; WBC  = white blood cell; wks  = weeks.  
[a] The Screening period is a maximum of [ADDRESS_495700] elapse between the 
2 Screening visits (SV1 and SV2) and between SV2 and the Baseline visit.
[b] The Follow -up visit can be performed either in person OR via the telephone.
[c] EOT will be performed when the study is ended.  Subjects who premature ly discontinue study medication (vadadustat or darbepoetin alfa) for any reason should attend all subseq uent study visits 
and be continually monitored accordi ng to the Schedule of Activitie s for the duration of the study.
[d] An abbreviated ICF will be used for Pre -Screening.  If the subject is eligible for Screening, a separate full ICF will be used.   An optional consent form for collection of blood samples for future 
genetic analysis will be provided at SV1.  An additional optional consent form for participation in an adrenal function substudy in 200 subjects in the EU will also be provided at SV1.  
[e] If the Pre -Screen HemoCue® HGB  is between 8.0 and 11.0  g/dL (inclusive)  within the US or between 9.0 and 12.0  g/dL (inclusive) outside of the US , the investigative site may proceed with
Screening Visit 1 (SV1), preferably on the same day as Pre -Screening.  
[f] Inclusion/Exclusion criteria will be reviewed at the Pre -Screening and Screening visits (SV1 and SV2).  Final eligibility determination will occur following the Screening visits when  all data are 
available.
[g] Vitals: Heart rate and blood pressure to be a ssessed in the seated position after [ADDRESS_495701].  Height (SV2 only) and weight (SV2, Weeks 12, 24, 36, and 52, yearly thereafter , and at the EOT 
visit) will also be measured.
[h] Physical exam:  a physical exam is required at SV2 as outlined in the protocol.  Thereafter, an abbreviated symptom -directed physical exam should be performed at the discretion of the Investigator 
as clinically indicated.
[i] ECG should be performed prior to blood draws when possible and obtained after the  subject has been r esting comfortably in a supi[INVESTIGATOR_73414] 5 minutes.
[j]Serum pregnancy will be tested in women of childbearing potential at SV2.  (Eligible  subjects will be advised to use an adequate contraceptive method.)  Additional serum or local uri ne pregnancy 
tests should be conducted throughout the study in sufficient number, as determined by [CONTACT_245986] r egulations, to establish the absence of pregnancy during the study.  If 
positive at SV2, the  subject is not eligible t o enter the study.  If a subject becomes pregnant during the study, the subject must permanently discontinue study medication  and should  attend all 
subsequent study visits and be continually monitored  according to the Schedule of Activitie s for the duratio n of the study.
[k] Subjects may be retested and/or rescreened as detailed in Section s 7.4.1 , Retesting  and 7.4.2 , Rescreening . 
[l]Coagulation tests:  prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR).
[m] A CBC with differential will be performed at Baseline and twice annually at Weeks 28, 52, 76, 104 , 128, 156, 180, 208.  At all other noted visits, a CBC without differential will be performed.
CBC:   hemoglobin, hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpusc ular hemoglobin concentratio n (MCHC), red cell 
distribution width (RDW), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, b asophils), and platelets.
[n] If HGB  at SV1 is 11.1-11.5 g/dL in the US or 12 .1-12.5 g/dL outside the US , a single retest CBC should be performed prior to SV2.  If retest HGB  is >11 .0 g/dL in the US or >12.0  g/dL outside the 
US, the subject should not proceed with SV2.   If the HGB at SV1 is >11.5  g/dL in the US or > 12.5 g/dL outside of the US, the subject shoul d not proceed with any further S creening at this time.
[o] Iron indices:  ferritin, iron, total iron binding capacity (TIBC), and transferrin saturation (TSAT).

Protocol No.  AKB- 6548- CI- 0015  
Akebia — Company Confidential 
Page 78 of 80 [p] A full serum chemistry panel will be performe d at SV2, Baseline , and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208.  At all other noted visits, serum creatinine and eGFR will b e 
performed.  Serum chemistry:  sodium, potassium, bicarbonate, chloride, calcium, magnesium, phosphorus, gluco se, creatinine, blood urea nitrogen (BUN)/urea, creatine phosphokinase (CPK), uric
acid, albumin, and total protein.
[q] Liver function tests:  total bilirubin, alkaline phosphatase, alanine aminotrans ferase  (ALT/SGPT), aspartate aminotransferase (AST/SGOT ), and lactate dehydrogenase (LDH).
[r] Lipi[INVESTIGATOR_805]:  total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides.
[s] Hepcidin and vascular endothelial growth factor (VEGF) will be analyzed at Baseline and at Weeks 12, 2 8, and EOT.
[t]PK samples are to be drawn only for subjects randomized to vadadustat.  Subjects will be questioned regarding the timing of t heir last dose of vadadustat.  
[u] Additional blood and urine samples will be collected at Baseline and Week 28 wh ich may be used for exploratory measurement of biomarkers (eg, factors relating to the activation of the HIF 
pathway).  Subjects will also be asked to provide optional consent to obtain and store a blood sample for future genet ic analyses (eg, DNA, mRNA, e tc).
[v] The ACTH (cosyntropin) stimulation test will be performed on a subset of 100 subjects per treatment arm (200 subjects total) in t he EU as part of a substudy on adrenal function.
[w] The ACTH (cosyntropin) stimulation test will only be performed at the EOT visit for subjects who are part of the adrenal function substudy and who have permanently discontinued study 
medication early prior to the Week  52 study visit.  
[x] At each post-randomization  study visit, the subject must specifically be questio ned regarding the occurrence of any potential MACE endpoint events since the last study visit.  If a potential endpoint
event is reported, the date of the event should be recorded and the appropriate source documents should be collected accordin g to the en dpoint packet checklist.  
[y]Adverse events should be documented and recorded at each visit.  All adverse events (serious and non -serious, and related and non -related) will be documen ted and recorded through the follow -up
visit.  Subjects must be followed for adverse events until the final required protocol visit or until all drug -related toxicities and serious adverse events have resolved (or are considered
chronic/stable).
[z] Concomitant medications should be collected and recorded at each visit as noted .  All concomitant medications received up to and including 30  days prior to the start of study medication through the 
EOT visit will be recorded.
[aa] Subjects will be provided w ith a supply of vadadustat  at the Baseline visit and will be resupplied at su bsequent visits as needed.  Subjects will be instructed to complete 1 bottle prior to opening the 
next bottle.  The dose should be taken at approximately the same time each  day, preferably between 7 AM and 2 PM.  
[bb]Hemoglobin will be monitored via local H emoCue® throughout the study to determine if the dose of study medication will be adjusted or suspended.  
[cc] Refer to the approved local product label.   Vital signs and weight should be obtained prior to dosing per the local product label.
[dd] The dose w ill be adjus ted in accordance with the Dose Adjustment Guidelines.  Changes to dose will be accomplished by [CONTACT_245987].
[ee] Iron supplementation should be prescribed as needed during the study to maintain ferritin ≥ 100 ng/mL and TSAT ≥20%.  In general, only oral iron should be used for therapy.  Vadadustat  should
not be administered concurrently with the oral iron supplement (including multivitamins containing iron).  Oral iron suppleme nt should be taken at least 2 hours before or 2 hours after the dose of 
study medication.  (See study protocol for further details regarding iron administration and potential intravenous therapy).  

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 79 of 80 A
PPENDIX B:  CKD-EPI  [INVESTIGATOR_245901] (eGFR) will be calculated from serum creatinine (isotope 
dil
ution mass spectrometry [IDMS] calibrated in mg/dL) using the Chronic Kidney Disease 
Epi[INVESTIGATOR_394630] (C K D-EPI) creatinine equation ( L evey et al. 2009 ) . 
The
 CKD-EPI [INVESTIGATOR_245902]: 
eGFR = 141 x min(SCr/k,1)α x max(SCr/k,1)-1.209 x 0.993Age x [1.018 if female] x [ 1.159 if 
black] 
where: 
SCr is serum creatinine (in mg/dL) 
k = 0.7 for females 
k = 0.9 for males 
α
 = -0.329 for females 
α
 = -0.411 for males 
min = the minimum of SCr/k or 1 
max
 = the maximum of SCr/k or 1 

Protocol No.  AKB- 6548- CI- 0015 
Akebia — Company Confidential 
Page 80 of 80 A
PPENDIX C :  ACTH (COSYNTROPIN) STIMULATION TEST FOR 
ADRENAL FUNCTION MONITORING 
The adrenocorticotropic hormone (ACTH) stimulation test assesses the function of the adrenal 
g
lands and their ability to respond to ACTH.  Adrenocorticotropic hormone is a hormone 
produced in the pi[INVESTIGATOR_394631].  Cosyntropin 
is a synthetic form of ACTH.  The ACTH stimulation test is recognized as the gold standard 
assay of adrenal insufficiency. 
Sequential ACTH (cosyntropin) s timulation tests will be conducted at European Union (EU) 
sites in the first 200 subjects randomized and who agree to participate in the testing 
(a
pproximately 100 subjects per treatment arm).  Testing will be performed at the Baseline 
(pr
edose), Week 12, and Week 52 study visits, or at the end of treatment (EOT) visit if the 
subj
ect permanently discontinues study medication early prior to the Week [ADDRESS_495702] details: 
Obtain blood sample for pretest serum cortisol measurement (collected prior to
administering cosyntropin)
Administer 0.25 mg cosyntropin via intravenous (IV) push
Obta
in blood samples for serum cortisol measurements at 30 minutes and 60 minutes
a
fter dosing of cosyntropin
Samples for cortisol measurements will be sent to the central laboratory for analysis. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495703] S WITH NON -DIALYSIS -
DEPENDENT CHRONIC KIDNEY DISEASE (NDD- CKD)  
(PRO 2TECT - CONVERSION)  
Compound:  Vadadustat (AKB -6548)  
Protocol Number:  AKB -6548 -CI-0015  
US IND Number:  102,[ADDRESS_495704] Number  2015 -004774 -14 
Phase:  Phase 3  
Status/Date:  Amendment 7 -COL (  Colombia -specific 
protocol amendment) 
Amendment 6- COL ( ; Colombia- specific 
protocol amendment) 
Amendment 5- COL ( ; Colombia- specific 
protocol amendment) Amendment 4-COL ( ;  
Colombia- specific protocol amendment) 
Amendment 3-COL ( ; 
Colombia-specific protocol amendment) 
Amendment 2-COL ( ;  
Colombia-specific protocol amendment) 
Amendment 2 ( ) 
Amendment 1 ( ) 
Original protocol ( ) 
Sponsor:  Akebia Therapeutics, Inc.  
[ADDRESS_495705]  
Cambridge, MA [ZIP_CODE] [LOCATION_002] of America  
This document contains information that is confidential and proprietary to the Sponsor, Akebia Therapeutics, Inc .  This 
information is being provided to you solely for the purpose of evaluating and/or conducting a clinical study  for the Sponsor .  You 

Protocol No. AKB-6548-CI-[ADDRESS_495706], the 
[LOCATION_002] Food and Drug Administration, or duly authorized representatives of regulatory agencies for this purpose under the 
condition that they maintain confidentiality. The contents of this document may not be used in any other clinical study, disclosed 
to any other person or entity, and/or published without the prior written permission of the Sponsor. The foregoing shall not apply 
to disclosure required by [CONTACT_17140]; however, you will give prompt notice to the Sponsor of any such disclosure. 
1 SIGNATURE [CONTACT_118585] 
1.1 Protocol Approval 
Signature 
[CONTACT_394699] 
� 
Biostatis
ty and Pharmacovigilance 
, Clinical   
Date 
Date 
Akebia - Company Confidential 
Page 2 of 105 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495707] read and that I understand this protocol, any amendments to the protocol (if 
applicable, a history of protocol changes are appended at the end of this document), the Investigator ’s Brochure, and other product information provided by [CONTACT_1034].  I agree to 
conduct this study in accordance with the requirements of this protocol and also protect the rights, safety, privacy, and well-being of study subjects in accordance with the following: 
•The ethical principles that have their origin in the Declaration of Helsinki.
•International Conference on Harmoni sation Guidance for Industry, Good Clinical Practice E6.
•All applicable laws and regulations, including, without limitation, data privacy laws andregulations.
•Regulatory requirements for reporting serious adverse events defined in this protocol.
•Terms outlined in the Clinical Study Site Agreement.
Signature [CONTACT_63240] (print or type)  
Investigator’s Title  
Phone Number  
Full Address  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495708] Completion  ........................................................................................... 36  
7.5.3  Entire Study Termination  .................................................................................. 37  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495709] Discontinuation ................................................................... 37  
[IP_ADDRESS]  Temporary Interruption of Study Medication ............................................... 38  
[IP_ADDRESS]  Permanent Discontinuation of Study Medication ......................................... 38  
[IP_ADDRESS]  Complete Withdrawal from Further Study Visits/Assessments  ................... 38  
[IP_ADDRESS]  Procedures to Support Continued Study Participation ................................. 39  
[IP_ADDRESS]  Procedures to Prevent “Lost to Follow-up” .................................................. [ADDRESS_495710] Accountability and Destruction ................................................................  42 
Treatment of Subjects  ................................................................ ............................. 43  
8.4.1  Treatment Group Assignments  .......................................................................... 43  
8.4.2  Randomization ................................................................................................... 43  
8.4.3  Blinding ............................................................................................................. 43  
8.4.4  Dosing and Dose Adjustment Guidelines .......................................................... 44  
[IP_ADDRESS]  Vadadustat Dosing and Dose Adjustment Algorithms ................................. 45  
[IP_ADDRESS]  Darbepoetin Alfa Dosing and Dose Adjustment Algorithms ....................... 45  
8.4.5  Late or Missed Doses  ........................................................................................ 46  
8.4.6  Iron Supplementation ........................................................................................ 46  
8.4.7  Rescue Therapy  ................................................................................................. 46  
[IP_ADDRESS]  ESA Rescue (Optional)  ................................................................................. 46  
[IP_ADDRESS]  Red Blood Cell Transfusion (Optional) ........................................................ 47  
8.4.8  Phlebotomy (Optional)  ...................................................................................... 47  
8.4.9  Treatment Compliance  ...................................................................................... 47  
8.4.10  Continuation of Treatment ................................................................................ 48  
Prior and Concomitant Therapy ................................................................ ............. 48  
8.5.1  General  .............................................................................................................. 48  
8.5.2  Erythropoiesis- stimulation Agents .................................................................... 48  
8.5.3  Transfusions ...................................................................................................... 48  
8.5.4  Investigational Medications ............................................................................... 48  
8.5.5  HMG-CoA Reductase Inhibitors (Statins) ........................................................ 49  
8.5.6  Sulfasalazine and Other BCRP Substrates  ........................................................ 50  
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITI ES ................................ 50  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 6 of 105 
Administrative Procedures ..................................................................................... 50  
9.1.1  Informed Consent .............................................................................................. 50  
9.1.2  Documentation of Screen Failures  .................................................................... 51  
9.1.3  Contraception and Pregnancy Avoidance Measures ......................................... 51  
9.1.4  Laboratory Accreditation and Reference Ranges  .............................................. 51  
Study Procedures and Evaluations ................................................................ ......... 52  
9.2.1  Clinical Evaluations  ........................................................................................... 52  
9.2.2  Laboratory Evaluations ..................................................................................... 53  
Schedule of Activities  ................................................................ ............................ 55  
9.3.1  Pre-Screening Visit ............................................................................................ 55  
9.3.2  Screening Visits  ................................................................................................. 55  
[IP_ADDRESS]  Screenin g Visit 1 (SV1)  ................................................................................ 56  
[IP_ADDRESS]  Screening Visit 2 (SV2)  ................................................................................ 56  
[IP_ADDRESS]  Subject Retesting  .......................................................................................... [ADDRESS_495711] Rescreening  .......................................................................................... 56  
9.3.4  Baseli ne Visit (Day 1)  ....................................................................................... 57  
9.3.5  Year 1 Treatment Period Visits (Day 2 through Week 52) ............................... 57  
9.3.6  Year 2 -4 Monthly Hb Monitoring ..................................................................... 58  
9.3.7  Year 2 Treatment Period Visits (Weeks 53 through 104) ................................. 59  
9.3.8  Year 3/4 Treatment Period Visits (Weeks 116 through 208) ............................ 59  
9.3.9  End of Treatment (EOT) Visit  ........................................................................... [ADDRESS_495712] Status  .............................................................................. 61  
Study Medication Stoppi[INVESTIGATOR_1869] ................................................................ .......... 62  
10 ADVERSE EVENTS  .................................................................................................. 63  
Definitions  ................................................................................................ .............. 63  
10.1.1  Adverse Events  .................................................................................................. 63  
10.1.2  Serious Adverse Events ..................................................................................... 66  
Eliciting Adverse Event Information ................................................................ ..... 67  
Reporting ................................................................................................ ................ 67  
10.3.1  Reporting Period ................................................................................................ 67  
10.3.2  Reporti ng AEs  ................................................................................................... 67  
10.3.3  Reporting SAEs ................................................................................................. 68  
10.3.4  Reporting Study Endpoints ................................................................................ 68  
10.3.5  Relationship to Study Medication  ..................................................................... 69  
10.3.6  Severity  .............................................................................................................. 69  
10.3.7  Follow- Up of Un resolved Events ...................................................................... 70  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 7 of 105 
Exposure In Utero .................................................................................................. 70  
Special Situations  ................................................................................................ ... 71  
11 DATA ANALYSIS  ..................................................................................................... 71  
Sample Size Determination  ................................................................ .................... 72  
11.1.1  Sample Size for the Primary Efficacy Endpoint ................................................ 72  
11.1.2  Sample Size for the Primary Safety Endpoint ................................................... 72  
Study Analysis Populations ................................................................ .................... 73  
Analysis of Demographic and Pretreatment Variables  ................................ .......... 73  
Disposition of Subjects ................................................................ ........................... 73  
Missing Data  ................................................................................................ .......... 74  
Efficacy Analyses  ................................................................................................ ... 74  
11.6.1  Analysis of Primary Efficacy Endpoint ............................................................. 74  
[IP_ADDRESS]  Primary Analysis of Primary Efficacy Endpoint  .......................................... 75  
[IP_ADDRESS]  Sensitivity Analyses of Primary Efficacy Endpoint ..................................... 75  
11.6.2  Secondary Efficacy Analyses  ............................................................................ 75  
[IP_ADDRESS]  Key Secondary Efficacy Analyses  ................................................................ [ADDRESS_495713] KEEPI[INVESTIGATOR_1645]  ...................................................... 78  
Case Report Forms/Electronic Data Capture  ................................ ......................... [ADDRESS_495714] Retention  ................................................................................................ .... 79  
13 QUALITY CONTROL (QC) AND QUALITY ASSURANCE (QA)  ....................... 79  
Investigative Site Monitoring Visits  ................................................................ ...... 79  
Protocol Deviations ................................................................................................  79 
14 STUDY DISCONTINUATION/INVESTIGATIVE STUDY SITE  
TERMINATION  ......................................................................................................... 80  
Criteria for Premature Termination or Suspension of the Study ............................ 80  
Criteria for Premature Termination or Suspension of Investigational Study Sites 80  
Procedures for Premature Termination or Suspension of the Study or 
Investigational Sites  ................................................................ ............................... 80  
15 ETHICS  ....................................................................................................................... 80  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495715]/Independent Ethics Committee  ................................ .. [ADDRESS_495716] Confidentiality  ................................................................ ........................... 81  
16 PUBLICATION OF STUDY RESULTS  ................................................................... 82  
17 REFERENCES  ............................................................................................................ 82  
APPENDIX A:  SCHEDUL E OF  ACTIVITIES  ................................................................... 85  
APPENDIX B:  CKD- EPI [INVESTIGATOR_394632] ...................................................... 89  
APPENDIX C:  VADADUSTAT DOSING AND DOSE ADJUSTMENT 
ALGORITHMS  .......................................................................................................... 90  
APPENDIX D:  DARBEPOETIN ALFA DOSING AND DOSE ADJUSTMENT 
ALGORITHMS  .......................................................................................................... 94  
APPENDIX E:  END OF TREATMENT AND GLOBAL  STUDY COMPLETION 
SUBJECT FLOW  ....................................................................................................... 98  
APPENDIX F:  HISTORY OF AMENDMENTS TO THE PROTOCOL ........................... 99  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 9 of 105 2 PROTOCOL SYNOPSIS  
Study Title  Phase 3, Randomized, Open -Label, Active -Controlled Study Evaluating the Effica cy 
and Safety of Oral Vadadustat  for the Maintenance Treatment  of Anemia in Subjects 
with Non -Dialysis -Dependent Chronic Kidney Disease (NDD -CKD) 
(PRO 2TECT  - CONVERSION)  
Protocol Number  AKB -[ADDRESS_495717]  Vadadustat ; [ADDRESS_495718]  Darbepoetin alfa ; [COMPANY_010] , Inc. 
Study Population  The study population will consist of subjects ≥18  years of age with NDD -CKD , 
estimated glomerular filtration rate (eGFR) <60 mL/min/1.73  m2, and hemoglobin ( Hb) 
between 8 .0 and 11.0  g/dL (in clusive)  in the [LOCATION_002] ( US) and between 9.0 and 
12.0 g/dL (inclusive) outside of the US, who are currently treated with an 
erythropoiesis -stimulating agent (ESA) for anemia.  
Investigative Sites  Approximately  480 investigative sites  in North America, Latin America, Europe, and 
Asia Pacific . 
Planned Number of 
Subjects  Approximately 1850 subjects . 
Primary Objective  Demonstrate the efficacy and safety of vadadustat  compared with darbepoetin alfa for 
the maintenance treatment of anemia in subjects with NDD -CKD  after conversion 
from current ESA therapy . 
Study Design 
Overview  Phase 3, randomized, open -label, active -controlled study of the efficacy and safety of 
vadadustat  versus darbepoetin alfa for the maintenance treatment of anemia after 
conversion from cur rent ESA therapy.  Following a S creening period of up to 8 weeks  
(56 days) , subjects who meet all inclusion and no exclusion criteria will be randomized 
1:1 to vadadustat  or darbepoetin alfa.  
Randomization will be stratified by:  
•Geographic region (US versus European Union [EU] versus Rest of World
[ROW])
•[LOCATION_001] Heart Association  congestive heart failure (CHF ) Class 0 (no CHF)
or I versus II or III
•Study entry Hb (<10.0 versus ≥10.0  g/dL) .
Following randomization, there will be 3 periods during the study:  
•Conversion and Maintenance Period (Weeks 0 -52):  conversion to study
treatment for maintaining Hb (Weeks 0 -23), primar y efficacy evaluation
(Weeks 24- 36), and secondary efficacy evaluation (Weeks 40 -52)
•Long -Term Treatment Period (Weeks 53 -End of Treatment  [EOT] ):
continued study medication to assess long -term safety
•Follow -Up Period (EOT + 4 weeks):   post-treatment visit (either in person or
via te lephone)  for safety .

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 10 of 105 Study Duration  The study will be considered completed (end of trial) when approximately 631 major 
adverse cardiovascular events (MACE) have accrued over the 2 NDD -CKD studies 
(Studies  AKB -6548- CI-0014 and AKB -6548- CI-0015)  and all enrolled subjects have 
had the  the opportunity to have their Visit 13 (+/- 5 days) . All subjects will remain in 
the study until the global study completion (end of trial) at which time subjects will be 
scheduled for a final visit and the study wil l close.  Sites  will be notified of global 
study completion  date approximately 3  months prior to study closure (based on accrual 
of MACE  across the 2  studies) and  will have any subject that is active complete the 
EOT visit and Follow -Up visit, as applicabl e, and confirm the End of Study (EOS) 
status . 
Inclusion Criteria  1.≥18 years of age
2.Diagnosis of CKD with an eGFR ≤60  mL/min/1.73  m2 using the 2009
Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD -EPI) creatinine
equation during Screening and not expected to start dialysis within 6  months
of Screening
3.Currently maintained on  ESA therapy , with a dose received  within 6 weeks
prior to  or during Screening
4.Mean  Screening  Hb between 8.0 and 11 .0 g/dL (inclusive)  in the US and
between 9.0 and 12.0  g/dL (inclusive) outside of the US,  as de termined by [CONTACT_394647]  2 Hb values measured by  [CONTACT_245933]
5.Serum ferritin ≥100  ng/mL and transferrin saturation (TSAT) ≥20% during
Screening
6.Folat e and vitamin B 12 measurement s ≥lower limit of normal during
Screening
7.Understands the procedures and requirements of the study and provides
written informed consent and authorization for protected health informationdisclosure .
Exclusion Criteria  1.Anemia  due to a  cause other than CKD  or subjects with active bleeding or
recent blood loss
2.Subjects with sickle cell disease, myelodysplastic syndromes, bone marrow
fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia,
or pure red cell aplasia
3.Red blood cell  (RBC)  transfusion within 8 weeks prior to randomization .
4.Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase(SGOT),  alanine aminotransferase (ALT) /serum glutamic pyruvic
transaminase (SGPT), or total bilirubin >2.0 x upper limit of normal (ULN)
during Screening.  Subjects with a history of Gilbert’s syndrome are not
excluded.
5.Uncontrolled hypertension (confirmed diastolic blood pressure >110 mmHg
or systolic blood pressure >180 mmHg) during Screening
6.Severe heart  failure during Screening ( [LOCATION_001] Heart Association  Class IV)
7.Acute coronary syndrome (hosp italization for unstable angina or  myocardial
infarction), surgical or percutaneous intervention for coronary,
cerebrovascular, or peripheral artery disease (aorti c or lower extremity),
surgical or percutaneous valvular replacement or repair, sustained ventriculartachycardia,  hospi[INVESTIGATOR_10889], or stroke within 12  weeks prior to or
during Screening
8.History of active malignancy within 2  years prior to or during Screening,
except for treated  basal cell carcinoma of skin, curatively resected squamous
cell carcinoma of s kin, or cervical carcinoma in situ
9.History of deep vein thrombosis (DVT) or pulmonary embolism (PE)  within

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 11 of 105 12 weeks prior to  randomizatio n 
10.History of hemosiderosis or hemochromatosis
11.History of prior organ transplantation or scheduled organ transplant (subjects
on kidney transplant wait -list are not excluded), or prior hematopoietic stem
cell or bone marrow transplant (corneal transplants and stem cell therapy for
knee arthritis are not excluded)
12.Use of an investigational medication or participation in an investigationalstudy within 30  days or 5 half-lives of the investigational medication
(whichever is longer), prior to the Screening visit
13.Previous participation in this study, or previous participation in a study with a
hypoxia -inducible factor prolyl -hydroxylase inhibitor (HIF -PHI)  other than
vadadustat
14.Females who are pregnant or breast -feeding.  Women of childbearing
potential who are unable or unwilling to use an acceptable method of
contraception
15.Non-vasectomized male subjects who are unable or unwilling to use an
acceptable method of contraception
16.Any other reason that in the opi[INVESTIGATOR_394633]
17.Hypersensitivity to darbepoetin or vadadustat, or to any of their excipi[INVESTIGATOR_245904]/Rescreening  Retestin g is defined as repeating laboratory tests within the same Screening period. 
Subjects who initially fail to qualify for the study based on laboratory test results may be retested once for each laboratory parameter within the 8-week Screening period, per 
Investigator discretion . Subjects who fail to qualify for the study based on lo w TSAT, 
ferritin, folate, or B
12 values may receive replacement therapy based on the 
investigative sites’ standard of care during the screening period and retest the laboratory parameter(s).  Subjects who receive iron replacement may retest screening 
Hb a minimum o f [ADDRESS_495719]’s status has progressed and that the subject may now qualify for the study.  Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may be considered for rescreening after receiving 
replacement therapy.  Screening is limited to 3 attempts (initial Screening and 2 additional rescreening attempts).  
Efficacy Endpoints  Primary  
•Mean change in Hb between B aseline (mean pretreatment Hb) and the
primary evaluation  period (mean Hb from Weeks  24-36)
Key Secondary  
•Mean change in Hb value between B aseline (mean pretreatment Hb) and the
secondar y evaluation period (Weeks 40 -52)
•Proportion of subjects with Hb values within the target range  during the
primar y evaluation period (Weeks 24 -36)
•Proportion of subjects with Hb values within the target range during the
secondary evaluation period (Weeks 40 -52)
Other Secondary  
•Proportion of time with Hb values within the target range during the primary
evaluation period (Weeks 24 -36)
•Proportion of time with Hb values within the target range during the
secondary evaluation period (Weeks 40 -52)

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 12 of 105 •Proportion of subjects with Hb increase of >1.0g/dL from Baseline
•Time to achieve Hb increase of   >1.0g/dL from Baseline
•Mean change in Hb value between Baseline (mean pretreatment Hb) and the
primary evaluation period (mean Hb from Weeks 24 -36) stratified by [CONTACT_094] -
baseline ESA exposure
•Progression of CKD
•Proportion of subjects receiving IV iron therapy from Baseline  to Week 52
•
• Mean monthly dose of IV elemental iron administered from Baseline to Week 
[ADDRESS_495720] received IV iron  
•Proportion of subjects receiving RBC transfusion(s) from Baseline to Week
52
•ESA rescue
•Dose adjustments  from Baseline to Week 52
Safety Endpoints  •MACE, defined as all -cause mortality, non-fatal myocardial i nfarction  (MI) ,
or non -fatal stroke
•Individual components of MACE:
oAll-cause mortality
oNon-fatal myocardial infarction
oNon-fatal stroke
•Thromboembolic events:  arterial thrombosis, DVT, PE, or vascular access
thrombosis
•Hospi[INVESTIGATOR_19934] (HF)
•Expanded MACE, defined as all -cause mortality, non -fatal myocardial
infarction, non -fatal stroke, hospi[INVESTIGATOR_10889], or thromboembolic event
•Fatal/non -fatal MI
•Fatal/non -fatal stroke
•Sudden death
•Cardiovascular death
•Non-cardiovascular death
•Hospi[INVESTIGATOR_059]
•Hb >12.0  g/dL ,
 >13.0 g/dL, or >14.0 g/dL
•Hb < 8 .0 g/d L
•Hb increase >1.0  g/dL wi thin any 2 -week interval or >2.0  g/dL within any
4-week interval
•Adverse events (AEs) and serious adverse events (SAEs)
•Vital sign s and clinical laboratory values .
•Adrenal function assessment in a subset of subjects
Exploratory 
Endpoints  •Biomarkers (including, but not limited to , hepcidin and vascular endothelial
growth factor [VEGF]
•Time to achieve stable Hb values within the target range
•Proportion of subjects with Hb values within target range without evidence of
iron overload
Dosage and Regimens  Subjects will be randomized 1:1 to either:  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 13 of 105 Vadadustat  starting dose :  2 tablets once daily (300  mg/day)  
Darbepoetin alfa subcutaneous ( SC):  initial dose as follows  
•For subjects already on darbepoetin, the initial dosing  regimen in the study
should be based on the prior dosing regimen .
•For subjects taking other ESAs, the initial dose of  darbepoetin should be
based on the  current . Package Insert (PI) for investigational sites in the US,
and the European Summary of Product Characteristics (SmPC) for all other
investigational sites (non -US) for adult patients with CKD not on dialysis .
For all subjects, it is recommended that no additional ESA doses be administered after 
Screening visit 2 (SV2) and prior to the Randomization visit.  
Dose Adjustment Guidelines – All Treatment Groups  
Dosing will be initiated at the Baseline visit, and the first dose of study medication  
(vadadusta t or darbepoetin alfa)  will be administered at the investigative site after other 
Baseline procedures have been completed . The investigator may elect to postpone the 
initial dose of study medication until a subsequent visit b ased on the subject’s Hb level 
or Hb trajectory assessed at the Baseline visit,  or based on timing of the last ESA dose 
given during screening.  
For all subjects, it is recommended that no additional ESA doses be administered after SV2 and prior to the Randomization visit.  
Hemoglobin will be monitored via HemoCue
® point of care  device throughout the 
study to determine if the dose of study medication (vadadustat or darbepoetin alfa) will 
be adjusted , interrupted , or maintained .  
Year 1- 4 Treatment Period Visits  
From Week s 0 to 12, Hb will be measured via HemoCue every 2  weeks for monitoring 
for dose adjustment.  From Week  12 to Week  52, Hb via HemoCue  will be monitored 
every 4  weeks .  
From Week 53  through the end of the study , Hb will continue to be monitored via 
HemoCue to determine if the dose of study medication will be adjusted ,interrupted , or 
maintained .  Hemoglobin will also be assessed with a complete blood count (CBC) 
through the central laboratory for efficacy and safety evaluations; however, dose adjustments should be based  on the local HemoCue Hb value.  If the Investigator has an 
immediate clinical concern about a subject's HemoCue value, the Inv estigator may use 
clinical judg ment and repeat the HemoCue Hb, use local lab values or wait for central 
lab results. The test method utilized to inform the treatment decision must be recorded in the appropriate CRF   and the subject’s source. 
Year [ADDRESS_495721].  
The aim is to maintain a Hb level of 10 .0-11.0 g/dL in the US and 10 .0-12.0 g/dL 
outside the US throughout the stud y. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 14 of 105 Dose adjustment s will be guided by  [CONTACT_252632].  The Dose Adjustment  Algorithm for darbepoetin alfa will follow the 
Package Insert (PI) for investigational sites in the US, and the European Summary of 
Product Characteristics (SmPC) for all other investigational sites (non -US).  
. This protocol provides guidance for the treatment of subjects with anemia associ ated 
with CKD in order to achieve and maintain H b levels within the target H b range. Dose 
adjustment should be based on the investigator’s clinical discretion, incorporating the protocol guidance and considering the subject’s clinical condition, H b rate of  rise, H b 
rate of decline, Hb variability, and ESA responsiveness.  
In cases where the Investigator does not follow the dosing algorithm, the clinical 
circumst ances must be documented in the subject’s source
. 
For subjects who progress  to dialysis dependen t – chronic kidney disease ( DD-CKD ), 
and remain  on study treatment , the dose adjustment should be based on the  Dose 
Adjustment Algorithm s (Appendix C & D)  
Vadadustat  
Vadadustat  should be dosed according to the Dose Adjustment Algorithm s in 
Appendix C 
Darbepoetin alfa  
Subjects who are randomized to receive darbepoetin alfa, the initial dose will be  
according to the Dose Adjustment Algorithm (Appendix D).    
•For subjects already  on darbepoetin , the initial dosing  regimen in the study
should be based on the  prior dosing regimen .
For subjects taking other ESAs, the initial dose of  darbepoetin should be based on the  
Package Insert (PI) for investigational sites in the US, and the European Summary of 
Product Character istics (SmPC) for all other investigational sites (non -US). Following 
the dose conversion, darbepoetin alfa will be dosed SC, with dose adjustment s 
according to  the Dose Adjustment Algorithm . Darbepoetin alfa dosing is independent 
of the visit schedule, a nd the dosing schedule may shift per local standard of care and  
per Investigator discretion.  
Dosing Instructions  Vadadustat  
All subjects will start with 2 tablets daily ( 300 mg/day).  Dose levels of vadadustat  
include 150, 300, 450, and 600 mg (available tablet strength is 150  mg).  Each subject 
will take his/her  first dose of vadadustat  at the investigative site  at the Baseline visit.  
Thereafter, vadadustat  will be taken once daily on an outpatient basis.  Subjects may 
take vadadustat with or without foo d.  The  full dose should be taken at approximately 
the same time each da y.   The subject should be instructed to take any oral iron 
supplements  (including multivitamins containing iron), iron containing phosphate 
binders, or any medications containing iron  at least 2  hours before or 2  hours after the 
dose of vadadustat.  
Darbepoetin alfa  
Darbepoet in alfa will be administered, stored, and dispensed based on  the Dosing 
Algorithms, and Package Insert (PI) for investigational sites in the US, and the European Summary of Product Characteristics (SmPC) for all other investigational sites (non -US).  
Iron Supplementation  Investigators will prescribe iron supplementation during the study to maintain ferritin 
≥100 ng/mL or TSAT ≥20%.  In general, oral iron should be considered before 
initiating IV iron . Subjects already receiving oral iron supplementation as part of their 
treatment plan may continue their current treatment regimen.    
Important :  Because of the potential for oral iron to reduce the bioavailability of 
vadadustat, the study medication is not to be administered concurrently with an oral 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 15 of 105 iron supplement (including multivitamins cont aining iron ), iron containing phosphate 
binders, or any medications containing iron .  The subject should be instructed to take  
these medications at least 2  hours before or 2  hours after the dose of vadadustat.  
Rescue Therapy 
Guidelines  To ensure the safe ty of study subjects and to standardize the use of rescue in the study, 
rescue therapy guidelines are provided.   
1.ESA Rescue:   Starting at Week  6, subjects in both  treatment arm s will be allowed
(although will not be required) to have their Hb rescued with ESA therapy, per the
local standard of care.  If  possible, a  subject on vadadustat should be on the  maximum
dose of vadadustat  for [ADDRESS_495722] fulfill BOTH of the following:
•The subject has experienced worsening of symptoms of anemia (eg, fatigue,
weakness, shortness of breath, chest pain, confusion, or dizziness) compared
with Baseline
•The subject’s Hb is <9.0  g/dL
However, in the event the subject does not meet the above criteria for ESA rescue, ESA rescue is permitted when medically necessary at the discretion of the investigator.  
Reasons for ESA use will be captured in the appropriate CRF.  
The ESA rescue therapy should be administered as per the local institution’s guidelines 
and per the approved local product label .  While receiving ESA rescue therapy, 
subjects must temporarily discontinue taking study medication  (vadadustat or 
darbepoetin alfa) .  Hemoglobin will be monitored throughout the study at scheduled 
visits as defined in the Schedule of Activities using a HemoCue point of care device, 
and ESA rescue treatment should be stopped when Hb is ≥9 .5 g/dL.  A minimum 
interval must be observed prior  to restarting vadadustat after the last dose of rescue 
medication, and treatment may be resumed after the following intervals:  
•[ADDRESS_495723] dose of epoetin rescue
•[ADDRESS_495724] dose of darbepoetin alfa rescue
•[ADDRESS_495725] dose of methoxy polyethylene glycol -epoetin beta rescue.
Following ESA rescue, the study medication should be resumed at the same dose as 
previously used or one dose higher  and adjusted according to the Dose Adjustment  
Algorithms . 
2.RBC Transfusion:   Investigators will use their local institution’s transfusion
guidelines when determining whether to transfuse a study subject.  In general, in theevent of an acute or severe loss of blood, a RBC transfusion should be administered as
clinically indicated.  In less severe instances but where there may be worsening of
anemia or moderate to severe symptoms of anemia, RBC transfusions are permitted atthe discretion of the Investigator  given the medical necessity.  Reasons for RBC use
will be captured in the appropriate CRF.  Study medication  (vadadustat or darbepoetin
alfa) may be continued during the transfusion period .

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495726]’s Hb exceeds 14.0  g/dL or the rate of rise of Hb raises concern to the 
Investigator , the subject may be phlebotomized based on  the Investigator ’s judgment.  
The method of phlebotomy will be in accordance with the investigative site’s standard 
clinical practice.  
Study Medication 
Stoppi[INVESTIGATOR_245907] a subject meets one of the 
criteria.  
•ALT or AST >3x Upper Limit of Normal (ULN) and total bilirubin >2x ULN
•ALT or AST >3x ULN and INR >1.5
•ALT or AST >8x ULN
•ALT or AST remains >5x ULN over 2 weeks*
•ALT or AST > [ADDRESS_495727] with symptoms (e.g., fatigue, nausea, vomiting, right
upper quadrant pain, fever, rash) or eosinophilia
*Re-challenge generally should be avoided with ALT or AST >5x ULN unless there are
no other good therapeutic options .
Study Completion, 
Subject Completion, 
Premature Termination of Study 
Medication, or 
Withdrawal from the Study  Study Completion 
The study will be considered completed (end of trial) when approximately [ADDRESS_495728] accrued across the 2 NDD -CKD studies (Studies AKB -6548- CI-0014 and 
AKB -6548- CI-0015), and all enrolled subjects in this study have had the opportunity to 
have their Visit 13 (+/- 5 days).  
Subject Completion 
A subject will be considered as having completed the study, regardless of whether the 
subject is on or off study medication, and the subject is followed until global study end 
date as determined by [CONTACT_245935].   
Subjects who continue on the study medication up to global study completion will complete the EOT visit, followed by [CONTACT_98652] -up visit, which will include recording 
the end of study (EOS) status.  
It is important to note that a subject’s need for rescue therapy or initiation of dialysis, or the occurrence of MACE event(s):  
•Does not constitute study completion and
•Is not criteria for subject withdrawal from the study or
•Is not a requirement for permanent discontinuation of study medication(vadadustat or darbepoetin alfa).
Discontinuation of Study Medication Treatment  
Subjects who discontinue study medication prior to global study completion are 
expected to continue to be followed post discontinuation of study medication. These subjects are to have their EOT visit at the time of discontinuing study medication, have the Follow -up visit and continue to be followed through global study completion. At  
the time of global study completion, each subject will have an EOS assessment to complete participation in the study.   
Receipt of rescue therapy is not a reason for permanent stu dy medication 
discontinuation. While rec eiving ESA rescue, subjects must temporarily discontinue 
study medication, but are to resume study medication following the end of rescue therapy.  
During this study, it is anticipated that some subjects may permanently discontinue 
study medication (vadadustat or darbepoetin alfa) for any of the following reasons:  
•Unacceptable toxicity or drug intolerability
•Investigator discretion

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 17 of 105 •Subject withdrawal of consent
•Subject becomes pregnant
•Receipt of a kidney transplant
•Lack of efficacy
•Other reasons.
Subjects who undergo a solid organ (including kidney), hematopoietic stem cell, or 
bone marrow transplantation will have their study medication (vadadustat or darbepoetin alfa) permanently discontinued.   
It is important to continue to follow s ubjects  that permanently discontinue study 
medication  through global study  completion. Please, see “Procedures to Avoid 
Withdrawal or Lost to Follow -Up” for options to maintain subjects in the study. 
Complete
 Withdrawal from Study Visits/Assessments  
A subject has the right to withdraw consent for participation in the study at any time. 
Withdrawal of consent is a subject’s refusal of ALL methods of follow -up noted in the 
informed consent form:  procedures, participation in reduced procedures/study visits, telephon e contact [CONTACT_245936], source document or designated 
alternative contact, or access to medical records from alternative sources .It is important 
for the Investigator to review options with a subject that would allow follow -up 
through gl obal study completion before the subject withdraws consent. For patients 
considering withdrawal of consent, the Investigator should consult with the Medical Monitor to ensure all options have been explored and that there is complete understanding by [CONTACT_245989].  
Procedures to Avoid 
Withdrawal or Lost to Follow -Up Avoiding Withdrawal of Consent or Lost to Follow -Up 
As part of the informed consent process, only subjects who fully understand and agree to full participation and long -term follow -up should be consented to participate.  
It is important that subjects understand the long -term duration and purpose of a 
cardiovascular outcome trial and that the subject (or designee) continue to allow follow -up through global study completion which could be several years, even post 
subject’s permanent discontinuation of study medication.  
In all cases of impending study medication discontinuation  or subject request for  
stoppi[INVESTIGATOR_394634], Investigators will discuss wi th the subject their options of 
continuing in the study.  It is important to continue to follow subjects that discontinue 
study medication through global study completion at a frequency and approach that is agreed to between the Investigator and subject. Visit schedule and assessments are flexible and at the discretion of the Investigator and subject and will be clearly documented in the medical chart. Optimal data collection would include the following 
assessments through global study completion.  
•EOS subjec t status (must collect at minimum)
•MACE Endpoint Questionnaire
•AE Assessment
Alternative options to support continued follow -up include but are not limited to the 
following:  
1.Reduced frequency of on -site visits
2.Telephone visits in lieu of on -site visits
3.Telephone or any contact [CONTACT_394666]. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495729] method with an alternative person (family member
or medical designee)
5.Study team access to medical records for reporting MACE data or vital status
6.Reporting of vital status at the EOS visit which will o ccur at global study
completion
In the most extreme case, the protocol will accommodate minimal contact [CONTACT_4490] a 
subject or alternative method to obtain vital status at the global study completion. The 
objective is to keep a subject’s study status active to ascertain, at a minimum, vital status (alive or deceased) even if study medication is permanently discontinued (Section [IP_ADDRESS] ) or there is a significant change in a subject’s personal or medical 
situation (i.e., home move, dialysis unit/provider change, kidney transplant, long -term 
care facility admission).  
The Investigator will ensure understanding and documentation of the reasons for a 
subject’s desire to stop study procedures or stop study medication.  
Minimizing Lost to Follow -Up 
The Investigator must make every effort to contact [CONTACT_252606] “lost to follow -up” (LFTU). These 
actions must include, but are not limited to, the following:  
1.Contact [CONTACT_394667]/her listed contacts (to be
collected in the source at the subject’s entry into the study), as applicable.  This
includes making phone calls after normal business hours or on holidays or weekends.
2.Contact [CONTACT_423]’s primary care physician, referring specialist, pharmacist, or
other healthcare professional, as applicable.3.Send email, text, and postal mail with registered (traceable or trackable)  letters to
all the subject’s addresses and contact  [CONTACT_122473] , as applicable. R egistered (traceable or
trackable) letters need to be returned with a copy of the signature [CONTACT_246039], which can be compared to the ICF for vital status data. If undeliverable, then
send non- registered standard letters, which may be forwarded to  a new address if the
subject has moved.
4.Review available medical records/notes for details of hospi[INVESTIGATOR_602], clinic visits,
or other procedures that may indicate the status of the subject, as applicable.
5.Utilize the internet to search for additio nal contact [CONTACT_3031], as applicable.
6.Check local, regional, and national public records to locate the subject or search for
mortality status as allowed by [CONTACT_2371], as applicable.
It is important to obtain vital status at the global study completion for subjects that 
have been LTFU during the study. The Sponsor may utilize a third -party provider in 
accordance with all applicable guidelines and legislation to assist the site in locating contact [CONTACT_394668] (end of trial).  
Study Termination/  
Individual Study Site 
Termination  The entire study may be suspended or terminated by [CONTACT_394669].  If this occurs, prompt 
notification will be given to Investigators, Institutional Review Boards (IRBs)/Institutional Ethics Committees (IECs), and regulatory authorities in accordance with regulatory requirements. 
The Investigator must notify the Sponsor if the study is terminated by [CONTACT_394650]/IEC at the investigative site.  If the Investigator, IRB/IEC, or Sponsor 
decides to terminate or suspend the study conducted at a particular in vestigative site for 
safety, non- enrollment, non -compliance with the protocol, or other unanticipated 
reasons, the above parties will be promptly notified.  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 19 of 105 Statistical 
Considerations  Primary Efficacy Endpoint Analysis  
The primary efficacy endpoint is defined as the mean Hb change from Baseline (mean 
pretreatment Hb) to the mean Hb from Weeks 24 -36 (inclusive).  
The primary analysis will use an analysis of covariance (ANCOVA) with multiple 
imputation , stratified by [CONTACT_394670].  
A 2-sided, 95% confidence interval will be calculated for the difference between the 
vadadustat group and control group.  Noninferiority of vadadustat will be established if 
the lower limit of this confidence interval is ≥ -0.75 g /dL. 
Analysis of MACE and Expanded MACE Components  
The MACE endpoint (adjudicated result) will be analyzed as the time (days) from 
randomization dateto first MACE  +1.   Subjects who have not experienced an 
adjudicated MACE by [CONTACT_394671].  
Major adverse cardiovascular events will be analyzed using a stratified Cox 
proportional hazards model with a model containing treatment group.  The randomization strata will be used in this analysis.  The primary MACE an alysis will 
take place at study conclusion and will be based upon all subjects in the randomized 
population.  The hazard ratio (vadadustat/control) will be estimated, together with its 95% confidence interval.  As this individual study has not been powered  to provide a 
stand  alone assesment  of MACE, this interval will be considered as descriptive.  The 
time to first MACE will also be graphically presented using Kaplan -Meier curves.  
These analyses will be repeated with censoring occurring 4  weeks following e arly 
discontinuation of study medication.  
The following safety endpoints will also be summarized using time to event methods as for MACE:  
1)Individual components (all -cause mortality, non -fatal myocardial infarction,
non-fatal stroke) of MACE
2) Thromboembolic events (defined as arterial thrombosis, DVT, PE, or vascular
access thrombosis)
3)Hospi[INVESTIGATOR_19934]
4)Expanded MACE, defined as all -cause mortality, non -fatal myocardial
infarction, non -fatal stroke, hospi[INVESTIGATOR_10889], or thromboembolic event
For these endpoints the incidence ("yes"/"no") of the endpoint will be presented for 
each treatment arm.  Kaplan -Meier curves will be presented for each endpoint as the 
time of endpoint free survival (ie, time until endpoint or death).  
An independent statistical analysis center will perform analyses in support of the 
Independent Data Monitoring Committee (IDMC). 
Sample Size 
Estimation  For the primary efficacy analysis in this study, it will be assumed that the difference in 
mean change in Hb for vad adustat will be the same as the active control, darbepoetin 
alfa, and the common standard deviation for the mean change will be assumed to be 
1.5 g/dL.  The noninferiority margin of -0.75 g/dL will be used.  With these 
assumptions and approximately [ADDRESS_495730] >  90% power.  
The primary MACE analysis will be based upon all events that accrue across the 2 
NDD- CKD studies (Studies AKB -6548- CI-0014 and AKB -6548- CI-0015).  It has been 
calculated that [ADDRESS_495731] 80% power to establish 
noninferiority with a margin of 1.25, when evaluated with a 2 -sided 95% confidence 
interval assuming no difference between the treatments.  The power is >90% to 
establish a noninferiority ma rgin of 1.[ADDRESS_495732] ratio is 0.95 favoring vadadustat.  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 20 of 105 A MACE rate of 10% annually is anticipated in both treatment arms based on a 
comprehensive review of available epi[INVESTIGATOR_394635].   
Independent Data 
Monitoring Committee  An IDMC will be established to review and discuss the available study safety data as 
subjects are enrolled and followed.  The team will meet approximately twice per year throughout the course of the study.  The IDMC will be unblinded a nd will include, at a 
minimum, a nephrologist, a cardiologist, and a biostatistician.  The discussions of the 
IDMC will include a review of key safety data (ie, AEs, vital signs measurements, and  
laboratory assessments).  
Endpoint 
Adjudication 
Committee (E AC) An independent safety EAC, blinded to treatment group, will be formed prior to study 
commencement to adjudicate the components of the primary safety endpoints (eg,  all-
cause mortality, non -fatal myocardial infarction, and non-fatal stroke) .  
Thromboembolic events and hospi[INVESTIGATOR_245909].  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495733] OF ABBREVIATION S 
AE adverse event  
ALT  alanine aminotransferase (SGPT)  
ANOVA  analysis of variance  
AST  aspartate aminotransferase (SGOT)  
β-HCG beta human chorionic gonadotropin 
BCRP  breast cancer resistance protein  
BUN  blood urea nitrogen 
CBC  complete blood count 
CHF  congestive heart failure  
CIOMS  Council for International Organizations of Medical Sciences 
CKD chronic kidney disease 
CKD- EPI [INVESTIGATOR_245887] -Mantel -Haenszel  
CPK  creatine phosphokinase 
CRF  case report form  
CRO  contract research organization  
CRP  C-reactive protein
CS clinically significant
CV cardiovascular
CVD cardiovascular disease
DD-CKD dialysis -dependent chronic kidney disease
DILI Drug -Induced Liver Injury
dL deciliter
DNA deoxyribonucleic acid
DVT deep venous thrombosis
EAC Endpoint Adjudication Committee
ECG electrocardiogram
EDC electronic data capture
eGFR estimated glomerular filtration rate
EOS end of study
EOT end of treatment
EPO erythropoietin
ESC Executive Steering Committee
ESA erythropoiesis- stimulating agent
ESRD end-stage renal disease
EU European Union
FDA Food and Drug Administration
g gram
GCP Good C linical Practice
GFR glomerular filtration rate
GMP Good Manufacturing P ractice
HA health authority
Hb hemoglobin
HDL high-density lipoprotein

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 22 of 105 HF heart failure  
HIF hypoxia-inducible factor 
HIFPH  hypoxia-inducible factor prolyl- hydroxylase  
HIF-PHI hypoxia-inducible factor prolyl- hydroxyla se inhibitor 
IC50 50% inhibitory concentration 
ICH International Conference on Harmoniz ation  
ID identification  
IDMC  Independent D ata Monitoring C ommittee  
IDMS  isotope dilution mass spectrometry  
IEC independent ethics committee 
IMP Investigational Medicinal Product  
INR international normalized ratio  
IRB institutional review board  
IV intravenous (ly) 
IWR  interactive web response  
JSDT  Japanese Society for Dialysis Therapy  
JSN Japanese Society of Nephrology  
KDIGO  Kidney Disease:  Improving Global Outcomes 
kg kilogram 
LDH  lactate dehydrogenase  
LDL  low-density lipoprotein  
LLN  lower limit of normal 
LTFU  Lost to Follow Up 
MACE  major adverse cardiovascular events 
MCH  mean corpuscular (cell) hemoglobin  
MCHC  mean corpuscular (cell) hemoglobin concentration  
MCV  mean corpuscular ( cell) volume  
MedDRA  Medical Dicti onary for Regulatory Activities 
MI myocardial infarction  
µM micromolar  
mg milligram 
mL milliliter  
mmhg  millimeter s of mercury  
mRNA messenger ribonucleic acid   
NDD- CKD  non-dialysis dependent chronic kidney disea se 
ng nanogram 
NYHA  [LOCATION_001] Heart Association  
PD pharmacodynamics(s)  
PE pulmonary embolism  
PHD prolyl 4- hydroxylase domain  
PI  [INVESTIGATOR_245910] (s) 
PP per protocol 
PT prothrombin time 
PTT partial thromboplastin time  
QA quality assurance  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495734] of world  
SAE  serious adverse event  
SAP Statistical Analysis Plan 
SC subcutaneous (ly) 
SCr serum creatinine  
SGOT  serum glutamic oxaloacetic transaminase (AST)  
SGPT  serum glutamic pyruvic transaminase (ALT)  
SmPC  summary of product characteristics  
SV Screening visit  
TIBC  total iron binding capacity 
TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy 
TSAT  transferrin satu ration  
uACR  urine albumin- to-creatinine ratio  
ULN  upper limit of normal 
US [LOCATION_002]  
VEGF  vascular endothelial growth factor  
VHP  Voluntary Harmonisation Procedures 
WBC  white blood cell 
WHO World Health Organization  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 24 of 105 4 BACKGROUND INFORMATI ON 
Chronic kidney disease (CKD), defined as the presence of kidney damage or a decreased level of 
kidney function, is a major public health problem worldwide.  Globally, CKD is estimated to affect between 8 -16% of the population ( Jha et  al. 2013; KDIGO 2013).  At the most advanced 
stages of CKD, end -stage renal disease (ESRD), patients require chronic dialysis or kidney 
transplantation to sustain life.  Chronic kidney disease is not only a cause of ESRD, but is also a significant risk factor for cardiovascular disease (CVD), infection, cancer, and mortality ( Iseki 
and Kohagura 2007). 
Renal anemia often develops during the progression of CKD and is present in almost all patients 
with ESRD.  Anemia is defined as a decrease in circulating red blood cell (RBC) mass that is 
usually detected by [CONTACT_245944] ( Hb) concentration.  The causes of anemia in CKD include 
blood loss, shortened RBC lifespan, iron deficiency, erythropoietin (EPO) de ficiency, and 
inflammation ( Nurko 2006).  Although many factors contribute to anemia in CKD, it occurs 
primarily due to an inadequate synthesis of EPO by [CONTACT_8212], leading to a deficiency in the production of RBC progenitor cells by [CONTACT_245945].  Also contributing to anemia in CKD are impaired iron homeostasis and iron loss, which often necessitate iron supplementation (Nurko 2006).  Anemia in CKD patients usually occurs when the glomerular filtration  rate 
(GFR) falls below 60 mL/min/1.73 m
2, and is present in >90% of the patients undergoing 
dialysis (CKD Stage  5) (Goodkin et al. 2011). 
The main impact of anemia on organ function is reduced oxygen delivery to tissues leading to a constellation of symptoms including fatigue, shortness of breath, and exercise intolerance (Stauffer  and Fan  2014) .  In patients with anemia related to CKD, compensatory changes occur 
in cardiac structure and function, including an increase in cardiac output, the development of left ventricular hypertrophy, and, eventually, the development of heart failure ( Metivier  et al.  2000).  
Risk of stroke also increases with anemia, which may be an underlyi ng mechanism leading to 
stroke in CKD ( Abramson et al., 2003;  Iseki and Kohagura 2007 ).  Other consequences from 
anemia in CKD patients include impaired cognitive function, sleep disorders, and depressed immune function, which can impact the quality of life in these patients (Iseki and 
Kohagura 2007; NICE  2011).  Overall, anemia contributes to a poorer prognosis in patients with 
CKD (Nurko 2006; Iseki and Kohagura 2007). 
Erythropoiesis- stimulating agents (ESAs) administered either intravenously (IV) or 
subcutaneously (SC), along with oral or IV iron therapy, are currently the cornerstones for treating anemia in patients with CKD.  Treatment with exogenous recombinant ESAs can raise Hb levels, relieve symptoms, and reduce the complications of anemia, including RBC 
transfusions which carry the risks of infection, iron overload, and impact candidacy for kidney transplantation. 
Clinical practice guidelines and prescribing information for approved ESAs and guidelines 
provided by [CONTACT_24623] (US) Food and Drug Administration (FDA), the European Union (EU), the Japanese Society of Nephrology , and the Japanese Society for Dialysis Therapy 
Guideline Committee differ slightly in their recommendations for treatment of renal anemia, as summarized in  Table 1. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 25 of 105 Table 1 Treatment Guidelines and Prescribing Information for Renal Anemia in 
NDD- CKD  
KDIGO guidelines  Treatment should occur in symptomatic patients and when Hb generally falls below 
10 g/dL (Kidney Disease :  Improving Global Outcomes [KDIGO] 2012 ). 
US darbepoetin alfa 
label  Same as other approved ESAs, but also recommend that if Hb exceeds 10  g/dL in adults 
not on dialysis, the dose of ESA should be reduced or interrupted ( darbepoetin alfa 
[Aranesp®] US Package Insert 201 7). 
EU practice 
guidelines  Recommend that in high -risk patients with non-dialysis dependent CKD ( NDD -CKD ), 
treatment with ESAs should be initiated when the Hb levels are between 9  g/dL and 
10 g/dL, although in low -risk patients and those in whom a clear benefit of quality of life 
can be foreseen, the initiation of ESA therapy could be considered at higher Hb levels 
(Locatelli 2013 ). Detailed information on darbepoetin alfa in the EU is available on the 
European Medicines Agency web site. 
Japan practice 
guidelines  JSDT recommends that ESA treatment be initiated when Hb is below 11  g/dL following a 
diagnosis of renal anemia in NDD -CKD.  JSN 2013 does not provide a clear 
recommendation or maintenance range for Hb.  Both guidelines recommend that if the Hb 
exceeds 13  g/dL, the dose of ESA should be reduced or interrupted.  In patients with CVD  
or complications, ESA treatment should be reduced or interrupted if the Hb exceeds 
12 g/dL (Tsubakihara  2010; Japanese Society of Nephrology  2014 ). 
Abbrevi ations:  CVD  = cardiovascular disease; ESA  = erythropoietin stimulating agent; EU  = European Union; 
Hb = hemoglobin; JSDT  = Japanese Society for Dialysis Therapy; JSN  = Japanese Society of Nephrology; KDIGO  = Kidney 
Disease Improving Global Outcomes; NDD -CKD = non-dialysis dependent chronic kidney disease; US  = [LOCATION_002].  
The majori
ty of patients with CKD currently receive interventional therapy in the form of iron 
therapy, and may initiate therapy with an ESA if other interventions fail and Hb levels fall below 
9 to 11 g/dL, dependent upon local clinical practice guidelines. 
A number of large, prospective, randomized controlled trials in CKD (Stages 3 to 5) have 
explored the potential benefit of ESAs in patients with CKD with respect to overall mortality, cardiovascular (CV) events, and progression of CKD with higher Hb  targets (≥13 g/dL) (Besarab  
et al.  1998; Drüeke et al.  2006; Singh  et al.  2006; Pfeffer et al.  2009a ; Pfeffer et  al. 2009b) .  
These trials did not demonstrate the expected beneficial effects of correcting anemia on these outcomes, but suggested an increased risk of death and CV events when targeting higher Hb 
levels (Besarab  et al.  1998; Drüeke et al.  2006; Singh  et al.  2006; Pfeffer et al.  2009a ; Pfeffer  et 
al. 2009b) .  Additional analyses from these trials suggest that the risk of death or CV events 
appears to be highest in CKD patients who fail to respond to ESAs, as indicated by [CONTACT_245996] (Szczech  et al. 2008; Solomon et 
al. 2010) .  This suggests that in some subjects the ESAs themselves, and not the Hb  level, may 
be causative of the increase in events.  This is supported by [CONTACT_245997] ( Goodkin et al.  2011) . 
The risks identified with ESAs from these trials have led to changes in pr escribing information 
and practice guidelines in the US, the EU, and Japan that guide clinicians toward more cautious use of ESAs and targeting lower Hb  levels.  In the US, the mortality and CV risks associated 
with ESAs are outlined in a black-box warning in the prescribing information of ESAs with a recommendation to use the lowest dose possible to avoid transfusions.  While no similar major warnings exist in the EU Summary of Product Characteristics (SmPC) or on the approved labeling for ESAs in Japan, the EU SmPCs for ESAs do suggest caution with the use of these 
drugs, with a recommendation to keep Hb  levels below  12 g/dL, while the Japanese practice 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 26 of 105 guidelines recommend ESA treatment be reduced or interrupted if the Hb exceeds 12  g/dL in 
patients with CVD or complications.   Further, recent EU clinical practice guidelines (Locatelli  et 
al. 2013) recommend that risk factors for stroke (including a past history of stroke) and the 
presence of active malignancy or a past history of malignancy should be taken into account when 
making decisions to use ESAs for the treatment of anemia. 
The risks associated with ESAs, including an increased risk of death and CV events, highlight 
the need for additional therapi[INVESTIGATOR_245888] -based ESAs.  Therefore, the unmet medical need for the 
treatment of anemia in non -dialysis dependent CKD (NDD- CKD) patients remains high, 
especially from a CV safety perspective.   To fulfill this unmet need, the vadadustat clinical 
program is focused on developi[INVESTIGATOR_252584].  
 Hypoxia- Inducible Factor Prolyl -Hydroxylase Inhibitors 
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section. 
Vadadustat is a synthetic, orally bioavailable, small molecule being developed as an inhibitor of 
hypoxia-inducible factor prolyl- hydroxylases (HIFPHs) for the treatment of  anemia associated 
with CKD.  Hypoxia-inducible factor prolyl- hydroxylase enzymes are also referred to as prolyl 
4-hydroxylase domains (PHDs), of which the [ADDRESS_495735] commonly expressed are PHD2 and PHD3.Vadadustat is a slightly more potent inhibitor of PHD3 (50% inhibitory concentration[IC
50] = 0.08 µM) than of PHD2 (IC 50 = 0.19 µM).  The inhibition of PHD3 and PHD2 stabilizes
hypoxia-inducible factor (HIF)-2α and HIF-1α, which in turn stimulates the production of EPO.In vivo animal efficacy and messenger ribonucleic acid (mRNA) data indicate that vadadustatinduces the production of EPO from both renal and extra-renal sites (liver and brain), and thisincrease in EPO results in an increase in RBC production in the bone marrow.  In clinical trials,vadadustat has been shown to facilitate iron homeostasis by [CONTACT_394672].  Thisenables iron transport mechanisms that should enhance the terminal steps of erythropoiesis.Vadadustat offers the potential of flexible oral dosing that provides a more gradual and reliablemeans of titration than injectable hormones.  Therefore, vadadustat is being developed as analternative to the existing protein hormone ESAs.
 Summary of Clinical Experience  
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section. 
To date, the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of 
vadadustat have been characterized in   9 completed Phase 1 studies in healthy volunteers, 
including 1 ethno- bridging study in Caucasian and Japanese subjects , 1 completed Phase 1 study 
in subjects undergoing chronic hemodialysis, 3 completed Phase 2a s tudies in NDD- CKD 
subjects, 1 completed Phase 2b study in NDD- CKD  subjects , and  1 completed Phase 2 study in 
DD-CKD subjects.  The Phase 2a studies evaluated Stages 3, 4, and 5 CKD (not on dialysis)
subjects in a single -dose PK study, a multi-dose, 28-day, open-l abel, d ose escalation pi[INVESTIGATOR_799],
and a randomized, placebo-controlled study with 5 different dose groups dosed for 42 days.  ThePhase 2b study evaluated Stages 3, 4, and 5 CKD (pre- dialysis)  dosed for 20 weeks.  The phase 2

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495736] been accompanied by [CONTACT_394673] [TIBC] and decreases in hepcidin and 
ferritin.  Overall, the safety profile for vadadustat has  been acceptable and has supported further 
development. Vadadustat  has demonstrated dose proportional PK and dose-dependent PD  
(changes in serum EPO and/or Hb) in Phase 1 and Phase 2 studies covering the dose range of 80 
mg to 1200 mg after single administration and 500 to 900 mg after repeated daily administration. 
The plasma half -life of vadadustat was about 4 – 5 hours, 7 – 8 hours, and 9 to 10 hours in 
healthy subjects, NDD-CKD patients, and DD- CKD patients, respectively.   
Vadadustat is exte nsively metabolized. Vadadustat and its metabolites are eliminated from the 
body by [CONTACT_246000],  renal and fecal. The urinary excretion of vadadustat and its metabolites  has been shown to be less than 60% in healthy human volunteers. In a clinical study 
conducted to evaluate the effect of hemodialysis on the exposures to vadadustat, hemodialysis did not have an effect on the exposures of vadadustat or its metabolites. Given its short half- life 
and the dual routes of elimination, vadadustat is unlikely to accumulate in patients with CKD.   
The completed Phase 2b, randomized, double-blind, placebo-controlled study to assess the hematologic PD response, safety, and tolerability of oral vadadustat for 20 weeks was performed 
in 210 subjects w ith anemia associated with NDD -CKD.  Subjects were assigned to a study 
group based on their ESA status at Screening (naïve, previously treated, or actively treated) and were randomized 2:1 to receive either vadadustat at a starting dose of 450  mg/day or placebo.  
The dose of vadadustat was adjusted based on Hb levels and changes in Hb.  Compared with the 
placebo group, the vadadustat-treated group demonstrated a significantly higher proportion of responders, defined as subjects achieving  a Hb ≥11.0 g/dL or an increase ≥1.2 g/dL from baseline 
(54.9% versus 10.3%).
 Few vadadustat subjects exhibited Hb excursions >13.0 g/dL (4.0%), and 
favorable changes in iron mobilization and utilization were observed with treatment with vadadustat. 
The safety profile of vadad ustat in this study supported further development. 
Based on the Phase 1 and Phase  2 study results, vadadustat appears to  be a suitable candidate for 
continued development as a treatment for anemia in patients with CKD. 
 Potential Benefits and Risks  
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section. 
Trials of injectable erythropoiesis -stimulating agents (ESAs) in patients with anemia secondary 
to NDD- CKD or DD- CKD have demonstrated an increased risk of cardiovascular events 
associated with higher Hb targets  (Besarab 1998; Singh 2006; Pfeffer 2009 ). Post- hoc analyses 
pe
rformed by [CONTACT_394674] a
ssociation between these adverse outcomes 
and supraphysiologic serum EPO levels and/or Hb oscillations and overshoots ( McCullough 
2013, Unger 2010). In studies to date , oral vadadustat daily increased mean Hb with few 
excursions above the target range. In addition, serum EPO levels remained well below those 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495737] demonstrated that HIF stabilization downregulates the iron 
absorption regulator hepcidin, and upregulates the iron-mobilizing regulators ferroportin and transferrin (and its receptor) (Peyssonnaux et al. 2007). Potential clinical benefits include enhanced erythropoiesis and decreased exogenous iron requirements. 
The toxicological profile of vadadustat supports continued development in the ongoing Phase 3 
clinical trials.   Dose -limiting toxicity noted in the exploratory toxicology studies was due to 
hemoglobinuric nephropathy (rat) and emesis associated with body weight loss (dog).  Dose -
limiting toxicity noted in the sub -chronic and chronic toxicology studies was due to exaggerated 
pharmacology and the sequelae of events related to polycythemia (increased RBC mass, blood hyperviscosity and fibrin thrombi); polycythemia- related toxicity was consistent across species, 
monitor able and reversible.   In the completed clinical studies, vadadustat has had an acceptable 
safety profile to support further development. 
5 STUDY OBJECTIVES AND ENDPOINTS  
 Primary Objective  
The primary objective of this study is to demonstrate the efficacy and  safety of vadadustat 
compared with darbepoe tin alfa for the maintenance treatment of anemia in subjects with 
NDD- CKD after conversion from current ESA therapy. 
 Primary Efficacy Endpoint 
The primary endpoint used to assess the efficacy  objective will be the mean change in Hb 
between Baseline (mean pretreatment Hb) and the primary evaluation period (mean Hb  from 
Weeks  24-36). 
 Secondary Efficacy  Endpoints  
The k ey secondary efficacy endpoints include the following: 
•Mean change in Hb value between Baseline (mean pretreatment Hb) and the secondary
evaluation period (Weeks 40-52)
•Proportion of subjects with Hb  values within the target range  during the primary
evaluation period (Weeks 24 -36)
•Proportion of subjects with Hb values within t he target range during the secondary
evaluation period (Weeks 40-52)
Other secondary efficacy endpoints include: 
•Proportion of time with Hb values within the target range during the primary evaluation
period (Weeks 24-36)
•Proportion of time with Hb values within the target range during the secondary
evaluation period (Weeks 40-52)
•Proportion of subjects with Hb increase of >1.0 g/dL from Baseline

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 29 of 105 •Time to achieve Hb increase of >1.0 g/dL from Baseline
•Mean change in Hb between Baseline (mean pretreatment Hb) and the primary evaluation
period (mean Hb from Weeks 24-36) stratified by [CONTACT_094]-baseline ESA exposure
•Progression of CKD
•Proportion of subjects receiving IV iron therapy from Baseline visit to Week  52
•Mean monthly dose of IV elemental iron administered from Baseline to Week [ADDRESS_495738] received IV iron
•Proportion of subjects receiving RBC transfusion(s) from Baseline to Week 52
•ESA rescue
•Dose adjustments from Baseline  to Week 52
•
 Safety Endpoints  
Safety endpoints in this study include the following:  
•Major adverse cardiovascular events (MACE) , defi ned as all -cause mortality, non- fatal
myocardial i nfarction, or non- fatal stroke
•Individual components of MACE:oAll-cause mortality
oNon- fatal myocardial infarction
oNon- fatal stroke
•Thromboembolic events:  arterial thrombosis, deep vein  thrombosis (DVT), pulmonary
embolism (PE), or vascular access thrombosis
•Hospi[INVESTIGATOR_19934] (HF)
•Expanded MACE, defined as all -cause mortality, non-fatal myocardial infarction, non-
fatal stroke, hospi[INVESTIGATOR_10889], or thromboembolic event
•Fatal/non -fatal MI
•Fatal/non -fatal stroke
•Sudden death
•Cardiovascular death
•Non-cardiovascular death
•Hospi[INVESTIGATOR_059]
•Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL Hb < 8 .0 g/dL
•Hb increase >1.0  g/dL wit hin any 2-week interval or >2.0 g/dL within any 4 -week
interval
•AEs and SAEs
•Vital signs and clinical laboratory values
Exploratory Endpoints
•Biomarkers (including by [CONTACT_394675], and vascular endothelial growth factor[VEGF])
•Time to achieve stable Hb  values within the target range
•Proportion of subjects with Hb values within the target range without evidence of iron
overload

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 30 of 105 6 STUDY DESIGN 
 Study Design  
This is a P hase 3, randomized, open- label, active -controlled study of the efficacy and safety of 
vadadustat versus darbepoetin alfa for maintenance treatment of anemia after conversion from 
current ESA therapy in subjects with NDD- CKD.  Target enrollment in this study is 
approximately  1850 subjects at approximately 480 investigative sites in North Ame rica, Latin 
America, Europe, and Asia Pacific.  
Subjects will be randomized  at the Baseline visit using an Interactive Web Response (IWR)  
system to receive either vadadustat  or darbepoetin alfa  (based on the current PI [INVESTIGATOR_394636], a nd the SmPC for all other investigational sites (non- US) for adult 
patients with CKD not on dialysis).  For all subjects, it is recommend ed that no additional ESA 
doses be administered after Screening visit 2 ( SV2) and prior to the Randomization visit. 
Randomization will be stratified by [CONTACT_252612] (US versus EU  versus rest of world 
[ROW]), [LOCATION_001] Heart Association  congestive heart failure (CHF) Class 0 (no CHF) or I 
versus II or III, and study entry Hb level  (<10.0 g/dL versus ≥10.0 g/dL based on the most recent 
central laboratory Hb measurement prior to the Baseline/Randomization  visit).  Following 
randomization, there will be 3 periods during the study: 
•Conversion and M aintenance Period (Weeks 0 -52):  conversion to study medication for
maintaining Hb (Weeks 0 -23), primary efficacy evaluation (Weeks 24 -36), and secon dary
efficacy evaluation (Weeks  40-52)
•Long -term Treatment Period (Week 5 3-EOT ):  continued study medication to assess
long- term safety
•Follow-up P eriod  (EOT + 4 weeks):  post- treatment visit for safety (either in per son or
via telephone).
A HemoCue® point of care device will be used throughout the study to monitor Hb  to determine 
if the dose of study medication (vadadustat or darbepoetin alfa) will be adjusted.  From Weeks 0 to 12, HemoCue will be used to monitor Hb  every 2  weeks for dose adjustment.  From Week 12 
to Week 52, Hb  will be monitored via HemoCue every 4  weeks.  From Week  53 through the end 
of study, Hb  will continue to be monitored via HemoCue to determine if the dose of study 
medication will be adjusted , interrupted, or maintained.  Hemoglobin will also be assessed with a 
complete blood count (CBC) through the central laboratory for efficacy and safety evaluations; however, dose adjustments should be based on the HemoCue Hb  value.  
The aim  of the dosing strategy is to mai ntain  Hb level s of 10.0 g/dL to 11.0 g/dL in the US 
and 10.0 g/dL to 12.0 g/dL outside  of the US throughout the study.  
Subjects assigned to vadadustat will initiate dosing at 2  tablets once daily at the Baseline visit.  
Adjustments to doses for vadadustat will be guided by  [CONTACT_394676] ( Section  [IP_ADDRESS], Vadadustat Dosing and Dose Adjustment Algorithms ).   
Subjects assigned to darbepoetin alfa will be dosed SC at the Baseline visit and t he initial dose 
will be determined  based on the current PI [INVESTIGATOR_245912], and the SmPC for 
all other investigational sites (non -US) for adult patients with CKD not on dialys is.  Dose 
adjustments will be based on Hb concentration and Dose Adjustment Algorithms  ( Section  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 31 of 105 [IP_ADDRESS], Darbepoetin Alfa Dosing and Dose Adjustment Algorithms ). Darbepoetin alfa dosing is 
independent of the visit schedule, and the dosing schedule may shift per local standard of care 
and per I nvestigator discretion . 
Investigators will  prescribe iron supplementation during the study to maintain ferritin 
≥100 ng/mL or TSAT ≥20%  (see Section  8.4.6, Iron Supplementation for details regarding iron 
supplementation during the study). Subjects already receiving oral iron supplementation as part of their treatment plan may continue their current treatment regimen . 
Clinical and safety assessment s (including laboratory assays, PK evaluations [both vadadustat 
parent compound and metabolites], MACE endpoint data, vital sign measurements, and AE s) 
will be perform ed as indicated at Screening, during the Conversion and M aintenance Period 
(Weeks 0-52), during the Long- term Treatment Period  (visits approximately every 3 months), 
and during the Follow-up P eriod (4  weeks after the EOT).   Refer to Section  9, Study Procedures 
and Schedule of Activities  and Appendix A :  Schedule of Activities  for additional details.  
The study will be considered completed (end of trial) when  approximately 631 major adverse 
cardiovascular events  (MACE ) have accrued over  the 2- NDD-CKD studies (Stu dies 
AKB -6548- CI-0014 and AKB -6548- CI-0015), and all enrolled subjects have had the opportunity 
to have their Visit 13 (+/- 5 days). All subjects will remain in the study until the global study completion (end of trial), at which time subjects will be sche duled for a final visit, and the study 
will close (see  Section  11.1.2, Sample Size for the Primary Safety Endpoint ). 
  Rationale for Study Design 
During prior clinical trials, vadadustat has demonstrated  dose proportionate PK and dose-dependent PD.  Vadadustat  showed dose- dependent increases in EPO concentrations in Phase [ADDRESS_495739] been accompanied by [CONTACT_394677].  Overall, the 
safety profile for vadadustat  has been acceptabl e and has supported further development.  
Finally, the urinary excretion of vadadustat and its metabolites has been shown to be less than 
60% in humans.Given its short half life and the dual routes of elimination, vadadustat is unlikely to accumulate in patients with CKD. Based on the Phase [ADDRESS_495740] caution with the use of these drugs, with a recommendation to keep Hb  levels below 12  g/dL.  Recent clinical practice 
guidelines ( Locatelli  et al.  2013) recommend that risk factors for stroke and malignancy should 
also be taken into account when making treatment decisions to use ESAs for the treatment of anemia.  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 32 of 105 Given the concerns associated with marketed ESAs, a goal of this study will be to evaluate the 
CV events during the treatment of anemia with vadadustat.  The inclusion of a MACE endpoint in this study will allow for a statistical comparison of the rates of CV events between vadadustat and darbepoetin alfa treatment groups when used to treat anemia associated with NDD -CKD.  
While the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)  (Pfeffer  et 
al 2009b) compared different Hb  targets, the present study will have similar Hb targets between 
treatment arms .  Importantly, the Hb  goals for this study are lower than those used in TREAT 
and are consistent with practice guidelines and prescribing information for approved ESAs. 
This study will be performed as an open- label study.  Because Hb values are objective and will 
be measured via a central laboratory for all efficacy endpoints, efficacy assessments are not 
considered to be subject to bias with an open-label design.  Blinding of this study presented inherent practical problems, including potential dosing errors, inappropriate dose adjustments, and delays in dosing, which may also increase the safety risk to study participants.  Given the differing dosing regimens and routes for vadadustat (oral) and darbepoetin alfa (SC injection), a double-dummy design would have been required which also created ethical concerns and required extensive coordination to maintain the blind.   
To minimize bias, Sponsor and contract research organization (CRO) study teams will remain 
blinded to ‘by [CONTACT_3148]’ aggregated analyses , except for the unblinded statistician .  In addition, 
the study will involve blinded adjudication of MACE, the use of an independent data monitoring 
committee (IDMC), and an identical schedule of visits, procedures, and assessments for both treatment groups in order to reduce the potential for bias.  However certain  personnel directly 
involved in medical oversight of the study, regulatory reporting of safety information, and 
on-site monitoring activities may become unblinded to the treatment assignments of individual 
subjects during the course of the study.  
In addition, to reduce subjectivity of dose adjustment, adjustments to doses for vadadustat and 
darbepoetin alfa will be guided by [CONTACT_394678].  
 Dose Justification 
The starting dose and the proposed dosing algorithm in this study are designed to increase and maintain Hb in a predictable and controlled manner while minimizing abrupt increases or 
excessive rises in Hb levels.  Based on plasma concen trations and PD measures from previously 
conducted clinical studies with vadadustat, a population PK/PD model was developed.  Using this model and the proposed dosing algorithm, simulations were carried out to evaluate the effects of different starting dos es and the resulting Hb responses to support the dosing rationale.  
Results of the simulations indicated that a starting dose regimen of 300  mg once daily along with 
the proposed dosing algorithm are optimal to increase and maintain Hb  levels of 10.0 to 
11.0 g/dL in the US and 10.0 to 12.0 g/dL outside of the US while minimizing excessive rises.  
Executive Steering Committee and  Independent  Data Monitoring Committee  
6.4.1 Executive Steering Committee  
An Executive Steering Committee (ESC) will be established, which  will be blinded to the 
randomization, and will oversee the study and provide expert input to assure a high scientific standard. The ESC may function as the Publication Committee.  The ESC membership will comprise recognized academic leaders, including those from the field of nephrology and 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495741], and a biostatistician.  The discussions of the IDMC will include a review of key safety data (ie, AEs, vital signs, and laboratory assessments).  Written records of the IDMC meetings, the materials reviewed, and the decisions ma de will be maintained.  Details on the roles and responsibilities of 
the IDMC and guidelines for monitoring study safety data will be described further in the IDMC charter.  
 Endpoint Adjudication Committee  
An independent safety endpoint adjudication committee (EAC) will be formed prior to study commencement to adjudicate the primary safety endpoints ( all-cause mortality, non- fatal 
myocardial infarction, and non- fatal stroke).  Thromboembolic events and hospi[INVESTIGATOR_394637] E AC.  The committee will be blinded throughout the course of the 
study.  The EAC will be composed of independent experts with experience and training appropriate for adjudication of MACE, thromboembolic events, and hospi[INVESTIGATOR_10889].  Details on the responsibilities of the EAC will be described further in the EAC charter.  
[ADDRESS_495742] meet all of the following criteria .  No study procedures 
(including Screening  tests) may be performed until after  the informed consent has been legally 
signed . 
An optional Pre- Screen visit can be used to perform initial tes ting of the Hb  level using a  
HemoCue point of care devi ce to evaluate whether a subject should progress to full Screening 
procedures.  A separate Pre-Screen informed consent (distinct from the full protocol informed consent) will be implemented for the Pre -Screen visit.  To be eligible for the Pre -Screen Hb 
measurement, a study subject or their legally acceptable representative must provide  valid 
informed consent prior to the Pre-Screen procedure.  For a better understanding of the Pre-Screening visit, please see Section  9.3.1, Pre -Screening Visit . 
 Inclusion Criteria  
Subjects must meet all of the following inclusion criteria to be eligible:  
1.At least 18  years of age
2. Diagnosis of C KD with an estimated glomerular filtration rate ( eGFR ) ≤60 mL/min/1.73 m2
using the 2009 Chr
onic Kidney Disease Epi[INVESTIGATOR_10444] (C KD-EPI) creatinine
equation during Screening (see Appendix B :  CKD- EPI [INVESTIGATOR_394638]) and not
expected to start dialysis within 6  months of Screening

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 34 of 105 3. C urrently maintained on  ESA  therapy  with a dose received  within  6 weeks prior to or during
Screening
4.Mean  Screening  Hb between 8.0 and 11.0 g/dL (inclusive)  in the US and between 9.0 and
12.0 g/dL (inclusive) outside of the US,  as determined by [CONTACT_144372] 2  Hb values
measured by [CONTACT_394679] S creening
5.Serum ferritin ≥ 100 ng /mL and TSAT ≥ 20% during S creening
6.Folate and vitamin B 12 measurement s ≥lower limit of normal (LLN)  during S creening
7. Understands the procedures and requirements of the study and provides written informed
consent and authorization for protected health information disclosure.
 Exclusion Criteria  
Subjects presenting with any  of the following will not qualify for entry into the study:  
1.Anemia d ue to a cause other than CKD or subjects with active bleeding  or recent blood loss
2.Subjects with sickle cell disease, myelodyspl astic syndromes, bone marrow fibrosis,
hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
3.RBC  transfusion within 8 weeks prior to randomization
4.Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase ( SGOT), alanine
aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), or total bilirubin
>2.0 x upper limit of normal (ULN) during Screening.  Subjects with a history of Gilbert’s
syndrome are not excluded.
5. Uncontrolled hypertension (confirmed diastolic blood pressure >110 mmHg or systolic blood
pressure >180 mmHg) during Screening
6.Severe heart failure during Screening ( New Yor k Heart Association Class IV)
7. Acute coronary syndrome (hospi[INVESTIGATOR_252587] ),
surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral arterydisease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair,sustained ventricular tachycardia,  hospi[INVESTIGATOR_10889], or stroke within 12 weeks prior to
or during Screening
8.History of active mali gnancy within 2 years prior to or during Screening, except for treated
basal cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, or cervical
carcinoma in situ
9.History of DVT or PE within 12 weeks prior to  randomization
10. History of hemosiderosis or hemochromatosis11. History of prior organ transplantation or scheduled organ transplant (subjects on kidney
transplant wait-list are not excluded), or prior hematopoietic stem cel l or bone marrow
transplant (corneal transplants and stem cell therapy for knee arthritis are not excluded)
12.Use of an investigational medication or participation in an investigational study within30 days or 5 half- lives of the investigational medication (whichever is longer), prior to t he
Screening visit
13. Previous participation in this study, or previous participation in a study with a hypoxia-
inducible factor prolyl-hydroxylase inhibitor (HIF- PHI)  other than vadadustat
14.Females who are pregnant or breast -feeding.  Women of childbearing potential who are
unable or unwilling to use an acceptable method of contraception  (refer to Section  9.1.3,
Contraception and Pregnancy Avoidance Measures )
15.Non-vasectomized male subjects who are unable or unwilling to use an acceptable method of
contraception (refer to Section  9.1.3, Contraception and Pregnancy Avoidance Measures )

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495743] not suitable
for participation in the study
17. Hypersensitivity to darbepoetin or vadadustat, or to any of their excipi[INVESTIGATOR_394639]/or rescreened at the discretion of the Investigator. 
7.4.[ADDRESS_495744] any 
individual laboratory parameter retested 1 time within the 8-week Screening period at the 
discretion of the Investigator.  Retesting within the 8-week Screening period does not constitute 
rescreening; however, if retesting falls outside of the 8-week  Screening period, it should be 
considered a rescreen.  All Screening laboratories, including any repeat measurements, must be 
performed within the 8- week Screening window with a minimum of [ADDRESS_495745] 
qualifying repeat measurement and the Baseline visit.  
For eligibility, the average of 2 Hb values measured by [CONTACT_245933] (SV1, SV2, or retest) must be < 11.0 g/dl in the US or < 12.0 g/dl outside the US.  
Subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may 
receive replacement therapy based on the investigative sites’ standard of care during the 
screening period and retest the laboratory parameter(s).  Subjects who receive iron replacement may retest screening Hb a minimum of [ADDRESS_495746]’s status has progressed and that the subject may now qualify for the study.  Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may be 
considered for rescreening after receiving replacement therapy.  
Screening is limited to 3 attempts (Screening and 2 additional rescreening attempts). 
Subjects who fail to qualify for the study at the initial Screening visit will receive a new subject number for each rescreening attempt.  If rescreened, the subject will also sign a new informed consent form and will repeat all Screening procedures for each rescreening attempt.  
Study C ompleti on, Subject Completion, Study Discontinuation, and Withdrawal of 
Subjects  
7.5.1 Study Completion 
The study will be considered completed (end of trial) when approximately [ADDRESS_495747] accrued across  the 2 NDD- CKD studies (Studies AKB -6548- CI-0014 a nd AKB-6548- CI-
0015), and all enrolled subjects have had  the opportunity to have their Visit 13 (+/- 5 days). 
These 2 NDD -CKD studies were sized based on power considerations for the primary safety 
analysis of MACE events, and thus each study is highly pow ered (>90%) for the primary and 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495748] completed (or had the opportunity to 
complete) the primary evaluation period (Weeks 24-36). 
7.5.[ADDRESS_495749] will be considered as having completed the study, regardless of whether they are on or 
off study medication (vadadustat or darbepoe tin alfa), if the subject is followed until global study 
completion (end of trial) .  The tab le outlines the different categories of subjects and handling the 
global study completion activities.  
Subject Status at time of 
Global Study Completion End of Treatment (EOT)  End of Study (EOS)  
Subject on study medication 
(includes those on temporary interruption) After announcement of global 
study completion : 
•Perform EOT visit
•Perform the Follow-
up visit 4 weeks after
EOT visit and includeEnd of Study (EOS)subject statusNot applicable 
The EOS subject status will be captured  as part of the 
Follow-up visit 
Subject permanently 
discontinued study medication and continues to be followed in the study At time of permanent 
discontinuation of study medication : 
•Perform EOT  visit
•Perform the Follow -
up visit 4 weeks afterEOT visitOptimal data collection 
would include the following assessments: 
 
•EOS subject status
(must collect at
minimum)
•MACE Endpoint
Questionnaire
•AE Assessment
Subject Lost to Follow -up Not applicable Work with third party vendor 
to ascertain vital status and 
complete EOS subject status  
If subject -site contact [CONTACT_394680], 
collect available information 
for EOS subject status   
Subject Withdrawn Consent Not applicable  Complete the EOS subject 
status form at time of withdrawal of consent, absolute refusal of ALL methods of MACE and health status follow -up 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495750] 
status form at the time of 
death (see Section 10 
Adverse Events  for more 
details on other actions related to reporting a death) 
The need for
 rescue therapy does not constitute study completion and is not a criterion for 
subject withdrawal from the study.  Also, the occurrence of a safety endpoint, or if a subject 
progressed to chronic dialysis dependent CKD (DD -CKD) , does not constitute study completion 
and is not a criterion for subject withdrawal from the study or study medication (vadadustat or darbepoetin alfa).  
7.5.[ADDRESS_495751] Discontinuation  
During this study, it is anticipated that  some subjects may permanently discontinue study 
medication (vadadustat or darbepoetin alfa) for any of the following reasons: 
•Unacceptable toxicity or drug intolerability
•Investigator discretion
•Subject withdrawal of consent
•Subject becomes pregnant
•Receipt of a kidney transplant
•Lack of e fficacy
•Other reasons.
Lack of efficacy is defined as inadequate response to darbepoetin alfa or vadadustat in the investigator’s opi[INVESTIGATOR_1649]. 
Subjects who undergo a solid organ (including kidney), hematopoietic stem cell, or bone marrow 
transplantation will have their study medication (vadadustat or darbepoetin alfa) permanently discontinued. 
See Section 9.4, Study Medication Stoppi[INVESTIGATOR_245919]. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 38 of 105 It is important to continue to follow subjects that permanently discontinue study medication. 
Please see Sections  [IP_ADDRESS], Temporary Interruption of Study Medication and  [IP_ADDRESS], Permanent 
Discontinuation of Study Medication , and  Appendix A :  Schedule of Activities ). 
Receipt of rescue therapy is not a reason for permanent study medication discontinuation.  While 
receiving ESA rescue, subjects must temporarily discontinue study medication (vadadustat or darbepoetin alfa), but should resume study medication once rescue therapy has ended, as detailed in Section  8.4.7, Rescue Therapy . 
As part of the informed consent process, only subjects who fully understand and agree to full participation and long- term follow -up should be consented to participate. 
[IP_ADDRESS] Temporary Interruption of Study Medication  
Subjects who temporarily interrupt study medication (vadadustat or darbepoetin alfa) treatment after the first dose and prior to compl etion of the study will continue with study visits and 
assessments.  Unless contraindicated, treatment should be resumed wherever possible and 
routinely considered at every visit following study medication discontinuation.  If a subject does 
not return for a scheduled visit, every effort should be made to contact [CONTACT_423]. If a subject’s 
study medication has been temporarily interrupted for more than [ADDRESS_495752] the Medical Monitor before resuming study medication. 
[IP_ADDRESS] Permanent Discontinuation of Study Medication 
Subjects who permanently discontinue study medication  prior to global study completion are 
expected to continue to be followed post discontinuation of study medication. These subjects are to 
have their EOT visit at the time of permanent discontinuation of study medication have the Follow-
up visit [ADDRESS_495753] an End of Study (EOS) assessment to c omplete 
participation in the study. Receipt of rescue therapy is not a reason for permanent study medication 
discontinuation. While receiving ESA rescue, subjects must temporarily discontinue study 
medication but should resume study medication following the end of rescue therapy.  
For subjects who permanently discontinue study medication, the Investigator will resume 
standard of care treatment, including ESAs and iron therapy, as deemed appropriate.  
It is important to continue to follow subjects that permane ntly discontinue study medication.  
[IP_ADDRESS] Complete Withdrawal from Further Study Visits/Assessments  
A subject has the right to withdraw consent for participation in the studyWithdrawal of consent 
is a subject’s refusal of ALL methods of follow-up noted in the informed consent form:  
procedures, participation in reduced procedures/study visits, telephone contact [CONTACT_245936], source document or designated alternative contact, or access to medical records from alternative sources . 
It is impor t
ant to provide options for the subject to consider for long-term follow-up before the 
subject withdraws consent. It is important for the Investigator to review options with a subject that 
would allow follow-up through global study completion before the subject withdraws consent. For 
subjects considering withdrawal of consent, the Investigator should consult with the Medical Monitor 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495754] for 
what constitutes withdraw al of consent. 
[IP_ADDRESS] Procedures to Support  Continued Study Participation  
As part of the informed consent process, only subjects who fully understand and agree to full 
participation and long- term follow -up should be consented to participate. It is important that 
subjects understand the long -term duration and purpose of a cardiovascular outcome trial 
and that the subject (or designee) continue to allow follow -up through global study 
completion which could be several years, even  post subject ’s permanent discontinua tion of 
study medication.   
In all cases of impending study medication  discontinuation or subject request for  stoppi[INVESTIGATOR_245920], the Investigator will  discuss with the subject their options of continuing in the study.   
It is important to continue to follow every randomized subject, even  if discontinued study 
medication,  through global study completion at a frequency and approach that is agreed to 
between the Investigator and subject.  Visit schedule and assessments are flexible and at the discretion of the Investigator and subject and will be clearly documented in the medical chart . 
Optimal data collection would include the following assessments through global study completion :
 
•EOS subject status (must collect at minimum)
•MACE Endpoint Questionnaire
•AE Assessment
The protocol allows flexibility of follow -up to maintain the subjects in active status post 
permanent discontinuation of study medication. For those subjects who decline full participation in the study post discontinuation of study medication, other options for continued follow-up on a subject include (but are not limited to):  
1. Reduced frequency of on- site visits
2. Telephone visits in lieu of on- site visits
3. Telephone or any contact [INVESTIGATOR_12183] (e.g., email, site staff visit subject’s home, etc.) to
verify vital status
4. Telephone or any contact [CONTACT_245990] (family member or medical
designee)
5.Study team access to medical records for reporting MACE data or vital status
In the most extreme case, the protocol will accommodate minimal contact [CONTACT_4490] a subject or alternative method to obtain the subject’s vital status. The objective is to keep a subject’s study 
status active to ascertain at a minimum vital status (alive or deceased)  at the global study 
completion .  
The Investigator will ensure understanding and documentation of the reason(s) for a subject’s desire to stop study procedures or stop study medication.  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 40 of 105 [IP_ADDRESS] Procedures to Prevent “Lost to Follow -up” 
The Investigator must make every effort to contact [CONTACT_245954] “lost to follow -up.”  These actions must include, but are 
not limited to, the following:  
1. Contact [CONTACT_245955] (to be collected in source at the
subject’s entry into the study), as applicable.  This includes making calls after normalbusiness hours or on holidays and weekends.
2. Contact [CONTACT_423]’s primary care physician, referring specialist, pharmacist, and/or other
healthcare professional (using the contacts provi ded by [CONTACT_394681]), as
applicable
3.Send email,  text,  and postal mail with registered (traceable or trackable)  letters to  all the
subject’s addresses and contact [CONTACT_122473], as applicable. Registered (traceable or trackable)
letters will be returned with a copy of the signature [CONTACT_246040], which can becompared to the ICF for vital status data. If undeliverable, then send non- registered standard
letters, which may be forwarded to a new address if the subject has moved.
4.Review available medical records/notes for details of hospi[INVESTIGATOR_602], clinic visits, or otherprocedures that  may indicate the status of the subject, as applicable
5.Utilize the internet to search for additional contact [CONTACT_394682] .
6.Check local, reg ional, and national public records to locate the subject or search for mortality
status as allowed by [CONTACT_2371], as applicable.
It is important to obtain at a minimum vital status (alive or deceased) at the global study completion for all randomized subjects, including those that have been LTFU during the course of the study. 
The Sponsor may utilize a third-party provider in accordance with all applicable guidelines and 
legislation to assist the site in locating contact [CONTACT_394683] s tudy or in 
locating the vital status for all of their randomized subjects in anticipation of global study completion (end of trial). 
[ADDRESS_495755], Supplies, and Storage  
Oral vadadustat and darbepoetin alfa for injection will be provided and shipped by [CONTACT_245958]/distributor.  Both vadadustat and darbepoetin alfa will be supplied as open- label supplies.  All study medication supplies must be kept in a temperature -controlled, 
locked facility, accessible only to authorized study personnel. 
The Investigator or designated study personnel will be responsible for preparing study 
medication for dispensing to the subject ( Section  8.2, Dispensing Procedures ) and for study 
medication supply accountability ( Section  8.3, Product Accountability and Destruction).  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 41 of 105 8.1.1 Vadadustat 
Vadadustat will be provided as 150 mg white to off-white, round, bi-convex film- coated tablets 
for oral administration.  The tablets will be packaged in high-density polyethylene bottles with 
child -resistant closures, polypropylene liner, and induction seal.  Labeling will be in accordance 
with current Good Manufacturing Practices (GMP) and local regulatory requirements.  
Dose levels utilized in this study will include:  150 mg  (1 tablet), 300 mg  (2 tablets), 450 mg 
(3 tablets), and 600 mg  (4 tablets) per  day.  
Vadadustat should be stored per the product label .  Please consult the Pharmacy Manual for 
details on storage and managing temperature excursions.  
8.1.2 Darbepoetin Alfa  
Darbepoetin alfa will be provided in its commercially -approved primary packaging and stored 
per the Package Insert (PI) for investigational sites in the US, and the European Summary of 
Product Characteristics (SmPC) for all other investigational sites (non -US) for adult patients with 
CKD not on dialysis.. 
 Dispensing Procedures  
The Investigator will maintain  record of all vadadustat tablets and darbepoetin alfa injections 
dispensed to and returned from each subject during the study.  Subjects will receive ei ther 
vadadustat tablets or darbepoetin alfa according to the randomization assignments provided via the IWR system (see Section  8.4.2, Randomization ). 
8.2.[ADDRESS_495756]’s current vadadustat supply at a given study visit 
(Section  [IP_ADDRESS], Vadadustat Dosing and Dose Adjustment Algorithms ).  Subject s will be 
instructed to finish 1 bottle before opening a new bottle. 
At the Baseline visit, study subjects will be provided with 1  bottle of vadadustat.  Each bottle of 
vadadustat will contain 100 tablets of vadadustat (150 mg tablets).  
Subjects should be instructed to bring unused vadadustat and empty bottles to each study visit for product accountability.  Empty bottles will be collected at these study visits.  Previously dispensed bottles (whether opened or unopened) with remaining tablets may be re-dispensed to the subject during the dosing phase of the study. 
A Vadadustat Dosing Information Sheet will be provided to the subject at dispensing of study 
medication.  
8.2.2 Dispensing of Darbepoetin Alfa  
Darbepoetin alfa will be dispensed according to the IWR system assignment as follows: 
•For subjects already  on darbepoetin, the initial dosing regimen in the study should be
based on the prior dosing regimen.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 42 of 105 •For subjects taking other ESAs, the initial dose of  darbepoetin should be based on the
Package Insert (PI) for investigational sites in the US, and the European Summary of
Product Characteristics (SmPC) for all other investigational sites (non -US) for adult
patients with CKD not on dialysis. .
Dispensing of additional darbepoetin alfa at subsequent dosing visits wi ll be managed by [CONTACT_245959] ( Section  [IP_ADDRESS], Darbepoetin Alfa Dosing and Dose Adjustment Algorithms ). 
Darbepoetin alfa doses may be self -administered or staff administered at the site facility or by 
[CONTACT_394684]’s determination and local practice.  
Subjects should be instructed to bring the darbepoetin boxes to each study visit for drug 
accountability. There will be no physical accountability performed with used syringes. The investigative site will maintain site drug accountability records of the actual syringes dispensed and used by a subject. 
A Darbepoetin Alfa Dosing Information Sheet will be provided to the subject at dispensing of 
study medication.   
 Product Accountability and Destruction 
Product accountability should be an ongoing process throughout the study.  All study medication (vadadustat and darbepoetin alfa) must be accounted for and any discrepancies explained.  The Investigator or designated study personnel are responsible for keepi[INVESTIGATOR_252599], all supplies retained in inventory at the investigative site, and study medication dispensed to or returned from each subject.  Records will be maintained that accurately reflect the drug accountability of vadadustat and darbepoetin alfa at all times.  
Proper drug accountability includes, but is not limited to: 
•Continuously monitoring expi[INVESTIGATOR_245893]
•Frequently verifying that actual inventory matches documented inventory
•Verifying that the log is completed for all drug received and that all required f ields are
complete, accurate, and legible.
If any dispensing errors or discrepancies are discovered, the Sponsor must be notified 
immediately.  
During the study, the Investigator will be notified of any expi[INVESTIGATOR_252589].  If an expi[INVESTIGATOR_113982], the 
investigative site must complete all instructions outlined in the notification, including segregation of expi[INVESTIGATOR_394640] e for 
destruction. 
Prior to investigative site closure and at appropriate intervals during the study, a representative 
from the Sponsor will perform clinical study materia l accountability and reconciliation. 
At the end of the study, the Investigator will retain all original documentation regarding  study material  accountability, return, and/or destruction, and copi[INVESTIGATOR_245895]. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 43 of 105 All unused and/or partially used vadadustat or darbepoetin alfa should be returned to the Sponsor 
or destroyed at  the investigational site, as specified by [CONTACT_1034].  Appropriate records of the 
disposal will be documented and maintained.  No unused vadadustat or darbepoetin alfa may be disposed of until fully accounted for by [CONTACT_1034]’s monitor (or designee).  Empty containers may be disposed of according to local procedures. 
Treatment of Subjects  
8.4.1 Treatment  Group Assignments  
Subjects will be randomized in a 1:1 ratio via the IWR system to either: 
•Vadadustat (starting dose of 2 tablets once daily [300 mg/day])
•Darbepoetin alfa (starting dose based on the current PI  [INVESTIGATOR_245912],
and the SmPC  for all other investigational sites (non -US) for adult patients with CKD not
on dialysis)
For all subjects, it is recommended that no additional ESA doses be administered after SV2 and 
prior to the Randomization visit. 
Target enrollment for each treatment group is approximately 925 subjects . 
8.4.2 Randomization 
This study will be open to up to approximately 1850 subjects with NDD -CKD with an eGFR  
≤60 mL/min/1.73 m2 (pre-dialysis).  
Using an IWR system, eligible subjects will be assigned using permuted block randomization 
and a 1:[ADDRESS_495757] to:  1) geographic region (US versu s EU v ersus 
ROW); 2) [LOCATION_001] Heart Association CHF Class (0  (no CHF) or I v ersus II or III); and 3) 
study entry Hb level (<10.0  versus ≥10.0 g/dL, based on the most recent central laboratory Hb  
measurement prior to the Baseline/Randomization  visit).  
8.4.3 Blinding  
This will be an open-label study.  Treatment assignment will be done through the IWR system 
and the Investigator, Sponsor, and CRO teams  will not be aware of which treatment will be 
assigned next.  Treatments will be administered in an open -label fashion .The Sponsor and CRO 
study teams will be blinded to ’by [CONTACT_3148]’ aggregated analyses  except for the unblinded 
statistician .  In addition, the study will involve blinded adjudication of MACE, the use of an 
IDMC, and an identical schedule of visits, procedures, and assessments for both treatment groups in order to reduce the potential for bias.  However certain Sponsor personnel directly involved in medical oversight of the study, regulatory reporting of safety information, and on- site monitoring 
activities may become unblinded to the treatment assignments  of individual subjects during the 
course of the study.  
The EAC will remain blinded throughout the full course of the study. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495758] dose of study medication (vadadustat 
or darbepoetin alfa) will be admini stered at the investigative site after other Baseline visit 
procedures have been completed.  The investigator may elect to postpone the initial dose of study 
medication until a subsequent visit based on the subject’s Hb level or Hb trajectory assessed at 
the Baseline visit , or based on timing of last ESA dose given during Screening . 
For all subjects, it is recommended that no additional ESA doses be administered after SV2 and prior to the Randomization visit. 
Year 1 -4 Treatment Period Visits  
Hemoglobin will be monitored via HemoCue throughout the study to determine if the dose of study medication (vadadust at or darbepoetin alfa) will be adjusted , interrupted, or maintained.  
From Weeks  [ADDRESS_495759]’s source when a Hemocue is taken .   Hemoglobin will also be assessed with a 
CBC through the central l aboratory for efficacy and safety evaluations; however, dose 
adjustments should be based on the HemoCue Hb  value.  If the Investigator has  an immediate 
clinical concern about a subject’s HemoCue value, the Investigator may use clinical judgment 
and repeat t he HemoCue Hb, use local lab  values , or wait for central lab results. The test method 
utilized to inform your treatment decision must be recorded in the appropriate CRF and subject’s 
source.   
Year [ADDRESS_495760]. The aim is to maintain a Hb level of 10.0-11.0 g/dL in the US and 10.0-12.0  g/dL outside of the 
US throughout the study. Dose adjustments for vadadustat and darb epoetin alfa will be guided by [CONTACT_394685].  TheDose Adjustment Algorithm for darbepoetin alfa will follow 
the Package Insert ( PI) for investigational sites in the US, and the European Summary of Product 
Characteristics ( SmPC ) for all other investigational sites (non -US).  
This protocol provides guidance for the treatment of subjects with anemia associated with CKD 
in order to achieve and maintain Hb levels within the target Hb range. Dose adjustment should 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 45 of 105 be based on the Investigator’s clinical discretion, incorporating the protocol guidance and 
considering the subject’s clinical condition, Hb rate of rise, Hb rate of decline, Hb variability, 
and ESA responsiveness.  
In cases where the Investigator does not follow t he dosing algorithm, the clinical circumstances 
must be documented in the subject’s source.  
[IP_ADDRESS] Vadadustat Dosing and Dose Adjustment Algorithms  
Subjects assigned to vadadustat will initiate dosing at 2 tablets once daily (300  mg/day).  Dose 
levels of vadadustat utilized in this study include 150, 300, 450, and 600 mg (available tablet 
strength is 150 mg).  
Dosing will be initiated at the Baseline visit and the first dose of vadadustat will be administered at the investigative site (study physician’s clinic) after other Baseline visit procedures have been 
complete d.  The Investigator may elect to postpone the initial dose of study medication until a 
subsequent visit based on the subject’s Hb level or Hb trajectory assessed at the Baseline visit,  
or based on timing of the last ESA dose given during screening.  
Thereafter, vadadustat will be taken once daily on an outpatient basis.  Subj ects may take 
vadadustat with or without food and should be instructed to swallow the tablet(s) whole.  Subjects should be instructed to take vadadustat at roughly the same time each  day.  
During the study, vadadustat should be dosed according to the  Dose Adjustment Algorithm in Appendix C:  Vadadustat Dosing and Dose Adjustment Algorithms . 
For subjects progress ed to DD-CKD, and continuing on vadadustat, the dose adjustment should 
be based on the Dose Adjustment Algorithms ( Appendix C:  Vadadustat Dosing and Dose 
Adjustment Algorithms ).
 
[IP_ADDRESS] Darbepoetin Alfa Dosing and Dose Adjustment Algorithms  
For s ubjects randomized to receive darbepoetin alfa, the initial dose will be determined  as 
follows: 
•For subjects already on darbepoetin, the initial dosing regimen in the study should be
based on the prior dosing regimen.
•For subjects taking other ESAs, the initial dose of  darbepoetin should be based on the PI
[INVESTIGATOR_394641] e US, and the SmPC for all other investigational sites (non-
US) for adult patients with CKD not on dialysis.
For subjects progressed to DD- CKD and continuing on darbepoetin alfa, the dose adjustment 
should be based on the Dose Adjustment Algorithms  (Appendix D:  Darbepoetin Alfa Dosing 
and Dose Adjustment Algorithms ).  
Each subject will receive their first dose of darbepoetin alfa at the Baseline visit. The 
Investigator may elect to postpone the initial dose of study medication until a subsequent visit 
based on the subject’s Hb level or Hb trajectory assessed at the Baseline visit,  or based on 
timing of the last ESA dose given during screening. 
Subsequent adm inistration of darbepoetin alfa may occur at the clinic or may be 
self-administered at home per regional standard of care.  Darbepoetin alfa dosing is independent 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495761] experienced any problems related to the dosing of study medication  (vadadustat or 
darbepoetin alfa) . 
8.4.6 Iron Supplementation 
Investigators will prescribe iron supplementation during the study to maintain ferritin ≥100 ng/mL or TSAT ≥20%.  In general, oral iron should be considered before initiating IV iron.   
The use of iron-based phosphate binders (eg, ferric citrate) is permitted. For subjects who initiate dialysis, iron maintenance therapy via dialysate (eg, ferric pyrophosphate citrate) is also permitted. However, the duration, dosage, and frequency of intradialytic iron should be documented in CRF. 
Important :  Because of the potential for oral  iron to reduce the bioavailability of vadadustat, the 
study medication is not to  be administered concurrently with an oral iron supplement (including 
multivitamins containing iron ), iron containing phosphate binders, or medications containing 
iron.  The subject should be instructed to take these medications at least 2 hours before or 2 
hours after the dose of vadadustat. 
8.4.7 Rescue Therapy  
To ensure the safety of study subjects and to standardize the use of rescue in the study, rescue therapy guidelines are provided. 
[IP_ADDRESS] ESA Rescue (Optional)  
Starting at Week  6, subjects in both treatment arms will be allowed (although will not be 
required) to have their Hb rescued with ESA therapy per the local standard of care.  Drug 
product and supplies for ESA rescue will not be provided by [CONTACT_1034]. 
If possible, a subject on vadadustat should be on a maximum dose of vadadustat for [ADDRESS_495762] fulfill BOTH  of the following: 
•The subject has experienced worsening o f  symptoms of anemia (eg, fatigue, weakness,
shortness of breath, chest pain, confusion, or dizziness) compared with Baseline
•The subject’s Hb is <9.0 g/dL

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495763] does not meet the above criteria for ESA rescue, ESA rescue is 
permitted when medically nece ssary at the discretion of the Investigator.  Reasons for ESA use 
will be captured in the appropriate CRF.  
The ESA rescue therapy should be administered as per the local institution’s guidelines and per the approved local produc t label.  While receiving ESA rescue therapy, subjects must 
temporarily discontinue taking study medication (vadadustat or darbepoetin alfa).  Hemoglobin 
will be monitored throughout the study at scheduled visits as defined in the Schedule of Activities us ing HemoCue, and ESA rescue treatment should be stopped when Hb  is ≥9.5 g/dL.  
A minimum interval must be observed prior to restarting vadadustat after the last dose of rescue medication, and treatment may be resumed after the following intervals: 
•[ADDRESS_495764] dose of epoetin rescue
•[ADDRESS_495765] dose of darbepoetin alfa rescue
•[ADDRESS_495766] dose of methoxy polyethylene glycol- epoetin beta rescue.
Following ESA rescue, the study medication should be resumed at the same dose as previously used or one dose higher and adjusted according to the Dose Adjustment Algorithms  
(Section  8.4.4, Dosing and Dose Adjustment Guide lines ). 
If a subject’s study medication has been 
temporarily interrupted for more than [ADDRESS_495767] the Medical Monitor 
before resuming study medication.  
[IP_ADDRESS] Red Blood Cell Transfusion (Optional)  
Investigators will use their local institution’s transfusion guidelines when determining whether to 
transfuse a study  subject.  In general, in the event of an acute or severe loss of blood, a RBC 
transfusion should be admi nistered as clinically indicated.  In less severe instances but where 
there may be worsening of anemia or moderate to severe symptoms of anemia, RBC transfusions are permitted at the discretion of the Investigator given the medical necessity. 
Reasons for RBC 
transfusion will be captured in the appropriate CRF (e.g., worsening anemia due to CKD, blood loss, 
surgery, etc.).  Study medication (vadadustat or darbepoetin alfa) may be continued during the 
RBC transfusion period.  
8.4.8 Phlebotomy  (Optional)  
If a subject’s Hb exceeds 14.0  g/dL or the rate of rise of Hb raises concern to the Investigator, 
the subject may be phlebotomized based on the Investigator’s judgment.  The method of 
phlebotomy will be in accordance with the local institution’s guidelines and standa rd clinical 
practice.  
8.4.[ADDRESS_495768] experienced any problems related to the dosing of study medication (vadadustat or darbepoetin alfa).  The Investigato r will also maintain drug accountability logs itemizing all 
study medications dispensed to and returned from each subject during the study.  Treatment compliance will be determined from these forms along with the  subject questioning and the study 
medicatio n CRFs.  Dosing compliance for vadadustat or darbepoetin alfa is defined as 80 to 
120% over the course of the Treatment Period.   

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495769] dose of vadadustat prior to the 
PK samples at the Week 4, 12, 28, and 52 study visits.  The date and time of these doses will be 
recorded on the CRF. 
8.4.10 Continuation of Treatment  
Subjects may receive study medication (vadadustat or darbepoetin alfa) up until the EOT visit.  
Prior and Concomitant Therapy  
8.5.[ADDRESS_495770] udy medication will be recorded. 
8.5.2 Erythropoiesis -stimulation Agents  
For all subjects, it is recommended that no additional ESA doses be administered after Screening 
visit 2 (SV2) and prior to the Randomization visit.  
Non-protocol ESAs are prohibited from Randomization until the end of the study, unless the subject 
is rece iving ESA rescue therapy, interrupts study medication for other reasons, or permanently 
discontinues study medication. Reasons for ESA use will be captured in the appropriate CRF (e.g., 
adverse event, inadvertent administration, etc.).  
Concomitant use of an ESA with study medication is strictly prohibited. In the setting of ESA rescue therapy, the initial dose of ESA rescue therapy may be administered on 
the same day as the last vadadustat dose prior to vadadustat dose interruption (see Section [IP_ADDRESS], 
Temporary Interruption of Study Medication) if deemed medically necessary at the discretion of the Investigator. Guidelines for ESA administration as rescue therapy are provided in Section [IP_ADDRESS], ESA Rescue.  
All efforts will be made to avoid inadvertent administration of ESAs resulting from following routine 
ESA hemodialysis protocols (e.g., dialysis center ESA protocols for subjects on hemodialysis). If 
ESA is inadvertently administered to subjects actively receiving vadadustat treatment, vadadustat treatment will be stopped and the event will be reported as a protocol deviation
 
8.5.[ADDRESS_495771] received any investigational medications or participated in an 
investigational study within 30 da ys or 5  half-lives of the investigational medication, whichever 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495772] participated in a 
study with another HIF- PHI. 
Additionally, subjects should not take another investigational medication while participating in 
this study.  
8.5.5 HMG -CoA Reductase Inhibitors (Statins)  
Exposures to atorvastatin and an active metabolite (para -hydroxy atorvastatin ) were mildly 
increased in the setting of vadadustat co -administration in healthy adults.   No dose adjustment of 
atorvastatin is recommended.  
Exposures to simvastatin and an active metabolite (beta -hydroxy acid) were both mildly to 
moderately increased with co -administration of vadadustat in healthy adults.  For subjects taking 
vadadustat who are concomitantly taking simvastatin, the recommended maximum daily dose of simvastatin is [ADDRESS_495773] titration of other statins to higher doses should be carried out  with 
caution. 
A summary of results and management of concomitant administration of vadadustat with the 
various statins is provided below:    
Statin  Change in Statin Exposure 
When Dosed with Vadadustat*  Recommended Statin Dosing in Subjects 
Receiving Concomitant Vadadustat  
Atorvastatin  Mild increase  No dose adjustment  
Pravastatin  No increase  No dose adjustment  
Rosuvastatin  Moderate increase  Maximum daily dose of [ADDRESS_495774] titration to higher doses should be 
done  with caution  
* Based on FDA guidance, an increase in exposure of ≥  1.25- to < 2-fold, ≥  2- to < 5-fold, or ≥  5-fold is classified as a mild,
moderate, or strong interaction, respectively ( FDA 2017).

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 50 of 105 8.5.6 Sulfasalazine and Other BCRP Substrate s 
Exposure to sulfasalazine was moderately increased with co -administration of vadadustat based 
on a study in healthy adults; mesalamine exposure was mildly increased, and no increase was 
observed in exposure to the metabolite sulfapyridine.  Sulf asalazine and other breast cancer 
resistant protein ( BCRP ) substrates should be used with caution when taken concomitantly with 
vadadustat. 
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITI ES 
Please see Appendix A:  Schedule of Activities  for a detailed table of the Schedule of Activities.  
This study includes the following visits: 
•Optional P re-Screening
•Two Screening visits (SV1 and SV2)
•Baseline/Randomization  visit ( Week 0/ Day 1)
•Year 1 Treatment Period Study Visits/Evaluations while receiving study medication:
Weeks 2, 4, 6, 8, 10, 12 (± 3 days) , and every 4 weeks thereafter until Week 52  (± 5 days)
•Year 2 Treatment Period Study Visits/Evaluations while receiving study medication:
Weeks 64, 76, 88, and 104 (± 10 days)
•Year 3 Treatment Period Study Visits/Evaluations while receiving study medication:
Weeks 116, 128, 140, and 156 (± 10 days)
•Year 4 Treatment Period Study Visits/Evaluations while receiving  study medication:
Weeks 168, 180, 192, and 208 (± 10 days)
•EOT visit (± 7 days)
•Follow- up visit:  4 weeks after the EOT  (± 7 days).
•Unscheduled Visit(s)
The following sections describe the procedures to be completed during the study.  Subjects 
are to be assessed by [CONTACT_245961]. 
Administrative Procedures  
9.1.[ADDRESS_495775] entering into the study and before any protocol- directed procedures are p erformed (including Screening activities).  Subjects 
participating in the optional Pre -Screening visit must sign an abbreviated consent form or full 
consent form prior to Pre- Screening and, if eligible, may proceed with the Screening visit after 
full consent has been obtained (see  Section  9.3.1, Pre-Screening Visit  and Section  15.3, Subject 
Information and Consent  for additional details).  Additionally, subjects may be asked to provide 
a separate, optional consent to obtain and store a blood sample(s) for future genetic analyses. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495776] is found not to be 
eligible for randomization, the reason(s) for ineligibility must be documented by [CONTACT_737]. 
Screening numbers assigned to subjects who fail Screening will not be re-used. 
9.1.[ADDRESS_495777] dose tested of 160 mg/kg/day.  Peri-postnatal development studies have not yet been conducted with vadadustat, and there are 
no data on the transmission of vadadustat in breast milk or the effect of vadadustat on infants. 
Although the potential risk of vadadustat on the developi[INVESTIGATOR_245896], the study requires that all subjects must agree to use adequate contraception throughout the 
study and for [ADDRESS_495778] dose of study medication. 
Adequate contraception is defined as follows: Female subjects must be surgically sterile, postmenopausal (no menses for at least one year), or 
have negative pregnancy test results at Screening (serum).  
Female subjects not surgically sterile or postmenopausal (no menses for at least one year) and 
non-vasectomized male subjects must practice at least 1  of the following methods of birth 
control: 
•Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior
to Screening visit, throughout the study, and for [ADDRESS_495779] dose of study
medication)
•A vasectomized partner
•Hormonal contraceptives (oral, parenteral, or transdermal) for at least 3  months prior to
study medication  administration or intrauterine contraception/device throughout the
study, and for [ADDRESS_495780] dose of study medication
•Double-barrier method (such as male condom, female condom, diaphragm, sponge, or
cervical cap together with  spermicidal foam/gel/film/suppository)  (starting at S V1,
throughout the study, and for [ADDRESS_495781] dos e of study medication) .
9.1.4 Laboratory Accreditation and Reference Ranges  
The Investigator and the Sponsor will maintain a copy of the laboratory accreditation and the reference ranges for the central laboratory used for clinical laboratory evaluations.  Addit ionally, 
other accreditation(s) will be collected as required.  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 52 of 105 
Study Procedures and Evaluations  
9.2.1 Clinical Evaluations 
The following clinical evaluations will be conducted during the course of the study: 
•Medical history, demographics, and physical examinatio n:  Medical history, demographic
information, and physical examination (including height) will be collected at SV2.
Relevant medical history (with particular emphasis on previous medical conditions thatmay lead to exclusion) and significant ongoing medical conditions or diseases should bedocumented.  After SV2, an abbreviated, symptom-directed physical examination shouldbe performed at the discretion of the Investigator as clinically indicated.
•Vital signs:  Vital signs will include  heart rate and blood pressure.  Heart rate and blood
pressure should be assessed in the seated position after [ADDRESS_495782].  Vital signs will
be collected at SV1, SV2, Baseline, during study visits, and EOT and should be takenprior to blood draws when possible.
•Weight:  Weight will be collected for all subjects at SV2, at Weeks 12, 24, 36, and 52,
yearly thereafter , and at the EOT visit.  For subjects on darbepoetin alfa, subject s will be
weighed for dosing as per the local standard of care.
•12-Lead electrocardiogra m (ECG):  A standard 12- lead ECG will be performed at
Baseline.  The ECG should be obtained after the subject has been resting comfortably in asupi[INVESTIGATOR_73414] [ADDRESS_495783] of the tracing(s) will be made andretained with other source documents.
•Completion of MACE Endpoint Questionnaire :  At each post-randomization study visit,
the subject must specifically be questioned regarding the occurrence of any potentialMACE endpoint event since the last study visit.  IMPORTANT:  The endpo int
questionnaire electronic CRF must be completed in full at each visit even if no
potential MACE endpoints have occurred.   If a potential endpoint event is reported,
the date of the event should be recorded and the appropriate source documents should be
collected according to the endpoint packet checklist.
•AE Assessments:  AE collection will begin from time of randomization through global
study completion. T he Investigator and study personnel will review each  subject’s
laboratory and clinical evaluation findings and query the subject directly regarding AEs
(see Section  10, Adverse Events ).  Subjects must be followed for AEs until the final
required protocol visit or until all drug- related toxicities and SAEs have resolved (or are
considered chronic/stable), whichever is later.
•Concomitant Medication Recording:  All medications (both prescription and
non-prescription, and including vitamins, herbals, topi[INVESTIGATOR_8593], inhaled, and intranasal) takenduring the screening period and throughout the study, end ing at the final protocol
requi red visit, should be recorded on the appropriate CRF.  If the duration of screening
period is less than 30 days, all medications taken within 30 days prior to the start of studymedication (vadadustat or darbepoetin alfa). At each study visit, subjects will be asked

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495784] dose wil l be recorded. 
9.2.2 Laboratory Evaluations 
Samples for laboratory assays will be sent to a central laboratory for analysis.  Detailed instructions for the collection, processing, and shipment of laboratory samples will be provided by [CONTACT_245962].  The Investigator is responsible for reviewing laboratory results for clinical significance.  
The following laboratory evaluations will be conducted during the course of the study: 
•Pregnancy test :  A serum pregnancy test will be performed at SV2 for females of
childbearing potential.  Additional serum or local urine pregnancy tests may beconducted throughout the study in sufficient number, as determined by [CONTACT_394686], to establish the absence of pregnancy during the study.  TheSV2 results must be available and must be negative before the subject takes the first dose
of study medication.
•Complete Blood Count ( CBC ):  A CBC with differential will be performed a t Baseline
and twice annually at Weeks  28, 52, 76, 104, 128, 156, 180, 208.  At all other noted visits
in Appendix A :  Schedule of Activities , including SV1 and SV2, a CBC without
differential will be performed.  The CBC with differential will include:  Hb, hematocrit,
RBCs, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), meancorpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW),white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes,eosinophils, basophils), and platelets.
Hemoglobin assessed by [CONTACT_245964] .Hemoglobin le vels assessed by [CONTACT_394687]  8.4.4 Dosing and Dose Adjustment Guidelines ). lf the
Investigator has an immediate clinical concern about a subject's HemoCue value, theInvestigator may use clinical  judg ment and repeat the HemoCue Hb, use local lab  values ,
or wait for central lab results. The test method utilized to inform the treatment  decision
must be recorded in the appropriate CRF and subject’s source.
For eligibility  purposes, one retest for Hb may be perform ed during the screening
window,  The average of 2 Hb values measured by [CONTACT_394688] (SV1, SV2, or retest) must be < 11.0 g/dl in the US and <12.0 g/dl outside theUS.
Refer to Sections  7.4.1, Retesting  and 7.4.2, Rescreening  for further details regarding
repeating laboratory measurements during the Screening period.
•Point of care Hb:  Using HemoCue, Hb  will be monitored throughout the study to
determine if the dose of study medication (vadadustat or darbepoetin alfa) will be

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 54 of 105 adjusted , interrupted, or maintained as described in  Section  8.4.4 Dosing and Dose  
Adjustment Guidelines . 
•Reticulocyte count :  An automated reticulocyte count (both absolut e and percent) will be
performed at Baseline and at Weeks 4, 12, 28, and 52.
•Coagulation tests :  Blood samples will be drawn at Baseline to assess the prothrombin
time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR).
•Folate and Vitamin B 12:  A b lood sample will be drawn at SV 1 to assess the folate and
Vitamin  B12 levels.  
•Urine albumin -to-creatinine ratio (uACR) :  A random urine spot sample should be
collected at the investi gative site during the Baseline, Weeks 28, 52, 104, 156, 208, and
EOT  to assess the uACR.  Subjects should refrain from heavy exercise [ADDRESS_495785].
•C-reactive protein  (CRP) :  A blood sample for CRP  will be collected at the Baseline,
Weeks 28, 52, 104, 156, and EOT.
•Serum Chemistry:  Blood  samples to assess serum chemistry will be collected at SV1,
Baseline, and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208, EOT .  At all
other noted visits in Appendix A :  Schedule of Activities , serum creatinine and eGFR
will be performed  only at Weeks 4, 8, 12, 20, 36, 44.  The serum chemistry will include
the following assays:  sodium, potassium, bicarbonate, chloride, calcium, magnesium,
phosphorus, glucose, creatinine, blood urea nitrogen (BUN), creatine phosphokinase(CPK), uric acid, albumin, total protein, and eGFR calculation .
Note:  When a ≥50% decline in eGFR from the Baseline value is observed, a repeat
central laboratory measure should be performed within 30 to 60 days.
•Liver Function Tests : Blood samples to assess liver function will be collected at SV1,
Baseline,  Weeks  4, 8, 12, 16, 20, 24, 28, 36, 44, 52, 64, 76, 88, 104, 116, 128, 140, 156,
168, 180, 192, 208, and EOT .  Liver function tests will include: total bilirubin, alkaline
phosphatase, ALT/SGPT, AST/SGOT, and lactate dehydrogenase (LDH).
•Iron indices :  Blood samples to assess the iron indices will be collected at SV1, Baseline,
Weeks 4, 8, 12, 20, 28, 36, 44, 52, 64, 76, 88, 104, 116, 128, 140, 156, 168, 180, 192,208, and EOT.  Assessments will include the following indices:  ferritin, iron, TIBC, and
TSAT.
•Lipid Profile :  Blood samples will be collected at the Baseline, Week 2 8, and Week 52
visits to assess the cholesterol levels and will be tested for the following types of lipi[INVESTIGATOR_805]:total cholesterol, low -density lipoprotein (LDL), high-density lipoprotein (HDL), and
triglycerides.
•Biomarkers (including, but not limited to, hepcidin, vascular endothelial growth factor
[VEGF] ):  Samples for biomarker analysis will be drawn at the Baseline, Week s 12, 28,
52, 104, 156, and EOT.
•EPO:   Blood samples for EPO analysis will be obtained at Baseline and at Weeks 4, 12,
28, and 52.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 55 of 105 •PK E valuations (samples to be drawn only for subjects randomized to vadadustat) :
Plasma samples for PK evaluation will be collected to analyze for both the parent
compound (vadadustat) and its metabolites.  Collection time points for PK will includeStudy Day 1 (Baseline), and Weeks 4, 12, 28, and 52.
oStudy Day 1 (Baseline Visit): Vadadustat will be administered on Study Day 1(Baseline Visit) in the clinic after the Baseline procedures, and the PK sample will becollected between 15 minutes to 1 hour after vadadustat administration. The times of
vadadustat dose and the PK sampling will be documented.
oWeek s 4, 12, 28, and 52 study visits: PK sampling will also be performed along with
other study laboratory samples being collected at the Week s 4, 12, 28, and [ADDRESS_495786] dose
of vadadustat prior to the collection of PK samples.  The date and time of these doseswill be recorded by [CONTACT_30107].
•Exploratory Samples :  Additional blood and urine samples will be collected at Baseline ,
Week s 28, 52, 104, 156, and EOT which may be used for exploratory measurement of
biomarkers (eg, factors relating to the activation of the HIF pathway).  Subjects will also
be asked to provide optional consent to obtain a blood sample at Baseline and EOT, to bestore d for future genetic analyses (eg, DNA, mRNA).
 Schedule of Activities  
The Schedule of Activities  (see Appendix A :  Schedule of Activities ) shows the timing of 
planned study procedures.  Every effort should be made to adhere to this procedure schedule and all assessments should be completed at each study visit. 
9.3.[ADDRESS_495787] a HemoCue Hb  prior to proceeding with full Screening.  Subjects will need to 
sign an abbreviated Pre-Screening informed consent form or full consent form prior to Pre-Screening.  If the Pre- Screen HemoCue Hb  is between 8.0 and 11.0 g/dL (inclusive)  in the 
US or between 9.0 and 12.0 g/dL  (inclusive) outside the US , the investigative site may proceed 
with SV1, which preferably will occur on the same day as Pre -Screening.  
9.3.2 Screening Visit s 
Subjects will need to sign a full consent form prior to S V1 procedures. The consent form may be 
signed in advance of SV1 procedures. The Screening period starts at the time the informed consent is signed and will be a maximum of  8 weeks  in duration.  Two Screening visits (SV1 and 
SV2) must be performed within 8 weeks  prior to d osing (Baseline visit or Day 1).  There must be 
a minimum of [ADDRESS_495788] and the Baseline visit.  
The Investigator will maintain a log of  subjects (both Pre- Screened and Screened) and indicate 
who of the Pre- Screened  subj ects were brought in for informed consent and Screening and who 
of the Screened  subj ects were enrolled or excluded and the reason for exclusion. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 56 of 105 After obtaining informed consent, subjects will undergo a number of Screening activities. 
[IP_ADDRESS] Screening Visit 1 (SV1)  
At SV1, the following activities/procedures will be performed:  
•Informed consent (including an additional optional consent for blood samples for future
genetic analyses .
•Review of eligibility criteria
•Vital signs including heart rate and blood pressure (assessed in seated position after5 minutes of rest and prior to blood draws)
•Laboratory procedures:oCBC (without differential)
oIron indices
oFolate and vitamin B
12 levels
oSerum chemistry including serum creatinine and eGFR
oLiver Function Tests
•Visit registration in IWR
Refer to  Sections  7.4.1, Retesting  and 7.4.2, Rescreening  for further details regarding repeating 
laboratory measurements during the Screening period. 
[IP_ADDRESS] Screening Visit 2 (SV2)  
At SV2, the following activities/procedures will be performed:  
•Review of eligibility criteria
•Physical examination
•Demographics and medical history
•Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495789] and prior to blood draws), as well as height and weight
•Laboratory procedures :
oCBC (without differential)
•Serum pregnancy test for females of childbearing potential (eligible subjects will be
advised to use an adequate contraceptive method)
•Prior and current medication use.
The mean  of [ADDRESS_495790] be between 8.0 and 11.0 g/dL 
(inclusive) in the US or between 9.0 and 12.0 g/dL (inclusive) outside the US to qualify for 
inclusion into the trial.  If the subject’s Hb does not qualify after S V1,SV2 , or retest  - Hb , the 
subject should be considered a Screen failure.  
[IP_ADDRESS] Subject Retesting  
Subjects who initially fail to qualify for the study based on laboratory test results may be retested 
once within the 8- week  Screening period, per Investigator discretion ( Section  7.4.1, Retesting ). 
9.3.[ADDRESS_495791] Rescreen ing 
Subjects who fail to meet the qualifying criteria for Hb or eGFR during the Screening period 
may be considered for rescreening at the discretion of the Investigator if it is felt that the 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495792]’s status has progressed and that the subject may now qualify for the study.  Additionally, 
subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B 12 values may 
be considered for rescreening after receiving replacement therapy.  Screening is limited to 3 attempts (Screening and 2 additio nal rescreening att empts) ( Section  7.4.2, Rescreening ). 
9.3.4 Baseline Visit (Day 1)  
The Baseline visit must be performed  at a minimum of [ADDRESS_495793] Screening visit (SV2) 
procedure including retest(s). 
At the Baseline visit, the following activities/procedures will be performed: 
•Randomization
•12-lead ECG (prior to vital sign assessments and blood draws ).
•Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495794] and prior to blood draws)
•Laboratory Procedures:
oRandom spot urine sample for uACR
oCoagulation Tests
oCRP
oCBC (including differential)
oReticulocyte count
oSerum chemistry  including serum creatinine  and eGFR
oLiver function tests
oIron indices
oLipid profile
oEPO
oBiomarkers
oPK (see Section  9.2.2, Laboratory Evaluations ; samples to be drawn only for subjects
randomly assigned to vadadustat)
oExploratory samples
•Review of medical history for new conditions since Screening visit
•Medication use since Screening v isit
•Study medication assessments and procedures:oSubject will take their first dose of study medication at the investigative site during
the Baseline visit
oHb by [CONTACT_394689] )
oOral iron su pplementation as needed to maintain ferritin ≥100 ng/mL or TSAT  ≥20%
(per local product label; see Section  8.4.6, Iron Supplementation)
•AE assessment as needed (after receiving the first dose of study medication) .
•Visit Registration in IWR
9.3.5 Year 1 Treatment Period Visits  (Day 2 through Week 52) 
During the Year  1 Treatment Period v isits at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 
44, 48, and 52, the following activities/procedures will be performed: 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 58 of 105 •Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495795] and prior to blood draws)
•Weight (Weeks 12, 24, 36, and 52)
•Laboratory proc edures:
•Random spot urine sample for uACR (Weeks 28 and 52)
oCBC (Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52; differential
at Weeks 28 and 52)
oReticulocyte count (Weeks 4, 12, 28, and 52)
oSerum chemistry (Weeks 28 and 52)
oSerum cre atinine and eGFR (Weeks 4, 8, 12, 20, 36, and 44; also at Weeks 28 and 52
as part of the serum chemistry)
oLiver function tests (Weeks 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52)
oIron indices (Weeks 4, 8, 12, 20, 28, 36, 44, and 52)
oLipid profile (Weeks 28 and 52)
oEPO (Weeks 4, 12, 28, and 52)
oCRP (Weeks 28 and 52)
oBiomarkers (Weeks 12, 28 , and 52)
oPK (Weeks 4, 12, 28, and 52; see Section  9.2.2, Laboratory Evaluations ; samples to
be drawn only for subjects randomized to vadadustat)
oExploratory samples (Week s 28 and 52)
•Record date and time of subject’s last dose of vadadustat prior to the PK sample
(Weeks  4, 12, 28, and 52)
•Safety assessments:
oAE assessment
oRBC transfusions and ESA rescue
oTherapeutic phlebotomy
oMACE endpoint questionnaire
•Medication assessments and procedures:oReview of concomitant medications
oHb by [CONTACT_394690]:  Study medication (vadadustat or darbepoetin alfa) reconciliation
will be conducted per the pharmacy manual instructions.
oVadadustat dispensing as needed per Section  8.2.1 , Dispensing of Vadadustat
oDarbepoetin alfa dispensing
oIron supplementation as needed to maintain ferritin ≥100 ng/mL or TSAT ≥20% (per
local product label; see Section  8.4.6, Iron Supplementation)
oQuestion subject regarding dosing compliance and whether they have questions orhave experienced any problems related to the dosing of study medication (vadadustator darbepoetin alfa).
•Visit Registration in IWR
9.3.6 Year 2 -4 Monthly Hb Monitoring 
•Monthly monitoring of Hb as part of local standard of care labs or at unscheduled vis its
for dose adjustment.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 59 of 105 9.3.7 Year 2 Treatment Period Visits  (Weeks 53 through 104) 
During the Year 2 Treatment Period v isits at Weeks 64, 76, 88, and 104, the following 
activities/procedures will be performed:  
•Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495796] and prior to blood draws)
•Weight (Week 104)
•Laboratory Procedures:
oRandom spot urine sample for uACR (Week 104)
oCBC (Weeks 64, 76, 88, and 104; differential at Weeks 76 and 104)
oSerum  chemistry including serum creatinine and eGFR  (Weeks 76 and 104)
oLiver function tests (Weeks 64, 76, 88, and 104)
oIron indices (Weeks 64, 76, 88, and 104)
oCRP (Week 104)
oBiomarkers (Week 104)
oExploratory samples (Week 104)
•Safety assessments:oAE assessment
oRBC tra nsfusions and ESA rescue
oTherapeutic phlebotomy
oMACE endpoint questionnaire
•Medication assessments and procedures:oReview of concomitant medications
oHb by [CONTACT_394690]:  Study medication (vadadustat or darbepoetin alfa) reconciliation
will be conducted per the pharmacy manual instructions.
oVadadustat dispensing as needed per  Section  8.2.1 , Dispensing of Vadadustat
oDarbepoetin alfa dispensing
oIron supplementation to maintain ferritin ≥100 ng/mL or TSAT ≥ 20% (per local
product label; see Section  8.4.6, Iron Supplementation)
oQues tion subject regarding dosing compliance and whether they have questions or
have experienced any problems related to the dosing of study medication (vadadustator darbepoetin alfa).
•Visit Registration in IWR
9.3.8 Year 3/4 Treatment Period Visits  (Weeks 116 through 208) 
During the Year 3/4 Treatment Period visits  at Weeks 116, 128, 140, 156, 168, 180, 192, 
and 208, the following activities/procedures will be performed: 
•Vital signs including heart rate and blood pressure (assessed in seated position after
[ADDRESS_495797] and prior to blood draws)
•Weight (Weeks 156 and 208)
•Laboratory Procedures:oRandom spot urine sample for uACR (Weeks 156 and 208)
oCBC (Weeks 116, 128, 140, 156, 168, 180, 192, and 208; differential at Weeks 128,
156, 180, and 208)

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 60 of 105 oSerum chemistry including serum creatinine and eGFR (Weeks 128, 156, 180, and
208)
oLiver function tests (Weeks 116, 128, 140, 156, 168, 180, 192, and 208)
oIron indices (Weeks 116, 128, 140, 156, 168, 180, 192, and 208)
oCRP ( Week 156)
oBiomarkers (Week 156)
oExploratory samples (Week 156)
•Safety assessments:
oAE assessment
oRBC transfusions and ESA rescue
oTherapeutic phlebotomy
oMACE endpoint questionnaire
•Medication assessments and procedures:oReview of concomitant medications
oHb by [CONTACT_394690]:  Study medication (vadadustat or darbepoetin alfa) reconciliation
will be conducted per the pharmacy manual instructions.
oVadadustat dispensing as needed per Section  8.2.1 , Dispensing of Vadadustat
oDarbepoetin alfa dispensing (per PI [INVESTIGATOR_245912], and the SmPC
for all other investigational sites (non -US)
oIron supplementation to maintain ferritin ≥ 100 ng/mL or TSAT ≥ 20% (per local
product label; see Section  8.4.6, Iron Supplementation)
oQuestion subject regarding dosing compliance and whether they have questions orhave experienced any problems related to the dosing of study medication (vadadustator darbepoetin alfa).
•Visit Registration in IWR
9.3.9 End of Treatment  (EOT) Visit  
The EOT visit  will be performed at  the time a 
 subject permanently discontinues study medication 
or for subjects on study medication at the time of notification  of  global study completion ( See 
Appendix A: Schedule o
f Activities ). 
At the EOT visit, the following activities/procedures will be performed:  
•Vital signs including heart rate and blood pressure (assessed in seated position after5 minutes of rest and prior to blood draws), as well as weight
•Laboratory Procedures:
oRandom spot urine sample for uACR
oCBC (without differential)
oSerum chemistry including serum creatinine and eGFR
oLiver function tests
oIron indices
oBiomarkers
oCRP
oExploratory samples
•Safety assessments:oAE assessment

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 61 of 105 oRBC transfusions and ESA rescue
oTherapeutic phlebotomy
oMACE endpoint questionnaire
•Recording of concomitant medications
•Drug reconciliation:  Study medication (vadadustat or darbepoetin alfa) reconciliation
will be conducted per the pharmacy manual instructions.
•Question subject regarding dosing compliance and whether they have experienced any
problems related to the dosing of study medication (vadadustat or darbepoetin alfa).
•Visit Registration in IWR
9.3.10 Follow- Up Visit  
The F ollow-up visit will be conducted in person or via the telephone 4 weeks after the EOT visit. 
The following activities/procedures will be performed: 
•AE assessment
•RBC transfusions and ESA rescue
•Therapeutic phlebotomy
•MACE endpoint questionnaire.
•Recording of concomitant medications
9.3.11 Unscheduled Visits  
Unscheduled assessments may be conducted at any time as medically warranted.  The following 
activities/procedures will be performed. At a minimum,  
•MACE Endpoint Questionnaire
•AE assessments
•Any other procedures that are medically warranted at the discreti on of the Investigator
9.3.[ADDRESS_495798] Status  
The End of Study (EOS) assessment documents the subject status at the global study completion or at 
the time of subject withdrawal of consent or when subject is deemed LTFU or upon death. The table 
below outlines how to handle each subject based on their status.  
The following activities/procedures will be performed. At minimum, 
•EOS subject status
Subject Status  Global Study Completion 
Subject on Study Medication (includes those 
on temporary interruption) at time of global 
study completion  •Perform EOT visit
•Perform the Follow-up visit [ADDRESS_495799] status

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495800] permanently discontinued study 
medication and continues to be followed in 
the study Optimal data collec tion would include the 
following assessments: 
•EOS subject status (must collect atminimum)
•MACE Endpoint Questionnaire
•AE Assessment
NOTE:  EOT and the Follow-up visit [ADDRESS_495801] status form at the 
time of death (see Section 10 Adverse Events  
for more details on other actions related to reporting a death).   
 Study Medication Stoppi[INVESTIGATOR_245925] a subject meets one of the criteria in Table [ADDRESS_495802] >3x ULN and total bilirubin >2x ULN  Permanently Discontinue Treatment  
ALT or AST >3x ULN and INR >1.[ADDRESS_495803] >8x ULN  Permanently Discontinue Treatment  
ALT or AST remains >5x ULN over 2 weeks* Permanently Discontinue Treatment  
ALT or AST >3x ULN with symptoms including e.g., 
fatigue, nausea, vomiting, right upper quadrant pain, fever, rash or eosinophilia Permanently Discontinue Treatment  
*Re-challenge generally should be avoided with ALT or AST >[ADDRESS_495804] unless there are no other good
therapeutic options . 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 63 of 105 ALT:  alanine transferase; AST:  asparagine tr ansferase; INR:  international normalized ratio; ULN:  upper limit of 
normal   
See Section 10.1.1, Adverse Events  for reporting requirements related to a subject being 
permanently discontinued based on meeting the laboratory abnormalities list above in Table 2. 
[ADDRESS_495805] medical occurrence (including an 
abnormal laboratory finding) that occurs in the protocol-specified AE reporting period; the event does not necessarily have a causal relationship with that treatm ent or usage.  
An AE includes medical conditions, signs, and symptoms not previously observed in the subject that emerge during the protocol-specified AE reporting period, including signs or symptoms associated with pre -existing underlying conditions that were not present prior to the AE reporting 
period. 
Adverse events therefore include the following: 
•All AEs, whether suspected to be causally related to study medication  or otherwise
•All AEs secondary to any medication overdose, medication error, abuse, wi thdrawal,
sensitivity, or toxicity
•Illnesses apparently unrelated to study medication , including the worsening of a pre-
existing illness (see paragraph below on Pre-existing Conditions)
•Injury or accidents.  Note that if a medical condition is known to have caused the injury
or accident (eg, a fall secondary to dizziness), the medical condition (dizziness) and theaccident (fall) should be reported as 2 separate AEs .
•Abnormalities in physiological testing or physical examination findings that require
clinic al intervention or further investigation (beyond ordering a repeat [confirmatory]
test)
•Laboratory abnormalities that require clinical intervention or further investigation(beyond ordering a repeat [confirmatory] test) unless they are associated with an a lready
reported clinical event.  Laboratory abnormalities associated with a clinical event
reported as an AE (eg, elevated liver enzymes in a  subject with jaundice) should be
described under ‘ Comments ’ on the report of the clinical event rather than report ed as
separate AEs.
The following guidelines are to be used when reporting AEs for this study: 
Medical Diagnoses  – Whenever possible, a medical diagnosis term should be used to report AEs 
instead of signs and symptoms due to a common etiology, as determined by [CONTACT_245966].  For example, pneumonia should be the reported AE term, instead of fever and  
dyspnea, when the diagnosis has been established.  Signs and symptoms should be reported as 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 64 of 105 event terms only when the medical diagnosis remains unknown, and revised to a medical 
diagnosis term once it has been established. 
Procedures  – Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, 
should not be reported as AEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an AE.  For example, an acute appendicitis that begins during the AE reporting period should be reported as the AE and the resulting appendectomy noted under ‘ Comments ’. 
Pre-planned therapeutic procedures not associated with a new medical condition or worsening 
pre-existing condition should not be reported as AEs (with the exception of kidney transplant, 
see below).  
Pre-existing Conditions  – In this study, a pre- existing condition  (ie, a disorder present before 
the AE reporting period started and noted on the pretreatment medical history/physical examination form) should not be reported as an AE unless the condition worsens or epi[INVESTIGATOR_245926]. 
Abnormal Test Findings – All laboratory test results will be reviewed by [CONTACT_737].  The 
Investigator will utilize his/her judgment in determining if out of range laboratory values are 
clinically significant and will denote this using the ab breviation “CS” on the laboratory report for 
source documentation.  Laboratory tests that are labeled as clinically significant  should be 
reported as AEs, either separately or as part of a description of a symptomatic AE.  If there are significant changes in a laboratory report from a previous visit that are determined to be 
clinically significant, these should also be reported as AEs.  Any abnormal laboratory value which requires treatment or further diagnostic testing and/or results in discontinuation from study should be reported as an AE .  An expected laboratory abnormality from a condition that is part of 
the medical history is not considered clinically significant for the purposes of the study unless it represents a worsening of the condition. 
Abnormalities in ALT, AST and Total Bilirubin  - Abnormalities in ALT, AST and Total 
Bilirubin should be reported to the Sponsor’s Medical Monitor or CRO designee within 24 hours 
of awareness as SAE with “medical significance” criteria selected, if the foll owing conditions are 
met: 
•New elevation in ALT or AST > [ADDRESS_495806], with or without an elevation of total
serum bilirubin > [ADDRESS_495807]; AND
If new elevations in ALT or AST > [ADDRESS_495808], without  an elevation of total serum bilirubin 
>[ADDRESS_495809] are iden tified, the following steps are to be taken:
•Temporary discontinuation of Investigational Medicinal Product ( IMP);
•Repeat testing of ALT, AST, ALP , and total bilirubin, should be completed within 48 to
72 hours to confirm the abnormalities and to determine trend;
•IMP should not be resumed until monitoring indicates abnormalities have resolved or
have stabilized.
Details on the management of subjects with other ALT and AST abnormalities  are further 
described in Section 9.4, Study Medication Stoppi[INVESTIGATOR_1869] . 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 65 of 105 Worsening of Anemia – In this study, it is possible tha t some subjects may experience a 
worsening of anemia.  As the primary endpoint of this study assesses Hb  response, worsening of 
anemia is captured as part of this efficacy parameter.  Worsening of anemia should not be 
considered an AE unless the worsening of anemia is associated with a cause other than the 
subject’s CKD.  
Transplantation – During this long-term study, it is anticipated that some subjects may receive a 
kidney transplant. These events will not be recorded as AEs. Subjects will discontinue study 
medication for receipt of a kidney, other solid organ, hematopoietic stem cell or bone marrow 
transplant and should continue with the Schedule of Activities and safety assessments as described in Section [IP_ADDRESS], Permanent Discontinuation of Study Me dication . 
Malignancy – During this long-term study, some subjects may develop a newly diagnosed malignancy or a recurrence of a malignancy. At the discretion of the Investigator, these subjects may 
continue study medication (vadadustat or darbepoetin alfa). For reporting of adverse events of 
malignancy, see Section 10.1.2 Serious Adverse Events . 
Renal -Related Events  - Some subjects will experience a progression of their CKD over the 
course of this study as part of the natural course of the disease.  In addition, the study population 
is prone to experience acute, transient loss of kidney function of different etiologies, sometimes concomitantly complicated by [CONTACT_245967]. 
To ensure consistent reporting of renal events, the following guidelines are to be used when 
reporting a renal -related AE:  
•The following situations should always be reported as SAEs  with seriousness criterion
“medically important,” if no other seriousness criteria  are met (see Section  10.1.2,
Serious Adverse Events ):
oProgression of CKD leading to chronic dialysis: When a subject undergo es transition
to chronic maintenance dialysis an SAE should be reported using the verbatim term
of “end-stage renal disease”, with the outcome denoted as recovered with sequelae of
chronic dialysis.
oAny medical event requiring transient acute dialysis : When a subject  undergoes
transient acute dialysis , an SAE should be reported using the verbatim term reflecting
the indic ation for the dialysis. Examples of verbatim AE terms include: hyperkalemia,
volume overload, acute kidney injury, and uremia.
oKidney transplantation: When a subject  receives  a kidney transplant, an SAE should
be reported using the verbatim term “Progression of CKD”, with the outcome denoted
as recovered with sequelae of “k idney transplant.”
•The following situations will be reported as SAEs if they meet seriousness criteria
(see Section  10.1.2, Serious Adverse Events ); otherwise, they should be reported as AEs:
oAcute kidney injury not requiring dialysis – The reported AE term should reflect the
etiology for the impairment of the renal function.   Non -specific AE terms such as
“Decreased eGFR ” or “Increased creatinine” should be avoided whenever the
underlying etiology is known.
Examples of verbatim AE terms for prerenal impairment  include:  hypovolemia,
hepatorenal syndrome, and heart failure

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 66 of 105 Examples of verbatim AE terms for intrarenal impairment include:  acute tubular
necrosis, acute interstitial nephritis, and glomerulonephritis
Examples of verbatim AE terms  for postrenal impairment include:
hydronephrosis, pelvicaliectasis, and urinary tract obstruction.
oProgression of CKD  not requiring dialysis – If permanent loss of renal function due to
underlying CKD has occurred, the reported AE term should reflect the underlying
etiology.  Non- specific terms such as “D ecreased eGFR ,” “Increased creatinine,” or
“Worsening CKD” should be avoided whenever the underlying etiology is known.Examples of verbatim AE terms include:  worsening lupus nephritis, worsening
diabetic kidney disease, and worsening glomerulonephritis
oMedical conditions related to CKD that occur without acute kidney injury or
progression of CKD – If there is no decline in kidney function, the medical
complicat ion of CKD itself should be reported. AE terms such as “Progression of
CKD” or “Acute Kidney Injury,” should be avoided when there is no decline inkidney function, Examples of AE terms include:  edema and hyperkalemia .
10.1.2 Serious Adverse Events  
Each AE is to  be classified by [CONTACT_28135].  An AE that 
meets 1 or more of the following criteria/outcomes is classified as serious:  
•Death
•Life-threatening (see paragraph below on life-threatening)
•In-patient hospi[INVESTIGATOR_1081] (see paragraph below
on hospi[INVESTIGATOR_059])
•Persistent or significant disability/incapacity (see paragraph below on disability)
•Congenital anomaly/birth defect
•Is considered a medically important event not meeting the above criteria, but which may
jeopardize a subject, or may require medical or surgical intervention to prevent one of the
criteria listed in this definition.
In addition to the above criteria for classifying AEs as serious, the following situations will also be class ified as serious for purposes of this study: 
•Dialysis  or Transplantation  - Events requiring transition to chronic, ongoing dialysis, or
requiring an acute transient course of dialysis, or requiring an immediate kidneytransplantation (ie, not pre-planned) will be classified as serious.  Guidance for thereporting of these events is provided in Section  10.1.1, Adverse Events .
•Malignancies  – Newly diagnosed malignancies or a recurrence of a mal ignancy should
be reported as an SAE with the seriousness criterion “medically important” if no otherseriousness criteria are met. If a subject develops b asal cell carcinoma of skin, squamous
cell carcinoma, or cervical carcinoma in situ  during the study, or has worsening of these
events from Baseline, the Investigator will determine if the event is reported as an AE or
SAE .

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 67 of 105 •Designated Medical Events  - The sponsor maintains a list of designated medical
events  (DME) that they will always classify as serious adverse events.   If an event on
the DME list is reported as an AE additional information on the event (e.g. investigator
confirmation of seriousness, causality) will be requested from the Investigator.
Serious also includes any other event that th e Investigator or Sponsor judges to be serious.  If 
there is any doubt whether the information constitutes an AE or SAE, the information is to be treated as an SAE.  
The Sponsor has a list of events that they classify as “always serious” events. If an AE is  reported 
that is considered to be an event per this classification as “always serious”, additional information on 
the event may be requested.  
Life-threatening – Any event in which the subject was at risk of death at the time of the event; 
“life-threatenin g” does not refer to an event which hypothetically might have caused death if it 
were more severe. For example, drug-induced hepatitis that resolved without evidence of hepatic 
failure would not be considered life threatening, even though drug-induced hepa titis of a more 
severe nature can be fatal.  
Hospi[INVESTIGATOR_059] – Hospi[INVESTIGATOR_225938] a 
minimum of [ADDRESS_495810] event occurs related to the procedure (eg, elective hospi[INVESTIGATOR_272] a total knee replacement due to a preexisting condition of osteoarthritis of the knee that has not worsened during the course of the study). 
Disability  – Defined as a substantial disruption in a person’s ability to conduct normal life 
functions. 
 Eliciting Adverse Event Information  
The Investigator is to report all directly observed AEs and all AEs spontaneously reported by [CONTACT_65850].  In addition, each study subject will be questioned about AEs at each visit following the initiation of treatment.  
 Reporting  
Each AE is to be classified by [CONTACT_28135].  
All AEs that occur in study subjects during the AE reporting period specified in the protocol must be reported, whether or not the event is considered related to study medication (vadadustat or darbepoetin alfa). 
10.3.1 Reporting Period  
The AE reporting period for this study begins  from time of randomization through global study 
completion. 
In addition, any AE that occurs subsequent to the AE reporting period that the Investigator 
assesses as related to the study medication should also be reported as an AE.  
10.3.2 Reporting AEs  
NONSERIOUS AEs are to be reported on the AE CRFs. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495811] be reported to the Sponsor’s Medical Monitor 
or CRO designee within 24 hours after the Investigator becomes aware of the SAE.  Compliance with this time requirement is essential so that the Sponsor may comply with its regulatory obligations. 
The initial SAE report should be completed as fully as possible but should contain, at a minimum:  
•Subject number/ID, sex, and age/date of birth
•The date of rep ort
•Name [CONTACT_225982]
•Name [CONTACT_225983]
•A description of the event , including event term(s), seriousness criteria, and a clinical
summary of the event
•Causality assessment .
Information about all SAEs (either initial or follow -up information) should be collected and 
recorded in English on the electronic SAE Report Form within the electronic data capture (EDC) 
system.  The Investigator must assess the relationship to each specific component of the study medication .  If the event meets  serious criteria and it is not possible to access the EDC system , a 
paper SAE Report Form should be sent to the CRO via email or fax or the Investigator will call the CRO SAE hotline within 24 hours of being made aware of the SAE (reference the site manual for contact [CONTACT_3031]).  When the EDC system becomes available, the SAE information must be entered within [ADDRESS_495812] report follow-up information relating to an SAE to the Sponsor’s Medical 
Monitor or CRO designee within [ADDRESS_495813] should be observed and monitored carefully until the condition resolves or stabilizes. 
All deaths are to be thoroughly investigated and reported.  Autopsy reports and death certificates 
are to be obtained, if possible. 
The Sponsor and/or its designee are responsible for reporting SAEs to all applicable regulatory 
agencies and the central ethics committees  within the required timeline.  
The Investigators are responsible for submitting required safety information to their local Institutional Review Board (IRB) or Independent Ethics Committee (IEC) as per local 
regulations.  This information includes, but is not limited to, any safety alert letter received from the Sponsor and any SAEs occurring at their investigative site. 
10.3.4 Reporting Study Endpoints  
Investigators will be counseled to report any event that they assess as potentially being a study 
endpoint requiring adjudication (death, myocardial infarction, stroke, thromboembolic events, and hospi[INVESTIGATOR_10889]).  All study endpoint events will be submitted blinded to the EAC for 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495814] the integrity of the trial, already adjudicated events will not be 
unblinded or reported to either Health Authorities (HAs) or Investigator s as safety reports unless 
otherwise requested by [CONTACT_245969].  After study completion, these events will be 
included in the final analysis which will b e unblinded and submitted to HAs with the study 
report.  
10.3.5 Relationship to Study Medication 
The causal relationship of the AE to study medication (vadadustat or darbepoetin alfa) will be 
assessed by [CONTACT_29548]. 
The assessment of cau sal relationship to study medication should be evidence-based, and not based 
on the premise that all AEs are possibly causally related to study medication until proven otherwise. 
Examples of evidence that would suggest a causal relationship between the study medication and the 
AE include the occurrence of an AE that is uncommon and known to be strongly associated with drug exposure (eg, angioedema, hepatic injury, and Stevens-Johnson syndrome) or an AE that is 
uncommon in the population exposed to the drug.
 
The causal relationship of the AE is assessed using a binary system, and AEs are classified as 
either ‘related’ or ‘unrelated’:  
Related : There is ‘reasonable possibility’ that the drug caused the AE. The AE follows a 
reasonable temporal sequence from the time of drug administration. There is supportive evidence (facts) to suggest a possible causal relationship, irrespective of the degree of certainty between the observed AE and the drug. 
Unrelated : An AE does not follow a reasonable temporal sequence from administration of the 
product and/or there is no reasonable possibility that the drug caused the AE. This assessment includes situations where the AE is related to other factors such as the subject’s clinical state, other therapeutic interventions, or concomitant drugs administered to the subject.  
Default assessments using the “related” category without supportive evidence for a causal relationship to study medication  is generally uninformative and does not contribute meaningfully 
to the development of the safety profile of the drug or to subject protection. 
Investigators are encouraged to choose the most plausible cause for the event(s) from the 
following list: medical history, lack of efficacy/worsening of treated condition, study medication , 
other treatm ent (concomitant or previous), withdrawal of study medication , administration error, 
protocol-related procedure, and others (specify). 
10.3.6 Severity  
The Investigator will assess each AE as either MILD, MODERATE, or SEVERE using the 
following guidelines to descr ibe the maximum severity of the AE:  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 70 of 105 MILD:  Does not interfere with subject's usual function 
MODERATE:  Interferes to some extent with subject's usual function 
SEVERE:   Interferes significantly with subject's usual function 
Note that a severe AE is not necessarily a serious  AE.  For example, a headache may be severe 
in intensity, but would not be class ified as serious unless it met [ADDRESS_495815]’s participation in the trial ends (ie, until a fin al report is completed for 
that subject).  
In addition, all SAEs and those nonserious events assessed by [CONTACT_245970]'s participation in the trial is over.  Such events should be followed until they resolve or until the Investigator assesses them as “chronic” or “stable”.  Resolution of such events is to be documented on the appropriate CRF. 
 Exposure In Utero  
A pregnancy in a female subject must be confirmed by a positive serum β human chorionic 
gonadotropin (β -HCG)  test.  
The study medication should be immediately discontinued once the pregnancy of a female study participant has been confirmed. 
If any study  participant becomes or is found to be pregnant while receiving a study medication 
(vadadustat or darbepoetin alfa) or within [ADDRESS_495816] be recorded on the Pregnancy Reporting Form/Exposure in Utero For m in the 
EDC within [ADDRESS_495817] should also be repor ted. 
The Pregnancy Reporting Form/Exposure in Utero Form must be completed with all known 
information regarding the pregnancy at the time of reporting.  Investigative site personnel will update the form with additional information regarding the pregnancy and the outcome of the pregnancy as it becomes available until the outcome of the pregnancy is reported. 
The Investigator will follow the subject (or female partner of a male subject) until completion of 
the pregnancy.  If the outcome of the pregnancy meets the criteria for classification as a SAE (ie, spontaneous abortion, stillbirth, neonatal death within 1 month of birth, or congenital anomaly [including that in an aborted fetus]), the Investigator will also follow the procedures for reporting a SAE withi n 24 hours of awareness.  A pregnancy in and of itself is not considered an AE; 
however, unexpected complications are considered AEs. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 71 of 105 Additional information about pregnancy outcomes follows: 
•Note that “spontaneous abortion” includes miscarriage and missed abortion.
•All neonatal deaths that occur within [ADDRESS_495818]
to causality, as SAEs.  In addition, any infant death after 1 month that the Investigatorassesses as related to the in utero exposure to the study medicati on should also be
reported.
•In the case of a live birth, the “normality” of the newborn can be assessed at time of birth.
•The “normality” of an aborted fetus can be assessed by [CONTACT_245971]-abortion laboratory findings suggestive of a congenital anomaly.
 Special Situations  
Certain safety events, called ‘Special Situations’, that occur in association with study 
medication(s) may require reporting.  These Special Situations include, but are not limited to, the following: 
•Overdose of the medicinal product
•Darbepoetin alfa Overdose: The  PI [INVESTIGATOR_245927].
•Vadadustat Overdose : There is no known antidote for vadadustat.  In cases of
suspected overdose, Subjects should be treated per standard medical practice based on
the Investigator’s judgment and dose delays and reductions may be implemented asnecessary.
Chronic overdosage with vadadustat may result in excessive production of red blood
cells and polycythemia.   Polycythemia can be potentially life threatening and may
result in severe thrombosis and death (known as hyperviscosity syndrome).  If
hyperviscosity syndrome is observed, vadadustat should be discontinued and standardtreatment for polycythemic hyperviscosity s yndrome should be initiated (i.e.,
phlebotomy).
•Suspected abuse/misuse of the medicinal product
•Inadvertent or accidental exposure to the medicinal product
•Medication error involving the medicinal product (with or without subject/patient
exposure to the Sponsor medicinal product, eg, name [CONTACT_2976])
•Drug -drug interaction .
Special situations should be reported on the Special Situations CRF whether they result in an 
AE/SAE or not.  Special situations with associated AE/SAE should also be reported on the corresponding AE/SAE forms, following applicable AE or SAE process. 
[ADDRESS_495819] listings.  Continuous variables will be summarized using number of subjects with 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495820] deviation, median, minimum, and maximum.  For categorical variables, the 
number and percentage of subjects in each category will be tabulated.  Summaries will be 
provided by [CONTACT_245972] (as defined in Section  11.2, 
Study Analysis Populations ) and by [CONTACT_7206]/time period as appropriate. 
For Hb, Baseline will be calculated  as the average of the central laboratory  Hb measurements  of 
samples taken at  the screening visit closest to the date of randomization and the measurement taken 
at randomization .  For other parameters, unless otherwise specified, Baseline will be defined as 
the last available value prior to the first dose of study medication. 
Hemoglobin values as assessed through the central laboratory will be used for efficacy and safety evaluations; local HemoCue Hb  values will be used only for dose adjustments. 
 Sample Size Determination  
The goal of this study is to demonstrate the efficacy and safety of vadadustat compared with  
darbepoetin alfa for the maintenance treatment of anemia in subjects with anemia secondary to NDD- CKD after conversion from current ESA therapy.  The sample size is calculated to ensure 
sufficient power for testing both efficacy in this trial and the primary safety endpoints as part of a 
pooled analysis. 
11.1.1 Sample Size for the Primary Efficacy Endpoint  
The primary efficacy endpoint is defined as the mean change in Hb from Baseline (mean 
pretreatment Hb) to the average Hb over the primary evaluation period (mean Hb  from Weeks 
24-36).
The primary efficacy objective of this study is to show that vadadustat is noninferior to 
darbepoetin a
lfa within the noninferiority margin.  Noninferiority will be established based on a 
margin of -0.75 g/dL (for vadadust at minus darbepoetin alfa).  
For the primary efficacy analysis in this study, it is assumed that the mean change from Baseline in Hb  for vadadustat will be the same as for darbepoetin alfa, and the common standard deviation 
for the mean change from Baseline is assumed to be 1.5 g/dL.  Noninferiority will be established based on a 2-sided 95% confidence interval for the difference between the vadadustat group and darbepoetin alfa and using a noninferiority margin of -0.75 g/dL.  With these assumptions and approximately [ADDRESS_495821] >  90% power.  
11.1.[ADDRESS_495822] (ad judicated) MACE 
+1.
The primary safety  analysis will be based upon all events that accrue across the 2 NDD- CKD 
studies (Studies AKB -6548- CI-0014 and AKB -6548- CI-0015).  The sample size with respect to 
the MACE endpoint has been determined based on the number of events needed to demonstrate 
noninferiority of the 2-sided 95% confidence interval for the hazard ratio (vadadustat/darbepoetin alfa) .  It has been calculated that [ADDRESS_495823] 80% power to establish noninferiority with a margin of 1.25, and >90% power to establish noninferiority with a margin of 1.3, assuming no difference between treatment groups .  The 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 73 of 105 power is >90% to establish a noninferiority margin of 1.[ADDRESS_495824] ratio is 0.95 favoring 
vadadustat .  A MAC E rate of 10% annually is anticipated in both treatment arms based on a 
comprehensive review of available epi[INVESTIGATOR_394642].   
The number of MACE in each study will be a function of the actual pattern and size of enrollment as 
well as the duration of follow-up.  
 Study Analysis Populations  
The following analysis populations will be used in this study: 
•Randomized population:  def ined as all randomized subjects
•Full analysis population:  defined as randomized subjects re ceiving [ADDRESS_495825] one Hb assessment during the primary efficacy
evaluation period. This population will be analyzed based upon the randomizedtreatment.
•Per protocol (PP) population:  defined as all randomized subjects who received study
medication  (vadadustat or darbepoetin alfa) during the primary evaluation period, had at
least 2 Hb assessments during the primary evaluation period , received no rescue therapy
(with ESA or RBC transfusion) in the [ADDRESS_495826] no
protocol deviations affecting the primary endpoint analyses. Protocol deviations leading
to exclusion from the per protocol population will be specified prior to database lock on ablinded basis and recorded in a separate document.
•Safety population:  defined as all  subjects who received at least 1 dose of study
medication .  This population will be analyzed based upon the actual treatment received.
Efficacy analyses will utilize the randomized, full analysis, and  PP populations while safety 
analyses  (including MACE) will utilize the randomized population. 
 Analysis of Demographic and Pretreatment Variables  
Descriptive statistics will be generated for demographic and pretreatment variables  for each 
analysis population defined in Section  11.2, Study Analysis Populations . 
Medical history terms will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by [CONTACT_252625]. 
 Disposition of Subjects  
The number and percentage of subjects randomized and included in each analy sis population will 
be summa rized by [CONTACT_11763].  Reasons for excluding subjects from the analysis 
populations will be presented in a by- subject listing.  
The number of randomized subjects who completed each period of study medication treatment (maintenance and long- term treatment), discontinued from study medication early, and 
completed or discontinued from the study and reasons for discontinuation will be summarized by [CONTACT_6654]. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495827] of rescue therapy on study conclusions. 
In the primary analysis of the primary efficacy endpoint, all available qualifying Hb 
measurements during the pretreatment period and during the primary evaluation period 
(Weeks  24-36) will be used to calculate an average Hb during each period respectively , for each 
subject .  For any subject with no available Hb  measurements during the primary evaluation 
period, multiple imputation  will be used to impute a  change from Baseline value (details are 
provided in the SAP). In an  analogous manner, an average Hb will be calculated for the 
secondary evaluation period (Weeks 40-52) for each subject. Given the design of this study where the subjects will continue to be assessed after early study medication discontinuation, it is 
expected that there will be only a minimal amount of missing data and the primary analysis should not be substantially affected by [CONTACT_245974]. 
All data pertaining to the MACE endpoint collected at any point during the study, both during 
study medication tre atment and post study medication treatment discontinuation, and regardless 
of the rescue therapy, will be used for the primary analysis of the MACE endpoint and its individual components. 
Unless stated otherwise  in the SAP, missing data for all other secondary efficacy and safety 
endpoints will not be imputed and the analysis will be based on observed data.  For certain 
responder-type binary endpoints, subjects with no available data will be classified into one of the categories as described in the relevant  sections of the SAP 
 Efficacy Analyses 
The primary efficacy endpoint as well as all key and other secondary endpoints will be summarized using descriptive statistics by [CONTACT_1570], as well as by [CONTACT_245975]/or analysis period as appropriate.  Mean  values of Hb as well as selected other efficacy parameters 
will be plotted across study visits/periods by [CONTACT_1570]. 
11.6.1 Analysis of Primary Efficacy Endpoint  
The primary efficacy endpoint is defined as the mean Hb  change from Baseline (mean 
pretreatme nt Hb ) to the mean Hb from Weeks 24-36 (inclusive). 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 75 of 105 [IP_ADDRESS] Primary Analysis of Primary Efficacy Endpoint 
The primary analysis will use an analysis o f covariance (ANCOVA) with multiple imputation, 
stratified by [CONTACT_394691].   
A 2-sided 95% confidence interval (CI) will be calculated  for the difference between treatment 
groups ( vadadustat minus darbepoetin alf a). 
Noninferiority of vadadustat will be established if the lower limit of this CI is ≥-0.75g/dL.  
The prima ry analysis will be performed using the randomized population and the assigned 
treatment as described in Section  11.2, Study Analysis Populations .  All data collected during the 
study for subjects included in the randomized population at the time of analysis, including data 
collected at any point after the initiation of rescue therapy as well as after early discontinuati on 
of study medication  treatment , will be used for the primary analysis.  Missing data will be 
handled using multiple imputation methodology as described in the SAP.  
[IP_ADDRESS] Sensitivity Analyses of Primary Efficacy Endpoint 
•The following sensitivity analyses will be conducted: Primary analysis will be repeated
using the full analysis population .
•Primary analysis will be repeated using only subjects with available Hb data during the
primary evaluation period, ie, excluding subjects with no available data during the
primary evaluation period.
•Primary analysis will be repeated using the PP population with the actual treatment
received.
•Primary analysis will be repeated with alternate approaches to imputation of missing dataas described in the SAP.
•Primary analysis will be repeated with imputation of data which may have been affectedby a subject’s having received any f orm of rescue (transfusion of ESA). Details are
provided in the SAP.
11.6.2  Secondary Efficacy Analyses   
Secondary efficacy endpoints analyses will  be performed using the randomized and full analysis 
populations and the assigned treatment as d escribed in Section  11.2, Study Analysis Populations .  
Analysis for the key secondary efficacy endpoints will be repeated using the PP population with 
the actual treatment received.  
[IP_ADDRESS] Key Secondary Efficacy Analyse s  
Mean change in Hb value between Baseline and the secondary evaluation period (Weeks 40- 52) 
will be analyzed using the same methodology as specified for the primary efficacy endpoint. Sensitivity analyses similar to those of the primary efficacy endpoint will be performed and details will be provided in the SAP.  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 76 of 105 11.6.3 Subgroups  
Analyses of the primary efficacy endpoint and key secondary efficacy endpoints will also be 
performed using the randomized and full analysis populations, using the assigned treatment, for subgroups based on the following: 
•Hb stratification level
•NYHA CHF stratification level
•Due to use of different target Hb levels in the U.S. vs. non- US, the endpoints will also be
analyzed for subsets based on the target Hb level:othe U.S. subset will be assessed due to the target Hb range being 10.0-11.0  g/dL in the
U.S.
othe combined EU and ROW  ( non-US) subset will be assessed since the target Hb
range is 10 .0-12.0 g/dL in these two Regions
•Geographic region (U.S., EU, ROW)
•Age
•Gender
•Race
Safety Analyses
All analyses of safety data will use the random ized population. 
11.7.[ADDRESS_495828] adjudicated MACE, will be analyzed as [date of the first MACE  minus the date of  randomization +1].  A MACE is defined as all -cause mortality, 
non-fatal myocardial infarction, or non-fatal stroke.  Subjects who have not experienced a MACE by [CONTACT_252654].  The hazard ratio (vadadustat/darbepoetin alfa) and its 95% confidence interval will be obtained from a stratified Cox proportional hazards model.  As this study has not been designed to provide a stand -alone assessment of MACE, this analysis will be considered a descriptive analysis.  A 
similar analysis as described for the primary analysi s of the MACE endpoint will be performed 
with censoring of subjects [ADDRESS_495829] a MACE prior to that time. 
The following safety endpoints will also be summarized using time to event methods as for 
MACE:  
1) Individual components (all-cause mortality, non-fatal myocardial infarction, non- fatal
stroke) of MACE
2) Thromboembolic events (defined as arterial thrombosis, DVT, PE, or vascular access
thrombosis)
3)Hospi[INVESTIGATOR_394643]. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 77 of 105 4) Expanded MACE, defined as all-cause mortality, non-fatal myocardial infarction, non-
fatal stroke, hospi[INVESTIGATOR_10889], or thromboembolic event
For these endpoints the incidence ("yes"/"no") of the endpoint will be presented for each 
treatment arm.  Kaplan -Meier curv es will be presented for each endpoint as the time of endpoint 
free survival (ie, time until endpoint or death). 
The primary MACE analysis will be based upon all events that accrue over the 2 NDD- CKD 
studies (Studies AKB-6548- CI-0014 and AKB-6548- CI-0015) (see Section  11.1.2,Sample Size 
for the Primary Safety Endpoint ). 
The SAP for this pooled MACE assessment in NDD-CKD subjects provides details of the 
primary analyses for MACE, for individual components of MACE, and for an expanded version of MACE.   Details of sensitivity analyses and subgroup analyses are also provided in the MACE SAP.  
11.7.[ADDRESS_495830]- treatment AEs will be 
summarized by [CONTACT_245979].  Adverse events will also be summarized by [CONTACT_394692].  
Summaries will also be provided for the following types of AEs: 
•SAEs
•Related AEs (including all categories for relationship to study medication other than
“Unrelated”, as determined by [CONTACT_737])
•AEs leading to early discontinuation of study medication .
11.7.3 Remaining Safety Endpoints 
The analysis of the following safety endpoints will be detailed in the SAP : 
The analysis of proportion of subjects with Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL 
post- Baseline will classify a  subject as a “yes” if:  
•Any value Hb >12.0 g/dL at any time after  Day 1
•Any confirmed value Hb >12.0 g/dL at any time after  Day 1
•Any value Hb >13.0 g/dL at any time after  Day 1
•Any confirmed value Hb >13.0 g/dL at any time after  Day 1
•Any value Hb >14.0 g/dL at any time after  Day 1
•Any confirmed value Hb >14.0 g/dL at any time after  Day 1 .
A Hb  value above a set threshold will be considered as confirmed if there are 2 consecutive 
values above that threshold.  The second of the 2 consecutive assessments should be done at 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495831] -Baseline will be 
excluded  from this analysis.  All other subjects will be classified to the “no” category.  
The analysis of proportion of subjects with any Hb increase >1.0  g/dL within any 2 -week 
interval or >2.0 g/dL within any [ADDRESS_495832] as a “yes” 
if at least 1 of the following criteria at any point after  Day 1 is met:  
•Hb increase >1.0  g/dL within any 2 -week interval
•Hb increase >2.0  g/dL within any [ADDRESS_495833]- Baseline will be excluded from this analysis.  All 
other subjects will be classified to the “no” category.  
Observed values of continuous and categorical parameters a nd changes from Baseline for 
continuous parameters to each study visit will be summarized descriptively for vital signs and 
clinical laboratory results.  Graphical displays of selected laboratory parameters will also be provided. 
Additional Assessments  
11.8.1 Concomitant Medications  
Prior and concomitant medications will be coded using World Health Organization (WHO) Drug dictionary. 
Prior medications will be defined as any medications that were taken before the date of the first 
dose of study medication.  Concomi tant medications will be defined as any medications taken at 
any time from the date of the first dose of study medication through the date of the last dose of the study medication.  
11.8.2 Biomarkers  
Bioma rkers (including but not limited to, hepcidin  and VEGF ) will be summarized descriptively 
at Baseline and by [CONTACT_246026]- Baseline.  
11.8.[ADDRESS_495834] KEEPI[INVESTIGATOR_245928]/Electronic Data Capture  
This study will utilize an EDC system to manage data collection during this trial.  The system is fully C ode of F ederal Regulations [ADDRESS_495835] parties, except for authorized representatives of the Sponsor or appropriate regulatory authorities, without written permission from the Sponsor. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495836]’s chart at the hospi[INVESTIGATOR_225945]'s office.  In these cases, data collected on the CRFs must match the data in those charts.  
 Record Retention  
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator agrees to keep records, including the identity of all participating subjects (sufficient information to link records, eg, CRFs and hospi[INVESTIGATOR_1097]), all original signed informed consent forms, copi[INVESTIGATOR_4600], SAE forms, source documents, detailed records of drug disposition, and adequate documentation of relevant correspondence (eg, letters, meeting minutes,  telephone calls 
reports).  The records should be retained by [CONTACT_245981] ( ICH), local regulations, or as specified in the Clinical Study 
Agreement, whichever is longer. 
If the Investigator becomes unable for any reason to continue to retain study records for the 
required period (eg, retirement, relocation), the Sponsor should be prospectively notified.  The study records must be transferred to a designee acceptable to the Sponsor, such as anot her 
Investigator, another institution, or to the Sponsor.  The Investigator must obtain Sponsor’s written permission before disposing of any records, even if retention requirements have been met. 
13 QUALITY CONTROL (QC)  AND QUALITY ASSURANCE  (QA ) 
 Investigative Site Monitoring Visits  
During study conduct, the Sponsor or its agent will conduct periodic monitoring visits to ensure that the protocol and Good C linical Practice (GCP) are being followed.  The monitors will 
review source documents to confirm that the data recorded on the CRFs is accurate.  The Investigator/institution will allow the Sponsor’s monitors or designees and appropriate regulatory authorities direct access to source documents to perform this verification. 
The investigative site may also be  subject to QA audits performed by [CONTACT_394693], and/or review by [CONTACT_1201]/IEC, and/or to inspection by 
[CONTACT_4708]. 
It is important that the Investigator(s) and their relevant personn el are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.  
 Protocol Deviations 
The Investigator will not deviate from the protocol, except where necessary to eliminate an immediate h azard to study subjects.  Should other unexpected circumstances arise that will 
require deviation from protocol- specified procedures, the Investigator will consult with the 
Sponsor or designee (and IRB or IEC, as required) to determine the appropriate cour se of action.  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495837]’s source documents.  
In the event of a significant deviation, the investigative site should notify the Sponsor or its designee (and IRB or IEC, as required).  Significant deviations include, but are not limited to, those that involve fraud or misconduct, increase the health risk to the subject, or confound interpretation of primary study assessments.  
14 STUDY DISCONTINUATION/INVESTIGATIVE STUDY SITE TERMINATION 
The Sponsor reserves the right to discontinue the study prior to inclusion of the intended number of subjects, but intends only to exercise this right for valid scientific or administrative reasons.  After such a decision, the Investigator must contact [CONTACT_27936] a time period specified by [CONTACT_245983]. 
 Criteria for Premature Termination or Suspension of the Study  
The following criteria may result in either temporary suspension or early termination of the study:  
•New information regarding the safety or efficacy of the study medication that indicates a
change in the known risk/benefit profile for the compound, such that the risk/benefit is no
longer acceptable for  subj ects participating in the study
•Significant violation of GCP that compromises the ability to achieve the primary study
objectives or compromises subj ect safety.
The Sponsor reserves the right to discontinue the study for other valid administrative reasons. 
 Criteria for Premature Termination or Suspension of Investigational Study Sites  
A study site may be terminated prematurely or suspended if the study site (including the 
Investigator) is found to be in significant violation of GCP, protocol, contractual agreement, or is unable t o ensure adequate performance of the study.  
Procedures for Premature Termination or Suspension of th e Study or  Investigational 
Sites 
In the event that the Sponsor elects to terminate or suspend the study or the participation of an investigational study site, a study -specific procedure for early termination or suspension will be 
provided by [CONTACT_1034]; the procedure will be followed by [CONTACT_246029]. 
[ADDRESS_495838] of the Study  
The study will be conducted in accordance with the Declaration of Helsinki on Ethical Principles 
for Medical Research Involving Human  Subjects, adopted by [CONTACT_104584] ( 2013).  
In addition, the study will be conducted in accordance with the protocol, the ICH guideline on GCP, and applicable local regulatory requirements and laws. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495839]/ Independent Ethics Committee  
It is the responsibility of the Investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent forms, and other relevant documents, (eg, recruitment advertisements, if applicable) from the IRB/IEC.  All correspondence with the IRB/IEC should be retained in the Investigator File.  Copi[INVESTIGATOR_1099]/IEC approvals should be forwarded to the Sponsor or its designee. 
In case of substantial protocol amendment, the sponsor will obtain approval from responsible 
Regulatory Authorities before implementation.  
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that event, the Investigator must notify the IRB/IEC and the Sponsor in writing immediately after the implementation.  
 Subject Information and Consent  
It is the responsibility of the Investigator to give each  subject (or the subject’s acceptable 
representative), prior to inclusion in the study, full and adequate verbal and written information regarding the objective and procedures of the study and the possible risks involved.  The subjects must be informed about their right to withdraw from the study at any time.  
Furthermore, it is the responsibility of the Investigator, or a person designated by [CONTACT_737], to obtain signed informed consent from each  subject or the subject’s legally 
acceptable representative prior to inclusion in the study.  The Investigator will retain the original of each  subject's signed consent form. 
The informed consent forms will be in compliance with ICH GCP, local regulatory requirements, and legal requirements.  The informed consent forms used in this study, and any changes made during the course of the study, must be prospectively approved by [CONTACT_28150]/IEC and the Sponsor before use. 
 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP  
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_394694], or if the Investigator is aware of any new information which might influence t he evaluation of the benefits and risks of the investigational product, the Sponsor 
should be informed immediately. 
In addition, the Investigator will inform the Sponsor immediately of any urgent safety measures 
taken by [CONTACT_394695], and of any 
serious breaches of this protocol or of ICH GCP, defined as a breach that will likely affect the safety or physical or mental integrity of subjects or the scientific value of the trial, that comes to the attention of the Investigator. 
 Subject Confidentiality  
All parties will ensure protection of  subject personal data and will not include subject names on 
any Sponsor forms, reports, publications, or in any other disclosures, except where required by [CONTACT_2371].  In case of data transfer, the Sponsor will maintain high standards of confidentiality and 
protection of subject personal data. 

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495840]’s right to protection 
against invasion of privacy.  Throughout this study, a subject’s source data will only be linked to the Sponsor’s clinical study database or documentation via a unique identification number.  As permitted by [CONTACT_1763], limited  subject attributes, such as sex, age,  or 
date of birth, and subject initials may be used to verify the  subject and accuracy of the subject’s 
unique identification number. 
To comply with ICH guidelines for GCP and to verify compliance with this protocol, the 
Sponsor requires the Investigator t o permit its monitor or designee’s monitor, representatives 
from any regulatory authority (eg, FDA), the Sponsor’s designated auditors, and the appropriate IRBs and IECs to review the subject’s original medical records (source data or documents), including, but not limited to, laboratory test result reports, ECG reports, admission and discharge summaries for hospi[INVESTIGATOR_1684] a subject’s study participation, and autopsy reports.  Access to a subject’s original medical records requires the specific authorization of the subject as part of the informed consent process. 
Copi[INVESTIGATOR_185660] (i e, subject name, address, and other identifier fields 
not collected on the subject’s CRF).  
16 PUBLICATION OF STUDY RESULTS  
No publication or disclosure of study results will be permitted, except under the terms and conditions of a separate, written agreement between Sponsor and the Investigator and/or the Investigator’s institution.  The Sponsor must have the opportunity to review and approve all proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation.  Any information identified by [CONTACT_394696]. 
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publications and authorship, including:  Section II - “Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by [CONTACT_4717].  
[ADDRESS_495841], Vaccarino V et al. Chronic kidney disease, anemia, and incident stroke in a middle- aged, community -based population: the ARIC study.  Kidney Int (2003) 
64(2): 610-615. 
Aranesp (package insert). Tousand Oaks, CA: [COMPANY_010], Inc.; 2017. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al.  The effects 
of normal as compared with low hematocrit values in patients with cardiac disease who are 
receiving hemodialysis and epoetin.  N Engl J Med (1998) 339(9):584-590. 
Darbepoetin alfa: Information on darbepoetin alfa in the US is available in the package insert for 
Aranesp ( [COMPANY_010], Thousand Oaks, CA; 2017) ; and detailed information on darbepoetin alfa in 
the EU is available on the European Medicines Agency web site.  

Protocol No. AKB -6548 -CI-0015 
Amendment 7-COL  
Akebia  — Company Confidential  
Page 83 of 105 Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al.  Normalization 
of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med (2006) 
355(20):2071-2084. 
FDA Guidance: Clinical Drug Interaction Studies 2017.  Available at: 
https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf . 
Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, et al.  Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.  J Am Soc Nephrol (2011) 22(2):358-365. 
Iseki K and Kohagura K.  Anemia as a risk factor for chronic kidney disease.  Kidney Int (2007) 
Suppl 72:S4 -9. 
Japanese Society of Nephrology.  Evidence-based clinical practice guideline for CKD 2013. Clin Exp Nephrol (2014) 18(3):346-423. 
Jha V, Garcia- Garcia G, Iseki K , et al. Chronic kidney disease: global dimension and 
perspectives. Lancet (2013) 382(9888): 260-272.  KDIGO CKD Working Group. KDIGO clinical practice guideline for the evaluation and 
management of chronic kidney disease. Kidney Int Suppl (2013) 3(1): 1-150. 
KDIGO.  KDIGO clinical practice guideline for anemia in chronic kidney disease.  Kidney Int 
(2012) 2(4):1-64.  Available at: 
http://www2.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm 
Levey AS, Stevens LA, Schmid CH, et al.  A new equation to estimate glo merular filtration rate. 
Ann Intern Med (2009) 150(9):604-612. Locatelli F, B árány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al.  Kidney 
Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney 
disease: a European Renal Best Practice position statement.  Nephrol Dial Transplant (2013) 28(6):1346-1359. 
McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, 
Califf RM. Cardiovascular toxicity of epoetin -alfa in patients with chronic kidney disease.  2013; 
37 (6): 549-58. Doi:10.1159/000351175. Epub 2013 May 25. 
Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM.  Pathophysiology of anaemia: 
focus on the heart and blood vessels.  Nephrol Dial Transplant (2000) [ADDRESS_495842] 3: 14-18. 
National Institute for Health and Care Excellence (NICE).  Chronic kidney disease: managing 
anaemia. NICE clinical guideline. Published: 3 June 2015. http://nice.org.uk/guidance/ng8Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment.  Cleve Clin J Med (2006)73(3):289-297.
Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 
(2006) 73(3):289-297. 
Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, and 
Johnson RS.  Regulation of iron homeostasis by [CONTACT_245985]- inducible transcription factors 
(HIFs).  J Clin Invest (2007) 117(7):1926-1932. 

Protocol No. AKB -6548 -CI-0015 
Amendment 7-COL  
Akebia  — Company Confidential  
Page 84 of 105 Pfeffer MA, Burdmann EA, Chen CY, et al.  A trial of darbepoetin alfa in type 2 diabetes and 
chronic kidney disease.  N Engl J M ed (2009a) 361(21):2019-2032. 
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al.  Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis (2009b) 54(1):59-69. 
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al.  Correction of anemia 
with epoetin alfa in chronic kidney disease.  N Engl J Med (2006) 355(20):2085-2098. 
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al.  Erythropoieti c 
response and outcomes in kidney disease and type 2 diabetes.  N Engl J Med (2010) 363(12): 
1146-1155. 
Stauffer ME  and Fan T.  Prevalence of anemia in chronic kidney disease in the [LOCATION_002]. 
PLoS One (2014) 9(1): e84943. Szczech LA, Barnhart HX, Inr ig JK, Reddan DN, Sapp S, Califf RM, et al.  Secondary analysis 
of the CHOIR trial epoetin -alpha dose and achieved hemoglobin outcomes.  Kidney Int (2008) 
74(6):791-798. Tsubakihara Y, Nishi S, Akiba T, et al.  2008 Japanese Society for Dialysis Therapy:  Guidelines 
for renal anemia in chronic kidney disease.  Ther Apher and Dial (2010) 14(3):240-275. 
Unger EF.  FDA perspectives on erythropoiesis- stimulating agents (ESAs) for anemia of chronic 
renal failure: Hemoglobin target and dose optimization (Slide presentation from the Sep 11, 2007 
Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee).  Retrieved from http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4315s1-10- FDA-Unger.ppt . 
Unger EF, Thompson AM, Blank MJ, and Temple R.  Erythropoiesis- stimulating agents - Time 
for a reevaluation.  N Engl J Med  (2010) 362(3):189-92. 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 85 of 105 APPENDIX A:  SCHEDULE OF ACTIVITIES  
Study Period  Optional  
Pre-
Screen  Screening Treatment Period  
Post  
Treatment BL/ 
rand . [a] Year 1 Year 2 Year 3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtm t Follow -
up [b] 
Week  -8 to 0 0 2 4 6  8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c] EOT 
+4
wks
[dd]
Visit Window (Days)  ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Procedures/Assessments  
Informed Consent  X [d] X [d] 
Pre-Screening Local Hb 
[e] X 
I/E Criteria [f ] X X X 
Vital Signs [g] X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Demographics, Med 
History  X 
Physical Exam [h] X 
12-Lead ECG [i] X 
Randomization  X 
Laboratory Procedures  
Pregnancy Test [j] X 
Folate and Vitamin B 12 X[k] 
Coagulation Tests  [l] X 
C-Reactive Protein X X X X X X 
Urine 
Albumin /Creatinine 
(uACR)  X X X X X X 
CBC [m] with periodic  
diff  X [k,]  X 
[k,n] X X X X X X X X X X X X X X X X X X X X X X X X X X 
Iron Indices [o] X[k] X X X X X X X X X X X X X  X X  X X X 
Serum Chem and  
eGFR [p] X[k] X X X X X X X X X X X X X X 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495843]  
Treatment BL/ 
rand . [a] Year 1 Year 2 Year 3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtm t Follow -
up [b] 
Week  -8 to 0 0 2 4 6  8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c] EOT 
+4
wks 
[dd] 
Visit Window (Days)  ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Liver Function Tests  [q] X[k] X X X X X X X X  X X  X X X X X  X X  X X X 
Lipid Panel [r] X X X 
Biomarkers [s]  X X X X X X X 
Reticulocyte Count  X X X X X 
Erythropoietin  X X X X X 
PK [t] X X X X X 
Exploratory Samples [u] X X X X X X 
Safety Assessments  
MACE Endpoint 
Questionnaire [v] X X X X X X X  X X X X X X X X X X X X X X X X X X X 
Adverse Event 
Assessment [w] X X X X X X X  X X X X X X X X X X X X X X X X X X X X 
Transfusions and ESA 
Rescue  X X X X X X X  X X X X X X X X X X X X X X X X X X X 
Therapeutic Phlebotomy  X X X X X X X  X X X X X X X X X X X X X X X X X X X 
Medication Assessments and Procedures  
Concomitant Med 
Review [ x] X X X X X X X  X X X X X X X X X X X X X X X X X X X X X 
Vadadustat Medication 
Dispensing [y] X X X X X X X  X X X X X X X X X X X X X X X X X X 
Drug Reconciliation  X X X X X X X  X X X X X X X X X X X X X X X X X X 
Visit Registration in IWR  X X X X X X  X X  X X X X X X X X X X X X X X X X X X X 
Hb via HemoCue for 
Dose Adjustment [z] X X X X X X X  X X X X X X X X X X X X X X X X X X 
Monthly Hb Monitoring 
[z] X X X X X X X  X 
Darbepoetin Alfa  Dosing accor ding to Dose Adjustment Algorithms  [aa] 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495844]  
Treatment BL/ 
rand . [a] Year 1 Year 2 Year 3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtm t Follow -
up [b] 
Week  -8 to 0 0 2 4 6  8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c ] EOT 
+4
wks
[dd]
Visit Window (Days)  ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Vadadustat Dose 
Adjustments [bb] Start at [ADDRESS_495845] dose as per Dose Adjustment Algorithms  
Oral or IV  Iron 
Supplementation [cc] As needed to maintain ferritin ≥100 ng/mL or TSAT ≥20%  
Abbreviations:  AE = adverse event; ALT/SGPT = alanine aminotransferase /serum glutamic -pyruvic transaminase; AST/SGOT  = aspartate aminotransferase /serum glutamic oxaloacetic transaminase; 
BUN  = blood urea nitrogen; CBC  = complete blood count; CPK  = creatine phosphokinase; CRF  = case report form; diff = differential; ECG  = electrocardiogram; eGFR  = estimated glomerular filtration 
rate; EOT  = end of treatment; ESA  = erythropoiesis -stimulating agent; HDL  = high density lipoprotein; Hb = hemoglobin; HIF  = hypoxia inducible factor; ICF = informed consent form; 
I/E = inclusion/ex clusion; INR  = international normalized ratio; IWR  = interactive web response; LDH  = lactate dehydrogenase; LDL  = low density lipoprotein; MACE  = major adverse cardiovascular 
event; MCH  = mean corpuscular hemoglobin; MCHC  = mean corpuscular hemoglobin conc entration; MCV  = mean corpuscular volume; med  = medication; PK  = pharmacokinetic; PS  = Pre-Screening; 
PT = prothrombin time; PTT  = partial thromboplastin time; RBC  = red blood cell; RDW  = red cell distribution width; SV1  = Screening visit 1; SV2  = Screenin g visit 2; TIBC  = total iron binding 
capacity; Trtmt  = treatment; TSAT  = transferrin saturation; uACR  = urine albumin to creatinine ratio; VEGF  = vascular endothelial growth factor; WBC  = white blood cell; wks  = weeks.  
[a] The Screening period is a maximum of [ADDRESS_495846] Screening visit   (SV2) , or date of last re -test. 
[b] The Follow -up visit can be performed either in person OR via the telep hone.
[c] The EOT visit will be performed at the time a subject permanently discontinues study medication (vadadustat or darbepoetin al fa) or for subjects on study medication at the time of notification of 
global study completion. It is important to continue to follow subjects that discontinue study medication through global study completion at a frequency and approach tha t is agreed to between the 
Investigator and subject. Visit schedule and assessments are flexible and at the discretion of the investigator and subject and will be clearly documented in the medical chart. 
[d] An abbreviated ICF will be used for Pre -Screening.  If the subject is eligible for Screening, a separate full ICF will be used , which may be signed in advance of the SV1 pocedures . The Screening 
period starts at the time the informed consent is signed and will be a maximum of 8 weeks in duration.   An optional consent form for collection of blood samples for future genetic analysis will be 
provided at SV1.  An additional optional co nsent form for participation in an adrenal function substudy in 200 subjects in the EU will also be provided at SV1.  
[e] If the Pre -Screen HemoCue Hb is between 8.0 and 11.0  g/dL (inclusive)  within the US or between 9.0 and 12.0  g/dL (inclusive) outside of the U S, the investigative site may proceed with Screening 
Visit 1 (SV1), preferably on the same day as Pre -Screening. 
[f] Inclusion/Exclusion criteria will be reviewed at the Pre -Screening and Screening visits (SV1 and SV2).  Final eligibility determination will occur following the Screening visits when all data are 
available.
[g] Vitals: Heart rate and blood pressure to be assessed in the seated position after [ADDRESS_495847].  Height (SV 2 only) and weight (SV2, Weeks 12, 24, 36, and 52, yearly thereafter , and at the EOT 
visit) will also be measured.
[h] Physical exam:  a physical exam is required at SV2 as outlined in the protocol.  Thereafter, an abbreviated symptom -directed physical exa m should be performed at the discretion of the Investigator
as clinically indicated.
[i] ECG should be performed prior to blood draws when possible and obtained after the  subject has been resting comfortably in a supi[INVESTIGATOR_73414] 5 minutes . 
[j]Serum pregnancy will be tested in women of childbearing potential at SV2.  (Eligible  subjects  will be advised to use an adequate contraceptive method.)  Additional serum or local urine pregnancy 
tests should be conducted throughout the study in sufficient number, as determined by [CONTACT_9332], to establish the absence of pregnancy during the study.  If
positive at SV2, the  subject is not eligible to enter the study.  If a subject becomes pregnant during the study,  the subject must permanently discontinue study medication and should  attend all 
subsequent study visits and be continually monitored according to the Schedule of Activities for the duration of the study.  
[k] Subjects may be retested and/or rescreened as detailed in Section  7.4 Retesting and Rescreening  
[l]Coagulation tests:  prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR).  
[m] A CBC with differential will be performed at Baseline and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208.  At al l other noted visits, a CBC without differential will be performed.

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 88 of 105 CBC:   hemoglobin, hematocrit, red blood cells (RBC), mean corp uscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell 
distribution width (RDW), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), and platelets.  
[n] Mean Screening Hb between 8.0 and 11.0  g/dL (inclusive) in the US and between 9.0 and 12.0  g/dL (inclusive) outside of the US, as determined by [CONTACT_144372] [ADDRESS_495848]’s  Hb does not qualify after SV1, SV2, or retest, the subject should be considered a Screen Failure.
[o] Iron indices:  ferritin, iron, total iron binding capacity (TIBC), and transferrin saturation (TSAT).  
[p] A full serum chemistry panel will be performed at SV1, Baseline, and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208.  At all other noted visits, serum creatinine and eGFR will b e 
performed.  Serum chemistry:  sodium, potassium, bicarbonate, chloride, calcium, magnesium, phosphorus, glucose , creatinine, blood urea nitrogen  (BUN)/urea, creatine phosphokinase (CPK), uric
acid, albumin, total protein , and eGFR. 
[q] Liver function tests:  total bilirubin, alkaline phosphatase, alanine aminotrans ferase  (ALT/SGPT), aspartate aminotransferase (AST/SGOT), and lactate de hydrogenase (LDH).
[r] Lipi[INVESTIGATOR_805]:  total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides.
[s] The biomarkers include, but are not limited to, hepcidin and VEGF.
[t]PK samples are to be drawn only for subjects randomized to vadadustat.  Subjects will be questioned regarding the timing of their last dose of vad adustat.  
[u] Additional blood and urine samples will be collected at Basel ine, Weeks 28, 52, 104, 156, and EOT  which may be used f or exploratory measurement of biomarkers (eg, factors relating to the 
activation of the HIF pathway).  Subjects will also be asked to provide optional consent to obtain a blood sample at Baseline and EOT to be stored for future genetic analyses (eg, DNA, m RNA).
[v] At each post-randomization  study visit, the subject must specifically be questio ned regarding the occurrence of any potential MACE endpoint events since the last study visit.  If a potential endpoint
event is reported, the date of the event should be recorded and the appropriate source documents should be collected according to the endpoint packet checklist.  
[w]Adverse events should be documented and recorded at each visit. The AE reporting period for this study begins upon randomization thr ough global study completion.  All adverse events (serious and
non-serious, and related and non -related) will be documented and recorded through the follow -up visit.  Subjects must be followed for adverse events until the final required protocol visit or un til all 
drug-related toxicities and serious adverse events have resolved (or are considered chronic/stable).  
[x] Concomitant medications should be collected and recorded at each visit as noted.  All concomitant medications received during the screening win dow  (minimum of  30 days prior to the start of
study medication) through the EOT visit will be recorded.
[y]Subjects will be provided with a supply of vadadustat at the Baseline visit and will be resupplied at subsequent visits as ne eded.  Subjects will be instructed to complete 1 bottle prior to opening the 
next bottle.  The dose should be taken at approximately the same time each  day.
[z]Hemoglobin will be monitored via local HemoCue throughout the study to determine if the dose of study medication will be adjusted , interrupted,  or maintained .  From Week 53,  Hb will be 
monitored monthly as part of local standard of care labs or  at unscheduled visits for dose adjustment . 
[aa] Refer to the Dosing Algorithm  adult patients with CKD not on dialysis . If the subject progresses to DD -CKD during the study and is able to continue study medication, use the Appendix Dosing 
Algorithms for adult patients with DD -CKD.  Vital signs and weight should b e obtained prior to dosing .    Darbepoetin alfa dosing is independent of the visit schedule, thus, the dosing schedule may 
shift per local standard of care and  Investigator discretion. . 
[bb] The dose will be adjusted in accordance with the Dose Adjustment Algorithms .  Changes to dose will be accomplished by [CONTACT_245987]. 
[cc] Iron supplementation will be prescribed during the study to maintain ferritin ≥100  ng/mL or TSAT ≥20%.  In general, only oral iron should be considered before initiating IV iron for therapy. 
Subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B 12 values may receive replacement therapy based on the investigative sites’ standard of care during the screening
period and retest the laboratory parameter(s). Subjects who receive iron replacement may retest screening Hb a minimum of 3 weeks after completi on of iron replacement therapy.   Vadadustat is not 
to be administered concurrently with the oral iron supplement (including multivitamins containing iron ), iron containing phosphate binders or any medications containing iron .  Oral iron supplement
should  be taken at least 2 hours before or 2 hours after the dose of study medication.  (See study protocol for further details regar ding iron administration and potential intravenous therapy).
[dd] End of Study status will be done to capture subject status at the global completion of the study or time of withdrawal of consent  or when subject deemed LTFU or death. Subjects active on the study 
(including those permanently discontinued from study medication and are being followed) will complete the Follow -up visit. For subjects active on the study medication at global study completion,
the EOS status will be collected at the at the Follow -up visit. For subjects that have permanently discontinued study medic ation and are being followed until global study completion, the EOS status 
will be as collected, which includes activities outlined at the Follow -up visit.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 89 of 105 APPENDIX B:  CKD -EPI [INVESTIGATOR_245901] (eGFR) will be calculated from serum creatinine (isotope 
dilution mass spectrometry [ IDMS ] calibrated in mg/dL)  using the Chronic Kidney Disease 
Epi[INVESTIGATOR_10444] (C KD-EPI) creatinine equation  (Levey et al.  2009). 
The CKD -EPI [INVESTIGATOR_245902]: 
eGFR  = 141 x min(SCr/k ,1)α x max(SCr/k,1)-1.209 x 0.993Age x [1.018 if female] x [1.159 if 
black]  
where: 
SCr is serum creatinine (in mg/d L) 
k = 0.7 for females k = 0.9 for males α = -0.329 for females α = -0.411 for males min = the minimum of SCr/k or 1  
max = the maximum of SCr/k or 1  

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 90 of 105 APPENDIX C:  VADADUSTAT  DOSING  AND DOSE ADJUSTMENT  ALGORITHMS  

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 91 of 105 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 92 of 105 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 93 of 105 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 94 of 105 APPENDIX D:  DARB EPOETIN  ALFA  DOSING  AND D OSE  ADJUSTMENT ALGORITHM S 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 95 of 105 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 96 of 105 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 97 of 105 

Protocol No. AKB -6548- CI-0015   
Amendment 7-COL  
Akebia  — Company Confidential  
Page 98 of 105 APPENDIX E:  END OF TREATMENT AND GLOBAL STUDY COMPLETION SUBJECT FLOW  

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 99 of 105 APPENDIX F:  HISTORY OF AMENDM ENTS TO THE PROTOCOL 
Amendment 1 (Version 2;   
Amendment 1 was issued based on requests from health authorities during review of the protocol 
under the European Voluntary Harmonisation Procedures (VHP). 
Amendment 1 was issued to a limited number of sites.  
The major changes introduced in the amendment are summarized below:  
•Added Exclusion Criterion No. 19: “Hypersensitivity to darbepoetin or vadadustat, or to
any of their excipi[INVESTIGATOR_840].”
•Clarified that the adrenal function assessment (adrenocorticotropic hormone [ACTH]stimulation test) will be conducted in a subset of 200 subjects in the European Union
(100 subjects from the vadadustat treatment arm and 100 subjects from the darbepoetinalfa treatment arm) across the 2  non-dialysis dependent chronic kidney disease (NDD-
CKD) studies AKB -6548- CI-0014 and AKB-6548- CI-0015.
•Defined that the s tudy completion date (end of trial) will take place when 631  major
adverse cardiovascular events (MACE) events have accrued over the 2 NDD -CKD
studies (Studies AKB-6548- CI-0014 and AKB-6548- CI-0015).
•Clarified that the double-barrier method should be pract iced starting at Screening Visit 1,
throughout the study, and for [ADDRESS_495849] dose of study medication.
•Added that “In case of substantial protocol amendment, the sponsor will obtain approval
from responsible Regulatory Authorities before implementation.”
Amendment 2 (Version 3;  
Amendment [ADDRESS_495850] also been included in Amendment 2. The major changes introduced in the amendment are summarized below : 
•To update the following exclusion criteria:
oExclusion Criterion No. 7: Additional clarification of exclusionary c ardiovascular
events  within 12 weeks prior to screening
oExclusion Criterion No. 8: To not exclude subjects with basal cell carcinoma who
have been successfully treated with cryotherapy instead of surgical resection
oExclusion Criterion No. 11: To specifically exclude subjects with a history of
hematopoietic stem cell transplant
oExclusion Criterion No. 13: Considering the short half-life of vadadustat andclinical experience in previous Phase 1 and Phase 2 studies in NDD- CKD and
DD-CKD subjects, it could  be beneficial for subjec ts who participated in previous

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page [ADDRESS_495851]  meets all eligibility criteria  
•To add hospi[INVESTIGATOR_19934] (HF) as an adjudicated safety endpoint in addition
to MACE and thromboembolic events
•To clarify that the darbepoetin alfa dosing adjustment guidelines is based on the approved
local product label for adult patients with CKD not on dialysis
•To allow subjects who transition to hemodialysis or peritoneal dialysis during the study
to continue to receive study medication (vadadustat or darbepoetin alfa). This is
supported by [CONTACT_246032] a recently -completed Phase 2 trial of vadadustat
in subjects  with dialysis -dependent chronic kidney disease (DD- CKD).
•To int roduce a binary causality system (ie, “related” or “unrelated”) for clinical trial
investigators to assign causality of adverse events to study drugs in accordance withrecommendations from the Council for International Organizations of Medical Sc iences
(CIOMS) VI Working Group
•Following discussions with the [LOCATION_002] Food and Drug Administration (US FDA),
it was requested that the sparse pharmacokinetic (PK) sampling scheme be described and
justified. The results of PK simulations indicated that collec tion of a sample between 0.[ADDRESS_495852] dose along with sparse samples collected duringWeeks  4, 12, 28 and 52 will provide additional information to help characterize the
population PK and PK/PD relationships
•Adverse even t reporting related to critically increased liver function test results were
aligned with the US FDA Drug -Induced Liver Injury (DILI) guidelines to provide
instructions to study sites regarding reporting for improved consistency and case quality
•To add vis it windows to provide flexibility to the subjects  and the study sites during
scheduling of study visits
•To clarify definitions for renal events to improve understanding and site compliance
Amendment 2 -COL (  Colombia- specific protocol amend ment)  
Amendment 2- COL was issued based on requests from the Instituto Nacional de Vigilancia de 
Medicamentos y Alimentos (Invima) during review of the protocol.  This amendment is country-specific and will only be issued to investigative sites in Colombia. 
Following is a list of the changes in Amendment 2- COL compared with the original protocol: 
•All changes to the original protocol that were included in Amendment [ADDRESS_495853] also been included in Amendment 2- COL.
•The protocol language specifying that site investigators should encourage patients (who
wish to discontinue study medication or withdraw from the study) to continue study
participation has been removed.
•The protocol language describing procedures to encourage patients to continue study
participation has been removed.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 101 of 105 Amendment 3 -COL  (Version 4;  
Amendment [ADDRESS_495854], and requests from study 
sites for additional clarification.  
The major changes introduced in the amendment are summarized below: 
•To update the study design from the current screening period of up to [ADDRESS_495855] screening Hb a minimum o f 3
weeks after completion of  iron replacement therapy .
•Inclusion Criterion No. 3 adjusted due to increase of screening period from up to 4 weeks
to up to 8 weeks.
•To update the following exclusion criterion:
oExclusion Criterion No. 3: Adjusted due to increase of screening period from up
to 4 weeks to up to 8 weeks.
oExclusion Criterio n No. 8: To clarify that benign colonic polyps is not a
malignancy, therefore removed to correct the error
oExclusion Criterion No. 9: Adjusted due to increase of screening period from upto 4 weeks to up to 8 weeks, and to clarify that chronic treatment withanticoagulants for a history of DVT or PE over 12 weeks prior to randomization isnot exclusionary.
•The number of total sites has been increased in efforts to increase enrollment.
•Vadadustat dosing and dose adjustment guidelines were updated to clari fy that patients
receiving 1 tablet of dosing prior to interruption will resume treatment with 1 tablet afterinterruption.
•Section 4.[ADDRESS_495856] information from
recently completed trials.
•Section 6.4.1 Exec utive Steering Committee has been added.
•To clarify Darbeopoetin alfa administration and accountability
oDarbepoetin alfa should be administered per the label.
oDarbepoetin alfa doses may be self -administered or administered by [CONTACT_246033], site facility, or at home  according to the investigator’s
determination and local practice.
oAdded additional information on return of darbepoetin for drug accountability and
compliance assessment.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 102 of 105 •9.2.[ADDRESS_495857] the following:
oModification to the frequency of protocol specified Biomarker sample collection
oAdditional exploratory sample collection
•A clarification of the study analysis populations has been provided.
Amendment 4-COL  (Version 5;  
Amendment 4 was issued based on sponsor internal assessment, external input from nephrology  
experts, and investigative sites.  
The major changes introduced in the amendment are summarized below : 
•Section 4.[ADDRESS_495858] eted trials and for alignment with  vadadustat Investigator ’s Brochure.
•Section [ADDRESS_495859] addition of several key
secondary, other secondary efficacy endpoints and Safety Endpoints  to align with the
Statistical Analysis Plan (SAP)
•Section 7.4.1 Retesting was updated for simplification
•Section 7.5.[ADDRESS_495860] the opportunity to complete ( at least) the week 36 visit.
•Section 7.5.[ADDRESS_495861] Discontinuation was updated to add Lack of Efficacy as
a reason for discontinuation for accurate data capture.
•Section 8.4.[ADDRESS_495862] completes ESArescue, the I nvestigator has the option to resume study drug at the same dose as
previously used or with one dose higher. Monthly Hb monitoring for dosing oversight  inYear 2 -4 was also added to this section.
•Section 8.4.6 Iron Supplementation was updated to align with published guidelines toprescribe iron supplementation during the study when serum ferritin is less than 100
mcg/L or when serum transferrin saturation is less than 20%
•Section [IP_ADDRESS] ESA Rescue (Optional) was updated to align with published guidelines
and to permit Investigator initiation of rescue when medically neces sary even if protocol
defined criteria are not met.
•Section 8.4.9 Dosing Compliance was updated to specify a range of 80% to 120% which
is commonly used in clinical trials with oral products.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 103 of 105 •Section 8.[ADDRESS_495863] dose of study medication will be recorded.
•Section 9.3.[ADDRESS_495864] of care labs or via anunscheduled visit.
•Section 10.1.1 was updated to add text defining overdose of study drugs.
•Section 10.1.2 Serious Adverse Events was updated to require all new and recurrent
malignancies (with a few exceptions) to be reported as a Serious Adverse Events (SAEs)
to standardize reporting. If a subject develops basal cell carcinoma of skin, squamous cellcarcinoma, or cervical carcinoma in situ during the study, or has worsening of theseevents from Baseline, the Investigator will determine if the event is reported as an AE orSAE.
•Section 10.5 Special Situations  was updated to add text defining overdose of study
drugs.
•Section 11.1.[ADDRESS_495865] a
change in the non- inferiority margin from -0.5 g/dl to -1.0 g/dl
•Section 11.1.2 Sample Size for the Primary Safety  Endpoint was updated with enrollment
projections as well as median study drug exposure times.
•Section 11.5 Missing Data was updated to align with Statistical Analysis Plan (SAP)
•Section 11.6.3 Subgroups is updated to pre-specify key subgroups for subsequent
analysis
•Section 11.7.2 Analysis of Adverse Events was updated and AE summaries will be
provided for specific sub groups.
Amendment 5 (Version 6; XX  )  
Amendment 5 was issued based on sponsor assessment, external input, regulatory authority 
engagement and investigative site s feedback.  
The major changes introduced in the amendment are summarized below: 
•Section 6.[ADDRESS_495866] number
•Section 7.5.1 Study Completion was updated to clarify that all enrolled subjects will be
allowed to complet e the primary evaluation period (Weeks 24-36) prior to global study
completion.
•Section 7.5.[ADDRESS_495867] Completion was updated to clarify procedures at time of global study
completion.
•Section 7.5.[ADDRESS_495868] Discontinuation was updated to emphasi ze the importance of
continuing to follow subjects through global study completion.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 104 of 105 •Section [IP_ADDRESS] Temporary Interruption of Study Medication was updated to state that if study
medication is temporarily interrupted for more than 60 days, Medical Monitor should becontact[CONTACT_246034].
•Section [IP_ADDRESS] Permanent Discontinuation of Study Medication was updated to have theEOT visit and Follow up visit performed at the time of permanent discontinuation of study
medication. Emphasized im portance of continuing to follow subjects through global study
completion.
•Section [IP_ADDRESS] Complete Withdrawal from Further Study Visits/Assessments is updated to
reflect all options that must be considered by [CONTACT_246035] a subject withdraws
consent.
•Section [IP_ADDRESS] Procedures to Support Continued Study Participation is added  to include all
options available to the Investigator to follow subjects that permanently discontinue studymedication.
•Section [IP_ADDRESS] Procedures to Prevent “Lost to Follow-up” details steps to support sites inefforts to identify subjects lost to follow-up.
•Section 8.4.[ADDRESS_495869] information for which the Sponsor and CROstudy teams will remain blinded.
•Section 8.4.[ADDRESS_495870] restarting of study medication after ESA
Rescue and RBC Transfusion .
•Section 8.5.2 Erythropoiesis-stimulating Agents was updated to provide clarity on study
medication dosing following ESA administration.
•Section 8.5.5 Rosuvastatin, Pravastatin, and Other HMG-CoA Reductase Inhibitors (Statins)was added to provide guidance on how to manage concomitant use of statins with vadadustat.
•Section 9.2.1 Clinical Evaluations was updated to include collection of AEs from the time of
randomization through global study completion.
•Section 9.3.9 EOT Visit was updated to include detail on managing subjects that permanentlystop study medication during the study and managing subjects on study medication at globalstudy completion.
•Section 9.3.[ADDRESS_495871] is deemed LTFU or upon death.
•Section 10.1.1 Adverse Events is updated by [CONTACT_394697].
•Section 10.1.2 Serious Adverse Events is updated to indicate that Sponsor has defined eventsthat will be classified as serious regardless of their assessment.
•Section 10.3.1 Reporting Period is updated to clarify that the AE reporting period begins atthe time of randomization and continues through global study completion.
•Section [ADDRESS_495872] how Baseline will be calculated for Hb.
•Section 11.1.[ADDRESS_495873] a change inthe non-inferiority margin from -1.0 g/dL to -0.75g/dL.
•Section 11.1.2 Sample Size for the Primary Safety Endpoint was modified to include updated
definition for primary safety endpoint and how noninferiority is established between
treatment groups.

Protocol No. AKB -6548- CI-0015  
Amendment 7-COL  
Akebia  — Company Confidential  
Page 105 of 105 •Section 11.2 Study Analysis Populations is updated with definition of full analysis
population.
•Section [IP_ADDRESS] Primary Analysis of Primary Efficacy Endpoint is updated with use of
ANCOVA with multiple imputation, stratified by [CONTACT_394698].
Amendment 6-COL  (Version 7.0;  
Amendment 6- COL  was issued based on preliminary results of a drug-drug interaction study. 
The major changes are summarized below:  
•Section 8.1.1 Vadadustat was updated to include reference to the Pharmacy Manual
which provides further details on storage and managing temperature excursions.
•Section 8.5.5 HMG-CoA Reductase Inhibitors (Statins) was updated to provide furtherguidance regarding concomitant use of simvastatin drug interactions with vadadustat.
•Section 8.5.6 Sulfasalazine and Other BCRP Substrates was added to provide guidance
regarding concomitant use of BCRP substrates with vadadustat.
•Section 10.[ADDRESS_495874] recent results of investigative
toxicology studies.
•Liver function tests were increased in Year 2, 3, and 4 to include Week 64, 88, 116, 140,168, and 192 for gathering data to better understand the hepatic profile of vadadustat.
This change is reflected in Section 9.2.2 Laboratory Evaluations, Section 9.3.7 Year 2Treatment Period Vis its (Weeks 53 through 104), Section 9.3.8 Year 3/4 Treatment
Period Visits (Weeks 116 through 208), and Appendix A: Sc hedule of Activities .
Amendment 7-COL  (Version 8.0;  
Amendment 7-COL was issued based on FDA guidance regarding potential drug-induced liver injury. 
•Section 7.5.[ADDRESS_495875]
abnormalities.
•Section 9.[ADDRESS_495876] results that would require permanent discontinuation of vadadustat.
•Section 10.1.[ADDRESS_495877]>[ADDRESS_495878] with an elevation of total serum bilirubin >[ADDRESS_495879] from conditions
of temporary discontinuation, as this is now a condition for permanent discontinuation.
•Sectio n 10.1.2 Serious adverse events was updated to include information defining
designated medical events.

Protocol No. AKB -6548 -CI-0015  
Amendment 7-COL 
Akebia  — Company Confidential  
Page 1 of 5 1.IDENTIYFING I
NFORMATION FOR AMENDMENT
Protocol Title: Phase 3, Randomized, Open -Label, Active -Controlled Study Evaluating the  Efficacy 
And Safety Of Oral Vadadustat  For The Maintenance Treatment Of Anemia In 
Subjects With Non -Dialysis -Dependent Chronic Kidney Disease ( NDD-CKD) 
(PRO2TECT – CONVERSION) 
Protocol Number: AKB -6548 -CI-0015 
Compound:  Vadadustat (AKB -6548) 
Status / Date:  Original Protocol;  
Amendment 1;  
Amendment 2;  
Amendment 2 -COL;  (Colombia -specific  
protocol amendment)  
Amendment 3 -COL;  (Colombia -specific 
protocol amendment)  
Amendment 4 -COL;  (Colombia -specific  
protocol amendment)  
Amendment 5 -COL;  (Colombia -specific protocol amendment)  
Amendment 6 -COL;  (Colombia -specific protocol amendment)  
Amendment 7 -COL;  (Colombia -specific protocol amendment)  

Protocol No. AKB -6548 -CI-0015  
Amendment 7-COL 
Akebia  — Company Confidential  
Page 2 of 5 2.PROTOCOL CHANGES DETAILS
Amendments to the protocol are detailed below, except for editorial changes and minor clarification changes. If it is necessa ry to clarify 
the edits, newly added text is identified using in blue and deleted text is identified by [CONTACT_246038], red  font. 
Protocol Section  Text in Version 7.0 (Amendment 6-COL ) Changes through Version 8.0 (Amendment 7-COL ) Rationale for Change  
Section 7.5.5  (Paragraph 3) 
Subjects who undergo a solid organ 
(including kidney), hematopoietic stem cell, or bone marrow transplantation will have 
their study medication (vadadustat or darbepoetin alfa) permanently discontinued.  (Paragraph 3) 
Subjects who undergo a solid organ (including kidney), hematopoietic stem cell, or bone marrow transplantation will have their study medication (vadadustat or darbepoetin 
alfa) permanently discontinued.  
See Section 9.4, Study Medication Stoppi[INVESTIGATOR_394644].  To include a reference to 
Study Medication 
Stoppi[INVESTIGATOR_394645].  
Section 9.4 
(added)  Study Medication Stoppi[INVESTIGATOR_245925] a subject meets one of the criteria in  Table [ADDRESS_495880] results 
that would require 
permanent 
discontinuation of vadadustat.  

Protocol No. AKB -6548 -CI-0015  
Amendment 7-COL 
Akebia  — Company Confidential  
Page [ADDRESS_495881] >3x ULN and 
total bilirubin >2x ULN  Permanently 
Discontinue Treatment  
ALT or AST >3x ULN and 
INR >1.[ADDRESS_495882] >8x ULN  Permanently 
Discontinue Treatment  
ALT or AST remains >5x 
ULN over 2 weeks* Permanently 
Discontinue Treatment  
ALT or AST > 3x ULN with 
symptoms including e.g., 
fatigue, nausea, vomiting, 
right upper quadrant pain, 
fever, rash or eosinophilia  Permanently 
Discontinue Treatment  
*Re-challenge generally should be avoided with ALT or
AST >[ADDRESS_495883] unless there are no other good
therapeutic options.
ALT: alanine transferase; AST:  asparagine transferase;
INR:  international normalized ratio; ULN: upper limit of
normal
Section 10.1.1  (paragraph 8)  
Abnormalities in ALT, AST and Total 
Bilirubin  - Abnormalities in ALT, AST and 
Total Bilirubin should be reported to the 
Sponsor’s Medical Monitor or CRO designee 
within 24 hours of awareness as SAE with 
“medical significance” criteria selected, if the following conditions are met:  
•New elevation in AL T or AST > [ADDRESS_495884], with or without anelevation of total serum bilirubin >
[ADDRESS_495885]; AND
•No other reason was identified thatexplains the increased ALT/AST
with or without an increased(paragraph 8)  
Abnormalities in ALT, AST and Total Bilirubin  - 
Abnormalities in ALT, AST and Total Bilirubin should be 
reported to the Sponsor’s Medical Monitor or CRO designee within 24 hours of awareness as SAE with 
“medical significance” criteria selected, if the following 
condition s are met:  
•New elevation in ALT or AST > [ADDRESS_495886],
with or without an elevation of total serum
bilirubin > [ADDRESS_495887]; AND
•No other reason was identified that explains the
increased ALT/AST with or without an increased
bilirubin (eg, viral hepatitis, acute liver disease).To include language for 
elevations in ALT or 
AST >[ADDRESS_495888].  

Protocol No. AKB -6548 -CI-0015  
Amendment 7-COL 
Akebia  — Company Confidential  
Page 4 of 5 bilirubin (eg, viral hepatitis, acute 
liver disease).  
If new elevations in ALT or AST > [ADDRESS_495889], with or without  an elevation of total 
serum bilirubin >  [ADDRESS_495890] are identified, 
the following steps are to be taken:  
•Temporary discontinuation of
Investigational Medicinal Product(IMP);
•Repeat testing of ALT, AST, ALP
and total bilirubin, to be completed
within 48 to 72  hours to confirm the
abnormalities and to determine
trend;
•IMP should not be resumed untilmonitoring indicates abnormalities
have resolved or have stabilized.If new elevations in ALT or AST > [ADDRESS_495891], with or  
without  an elevation of total serum bilirubin >  [ADDRESS_495892] are identified, the following steps are to be taken:  
•Temporary discontinuation of InvestigationalMedicinal Product (IMP );
•Repeat testing of ALT, AST, ALP , and total
bilirubin, to should be completed within 48 to
72 hours to confirm the abnormalities and to
determine trend;
•IMP should not be resumed until monitoringindicates abnormalities have resolved or have
stabilized.
Details on the management of subjects with other ALT and 
AST abnormalities are further described in Section 9.4, 
Study Medication Stoppi[INVESTIGATOR_1869] . 
Section 10.1.2  (paragraph 2)  
In addition to the above criteria for classifying AEs as serious, the following 
situations will also be classified as serious 
for purposes of this study:  
•Dialysis  or
Transplantation-  - Events
requiring transition to chronic,
ongoing dialysis, or requiring an
acute transient course of dialysis, or
requiring an immediate kidne y
transplantation (ie, not pre -planned)
will be classified as serious.Guidance for the reporting of theseevents is provided in Section 10.1.1,
Adverse Events .
•Malignancies  – Newly diagnosed
malignancies or a recurrence of a(paragraph 2)  
In addition to the above criteria for classifying AEs as serious, the following situations will also be classified as serious for purposes of this study:  
•Dialysis  or Transplantation - - Events requiring
transition to chronic, ongoing dialysis, or requiringan acute transient course of dialysis, or requiring
an immediate kidney transplantation (ie, not pre -
planned) will be classified as serious.  Guidancefor the reporting of these events is provided in
Section  10.1.1 , Adverse Events .
•Malignancies  – Newly diagnosed malignancies or
a recurrence of a malignancy should be reported asan SAE with the seriousness criterion “medicallyimportant” if no other seriousness criteria are met.
If a subject develops basal cell carcinoma of skin ,
squamous cell carcinoma, or cervical carcinoma in
situ during the study, or has worsening of theseTo define a list of 
designated medical 
events that shall always be classified as serious 
adverse events (SAEs).  

Protocol No. AKB -6548 -CI-0015  
Amendment 7-COL 
Akebia  — Company Confidential  
Page 5 of 5 malignancy should be reported as an 
SAE with the seriousness criterio n 
“medically important” if no other 
seriousness criteria are met. If a 
subject develops basal cell carcinoma of skin, squamous cell 
carcinoma, or cervical carcinoma in 
situ during the study, or has worsening of these events from 
Baseline, the Investigator will 
determine if the event is reported as 
an AE or SAE.  events from Baseline, the Investigator will 
determine if the event is reported as an AE or SAE. 
•Designated Medical Events  - The sponsor
maintains a list of designated medicalevents  (DME) that they will always classify as
serious adverse events.   If an event on the DME
list is reported as an AE additional information onthe event (e.g. investigator confirmation of
seriousn ess, causality) will be requested from the
Investigator.
